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Antibodies form the main class of commercial therapeutic proteins and are intended for 
the treatment of several chronic diseases. The current trend is to formulate antibodies at 
high concentrations in order to deliver a large therapeutic dose in small volumes (1-2 mL) 
subcutaneously (SC). Thus, enabling patients to self-administer these medications at 
home rather than in a hospital setting through intravenous (IV) infusions. However, 
several challenges can be encountered when formulating proteins at high concentrations. 
In the liquid state, high concentration protein formulations are prone to aggregation and 
exhibit high viscosities. In the lyophilised state, they show high total solute concentrations 
and product dry layer resistance, that can prolong primary drying, increase overall process 
time, costs of manufacturing and extend reconstitution time.  
The overall aim of this thesis was to obtain a stable, lyophilised, high concentration 
antibody (immunoglobulin 1, IgG1) formulation via rational selection of the excipients 
(type and ratio) and optimisation of the lyophilisation process with the aid of  Quality by 
Design (QbD) approaches. 
Formulations selected include BSA as model protein and an IgG1 as the target protein. 
Arginine/arginine-HCl (arg/arg-HCl) and sucrose were selected as excipients as a result 
of an overview of the composition of liquid and lyophilised protein products approved in 
the European Union since 1995. Polysorbate 80 was also employed as a surfactant at a 
fixed concentration. The ratio of protein:excipients relative to the total solute 
concentration was determined with the aid of a mixture Design of Experiment (DOE) 
tool. The DOE was used to generate empirical models for critical temperatures 
optimisation and prediction. The lyophilisation cycle optimisation was conducted using 




range of temperature monitoring systems. CQAs of the optimised lyophilised 
formulations (glass transition temperature (Tg), residual moisture, product appearance, 
reconstitution time and biophysical stability) were assessed and stability was monitored 
over a six month period in the presence and absence of cold chain storage. 
The empirical model generated from the DOE provided formulations containing 100 
mg/mL of protein with maximised critical temperatures. The empirical model was also 
capable of accurately predicting both critical temperatures (glass transition of the 
maximally freeze concentrated solution, Tg’ and collapse temperature, Tc) within the 
design space. The lyophilisation process was successfully optimised. A significant 
reduction in primary drying time (45%, -11h) was obtained when shelf temperature (Tshelf) 
was increased from -25°C to -15 °C. Additionally, an aggressive lyo-cycle conducted at 
a Tshelf of 35 °C provided an extremely short primary drying time (4.75h). The lyophilised 
products obtained by this lyo-cycle did not show any collapse and had similar Tg and 
residual moisture to the products lyophilised at conservative conditions (95-100 °C and 
0.1-0.3% respectively).  
The high Tg renders these products good candidates for the elimination of cold chain 
during storage. Formulations selected were amorphous and maintained their physical 
solid state over six months storage and exposure to high relative humidity (up to 70%)  
conditions. The high concentration of the protein was capable of inhibiting excipient 
recrystallisation, providing a stable amorphous product. A non-destructive technique was 
used to determine the vial headspace residual moisture which correlated with product 
moisture and Tg. A correlation model was developed to estimate product moisture and 
Tg by performing a non-destructive technique and retaining the samples at each time point 




The lyophilised formulations were biophysically stable over six months in the presence 
and absence of cold chain. Aggregation was not detected. The challenge of prolonged 
reconstitution times for high concentration protein formulations was overcome by 
lyophilising the product at a low fill volume (1.1 mL). Finally, the addition of arg/arg-
HCl to the lyophilised formulations showed some advantages; reducing the specific 
surface area and improving the product visual appearance of lyophilised formulations. 
Furthermore, arg/arg-HCl provided a stabilising effect, reducing protein aggregation in 
formulations exposed to high intensity light. 
This study provides a rational approach, insights and strategies that can be applied to 
overcome some of the challenges encountered during formulation and manufacturing of 
lyophilised high concentration protein formulations. The use of QbD approaches aids the 
development of stable, lyophilised, high concentration antibody formulations. The 
formulation strategy identified allows reduction of the manufacturing time and enables 
storage of these formulations at ambient conditions rending the development of 



















1.1.1 Therapeutic proteins 
 
Therapeutic proteins are an emerging class of drugs utilised for the treatment of several 
chronic diseases such as diabetes, end stage renal disease, viral hepatitis, cancer, 
neutropenia, clotting disorders and inborn errors of metabolism (1-3). Therapeutic 
proteins included in commercial parenteral products are mainly antibodies, hormones, 
enzymes, cytokines, coagulation factors and fusion proteins, which are formulated in the 
liquid or solid formats (3-5). 
1.1.1.1 Proteins: structure and stability 
 
Proteins are large molecules, consisting of one or more chains of amino acids 
(polypeptides) that once folded in a specific three-dimensional structure provide a 
specific activity or function. The shape in which a protein naturally folds is defined as its 
native conformation, on the contrary the loss of the protein native conformation is defined 
as unfolding (6). The conversion of a protein from a folded to an unfolded state occurs 
through an intermediate or transition state (Figure 1.1). At this stage, the protein has a 
higher tendency to aggregate forming reversible or irreversible aggregates. The 
reversibility of protein aggregation is generally associated to the stage of the aggregation 
process (6, 7). The initial formation of soluble aggregates can be reversible, however, 
once the aggregates exceed certain sizes and solubility limits at a later stage they become 
irreversible, unless aggregation is artificially induced (6, 7). The conversion of the native 
protein to the initial aggregate is defined as nucleation. Higher hydrophobicity of the 
protein is generally associated with higher tendency to aggregation (6, 8).  





Figure 1.1 Scheme describing mechanism of physical protein aggregation (Revised (6)). 
 
Proteins can be organised in different structural levels: a) Primary structure – linear amino 
acid sequence which specify the final protein native structure (peptide bonds); b) 
Secondary structure – first step of the folding process that a protein takes to assume its 
native structure (through intramolecular hydrogen bonds). The most common secondary 
structure elements include: -helix, -sheet, -turns and random coils; c) Tertiary 
structure – protein is folded in its three-dimensional structure (through hydrophobic 
interactions and covalent bonds e.g. disulphide bridges); d) Quaternary structure – folded 
subunits of a protein or multiple polypeptides that once assembled form a fully functional 
protein (6, 9, 10) (Figure 1.2). 





Figure 1.2 Protein structural levels (Revised (11)). 
 
1.1.1.2 Antibodies: structure and stability 
 
Monoclonal antibodies are the largest class of therapeutic proteins (1, 3, 5, 12-14). 
Antibody, also known as immunoglobulin (Ig) is a globular Y-shaped protein. 
Antibodies’ structure is characterised by two identical heavy (H) chains and two identical 
light (L) chains with a typical molecular weight of 50 and 25 kDa, respectively. Therefore, 
the overall protein molecular weight is approximately 150 kDa. Two types of light regions 
can form the antibody: lambda () and kappa (). Their ratio varies in mice (20:1) and 
humans (2:1) (12). The heavy and light chains are linked together by disulphide bonds. 
Additionally, the antibody structure possesses two main regions: the variable region (V) 
which includes the antigen binding fragment (Fab) and the constant region forming the 
crystallizable fragment (Fc) for recognition and binding of the effectors (e.g. receptors). 
The hinge region provides a certain flexibility to guarantee the binding to the antigen 
(Fab) and the effector function (Fc) (Figure 1.3). 





Figure 1.3 Schematic representation of a typical IgG structure. 
 
Antibodies can be divided into five classes depending on their constant region (C): IgA, 
IgD, IgE, IgM and IgG. IgGs are monomers, whereas IgMs and IgAs are dimers and 
pentamers, respectively. IgGs can be further divided in subclasses: IgG1, IgG2, IgG3 and 
IgG4, due to differences in their heavy chains (1, 2, 3 and 4) (12, 15). The main 
structural differences are related to the number and location of disulphide bonds and the 
length of their hinge region (12). Most IgGs have four interchain disulphide bonds, two 
of which link the H chains and two the L chains, with some exceptions (12, 15). In 
addition, one oligosaccharide chain is included in the IgG structure, usually on the 
constant region. The oligosaccharide chain, fucosylated in some cases, is critical in 
relation to the conformation, function and antigenicity of the antibody (12, 16, 17). The 
secondary structure of antibodies is mainly characterized by the formation of anti-parallel 
-sheets (two domains- L chains, four domains- H chains) (12, 15). All these domains are 
folded in -barrel structures stabilised by disulphide bonds and hydrophobic interactions 




(12). Disulphide bonds and strong non-covalent interactions between the two H chains 
and H-L chains contribute to maintaining the characteristic Y-shape (12).  
The increased use of antibodies as therapeutic proteins is related to several advantages: 
1) their high specificity which enables a reduction of side effects, 2) their possible 
conjugation with other entities to guarantee an efficient delivery, 3) their possible use in 
diagnostic when conjugated with radioisotopes and 4) a reduction of the risk of 
immunogenicity due to significant improvements in the technology employed for their 
production (12). In early stage development, antibodies were mainly extracted from 
murine sources. Hence, murine antibodies were highly prone to induce an immune 
response in humans through the formation of human anti-mouse antibodies (HAMA). 
Subsequently, humanised chimeric antibodies (60-70% human) and highly humanised 
antibodies (90-95% human) were developed reducing the risk of immune response when 
administered (12, 16). Antibody fragments and nanobodies are novel therapeutic 
approaches in development (18). 
Although antibodies are generally more stable than other proteins, they can undergo 
physical and chemical degradation through a variety of pathways (6, 7, 12, 19, 20). 
Antibodies are an heterogenous class of proteins, hence IgGs belonging to the same 
subclass can have different stability behaviours and sensitivity to degradation pathways 
when exposed to the same conditions (12). Differences in their polypeptide sequence, 
glycosylation, extraction or purification, and terminal processing can all impact the 
production of a unique and sometimes unpredictable antibody entity  (1, 12). As well as 
other proteins, antibodies can undergo physical degradation through two main pathways 
(aggregation and denaturation) or chemical degradation through several pathways (cross-
linking, deamidation, isomerization, oxidation and fragmentation) (6, 7, 12, 19, 20). 
Antibody degradation can have a detrimental impact on therapeutic activity and efficacy, 




but also provokes an immune response that may lead to complete neutralization of the 
therapeutic antibody as well as of the human endogenous proteins (12, 21-23). pH, ionic 
strength, buffering agents, formulation composition, shaking/shearing, choice of the 
container, processing strategies (e.g. freeze/thaw or lyophilisation) (6, 24-26) are all 
factors that can negatively impact the rate of degradation of the specific antibody/protein 
in formulation (6, 12, 19, 27).  
Despite the common use of platform approaches, individual formulation and processing 
strategies can contribute synergistically to overcome these challenges and provide a stable 
antibody formulation through manufacturing and storage (12, 28).  
1.1.1.3 High concentration protein formulations 
 
Proteins such as monoclonal antibodies are often administered at high doses and with 
frequent regimens for a variety of therapeutic indications (12, 13, 28). In general, the 
current preferential route of administration for protein commercial products is 
intravenous (IV) infusion (29). However, pharmaceutical companies are increasingly 
showing interest in formulating high protein doses required at high concentrations 
(usually ≥ 100 mg/mL) and in small volumes (1-2 mL) to promote their delivery through 
subcutaneous (SC) administration. The main advantages in developing protein 
formulations intended for subcutaneous use are: (a) self-administration, especially in the 
context of home medication, (b) ease of use, (c) reduction of hospitalization and thus 
treatment costs, and therefore increased patient compliance (28, 29). However, the 
development of high concentration protein formulations can pose several challenges in a 
liquid format due to high viscosity (30, 31), high aggregation propensity and low 
solubility (12, 13). In a lyophilised format, high concentration protein formulations also 
present some challenges due to high solid content, cryo concentration during freezing, 
and high resistance to the water vapour flow which can prolong primary drying and 




reconstitution times (12, 13, 32). A number of studies have been published in relation to 
high concentration protein formulations (28-31, 33-35), but very little is published in 
relation to these formulations in the lyophilised state (32, 36-38). 
1.1.1.4 Parenteral protein formulations 
 
Parenteral protein products are generally formulated in two dosage forms: liquid or 
lyophilised. Depending on the format, the excipients included in the formulation can vary 
to promote the optimal stability of the therapeutic protein over its shelf-life. Liquid dosage 
forms are usually preferred as they are easier to administer and less expensive to 
manufacture (39, 40). On the contrary, lyophilisation is generally performed for APIs that 
are not adequately stable in the liquid dosage form, since lyophilisation is a time 
consuming and expensive process (39-42). Lyophilisation is also used to accelerate 
introduction of new products on the market, which would otherwise require a number of 
formulation optimisation studies to be commercialised in the liquid state. Recently, an 
increasing number of lyophilised products have been developed to ensure product 
stability, to prolong shelf-life and in some cases to eliminate the requirement for cold 
chain during storage (43, 44). The main excipient categories included in liquid and 
lyophilised parenteral protein formulations are summarised in Table 1.1.




Table 1.1 Summary of the excipient categories included in liquid and lyophilised protein 
formulations. 
Excipient Class Liquid Lyophilised 
Buffering agent Yes Yes 
Stabilisers Yes Yes 
Bulking agent No Yes 
Surfactants Yes Yes 
Preservatives Yes No 
Tonicifiers Yes Yes 
 
Chapter 2 provides a comprehensive and detailed overview of the excipients included in 
commercial parenteral protein products and approved in the European Union between 
1995-2018. The overview particularly focuses on antibody products, since they form the 
main class of commercialised therapeutic proteins. 
The minimum number of excipients capable to have a beneficial role and to improve 
protein stability should be included in protein formulations, providing a simple, but 
effective formulation strategy (liquid or lyophilised) (40). The mechanism by which some 
excipients are capable of stabilising proteins is not completely understood, however 
different hypothesis have been proposed (Figure 1.4) 





Figure 1.4 Schematic representation of the theoretical mechanisms of interaction occurring between 
protein and stabilising excipients in solution (liquid) and after dehydration (lyophilised). In the liquid 
state, preferential hydration occurs when the protein preferentially interacts with water. In contrast, 
preferential interaction occurs when the excipient preferentially interacts with the protein. In the 
lyophilised state, once the water is removed through dehydration, the excipient interacts with the 
protein replacing water (water replacement) or the excipient creates a glassy matrix around the 
protein (vitrification). 
 
Two are the most common hypothesis identified for protein stabilisation in the liquid 
state, preferential hydration or preferential interaction. Firstly, preferential hydration, 
which implies exclusion of the excipient from the protein surface considering that any 
molecule is larger than water (45). In this case, the excipient is excluded due to its larger 
hydrodynamic radius and water directly interacts with the protein which maintains its 
native structure. Secondly, preferential interaction, according to which water is partially 
excluded due to preferential interactions of the excipient with the protein (e.g. hydrogen 
bonds, H-bonds) (45). In this case, a certain excipient concentration is required to ensure 
formation of the bonds on the protein surface (45). During lyophilisation, the dehydration 
process removes free water, first during freezing due to water crystallisation and then 
during drying due to sublimation. The two most common stabilising hypotheses for 
lyophilised formulations include: 1) water replacement - the water is replaced by the 




excipient which directly interacts with the protein and 2) vitrification - the amorphous 
excipient (stabiliser) creates an amorphous glassy matrix around the protein, reducing 
protein mobility and the probability of protein-protein interactions leading to aggregation 
(45). 
1.1.2 Lyophilisation process 
Lyophilisation, also referred to as freeze-drying, is a process employed to manufacture 
pharmaceutical, biopharmaceutical and food products not sufficiently stable in the liquid 
or frozen forms (40, 46). Lyophilisation is generally employed to extend the shelf-life and 
stability of a product; however, it is a time consuming and expensive process (39-42). 
Hence, pharmaceutical companies execute lyophilisation process optimisation, aiming to 
reduce the process time while maintaining product critical quality attributes (CQAs) 
within specifications (39).  
The lyophiliser (or freeze-dryer) is the equipment used to conduct the lyophilisation 
process. Lyophilisers can have different configurations, designs, dimensions and capacity 
(47, 48). Laboratory and pilot freeze-dryers are employed at small manufacturing scale, 
whereas commercial freeze-dryers are used at the large manufacturing scale. In both 
cases, the main lyophiliser components (Figure 1.5) include: 
• Lyo chamber - where the shelves and the product vials are located. 
• Shelves - situated in the lyo chamber, shelves contain a thermal fluid (silicone 
oil) that circulates in a serpentine for temperature control. 
• Vacuum pump - compresses non-condensable gasses to the condenser. 
• Condenser - refrigerated coils or plates, internal or external to the lyo 
chamber. Differences between product temperature (Tp) at the sublimation 
interface and condenser temperature is the driving force of the primary drying 
step. The condenser traps the water during processing. To maximise the 




process efficiency, the condenser temperature should be at least 20 °C lower 
than the product temperature at the sublimation interface. 
• Isolation valve - separates the lyo chamber from the condenser chamber. 
• Refrigeration system - to cool shelf and condenser by using compressors or a 
refrigerant fluid. 
• PC/ Control system - to set up controlled values of critical process parameters 
(chamber pressure, temperature, ramp rate and soak time). 
 
Figure 1.5 Schematic representation of a Lyophiliser. 
 
The lyophilisation process (or lyo-cycle) consists of three steps: 
• Freezing is the step where temperature is reduced to completely freeze the 
bulk product solution below its critical temperatures. If the formulation 
includes amorphous and crystalline components, a crystalline ice phase and a 
freeze concentrated amorphous phase will form.  




• Primary drying is the step where the majority of the ice is converted into water 
vapour, by sublimation. Sublimation is a phase transition where the material 
changes from a solid to a vapour state, by-passing the intermediate liquid state. 
To guarantee sublimation completion, a reduction in pressure (below the triple 
point of ice at the specific product temperature, Figure 1.6) is required. 
 
Figure 1.6 Diagram of the triple point of ice and water phase transitions. 
 
• Secondary drying is the step where the residual unfrozen (bound) water is 
removed by desorption. During this step, temperature is increased to reduce 
moisture content in the lyophilised product to values typically below 1-3% 
(49-51). 
Additional steps in the overall process include loading (pre lyophilisation), vial 
backfilling in the lyo chamber with inert gas, vials stoppering and unloading (post 
lyophilisation). Vials backfilling is generally executed under partial vacuum (800-900 
mbar) to enable and preserve the sealing of the vials. 






Freezing is a stochastic process, difficult to control. Freezing is achieved by reducing the 
temperature from the loading temperature to a temperature value below the formulation 
critical temperatures. Critical temperatures include glass transition temperature of the 
maximal freeze concentrated solution (Tg’) of the amorphous components or below the 
eutectic temperature (Teu) of the crystalline components. Each formulation has a critical 
temperature below which it needs to be frozen and dried for complete solidification and 
prevention of physical/structural collapses that can compromise the quality of the product 
(52, 53).  
Tg’ is defined as the temperature at which the frozen amorphous material changes from 
a brittle to a flexible structure. Tc is the temperature at which the amorphous material 
softens to the point of not being able to support its own structure, whereas Teu is the 
temperature at which the eutectic mixture melts (54). Critical temperature values are 
dependent on the formulation components, their physical nature (amorphous or 
crystalline) and their ratio in the mixture. Typically, a difference of 1°C to 3°C has been 
reported between the Tg’ and Tc of a protein formulation (Tc>Tg’) (52, 55), however, at 
higher protein concentrations this difference can progressively increase up to 10 °C (32).  
If excipients used in the formulation have a tendency to crystallise, an annealing step is 
required to prevent occurrence of crystallisation during processing or upon storage (38, 
56, 57). If an amorphous excipient re-crystallises, provoking molecular re-arrangement 
and release of bound water in the lyophilised product, the stability of the product can be 
compromised (57, 58). Annealing is performed by conducting a stochastic freezing and 
re-heating the product to a set temperature above Tg’ of the amorphous fraction (56). The 
induced annealing increases mobility and restructures ice crystals to larger sizes (Ostwald 
ripening reaction), reducing primary drying time (56, 59). The re-crystallisation event 




also removes the excipient from the amorphous phase modifying formulation Tg (56). 
However, a certain period of time at the desired temperature is required to ensure 
complete conversion of the amorphous material to its crystalline form, which often results 
in prolonged freezing times.  
The freezing step is essential and can impact on the subsequent drying steps. The 
nucleation temperature is defined as the temperature at which ice crystals first form. The 
degree of supercooling is defined as the difference between the equilibrium freezing point 
and the nucleation temperature. The degree of supercooling is affected by the solution 
properties and process conditions (60). The freezing ramp rate has a significant impact 
on the formation and size of the ice crystals, that once removed through sublimation can 
leave pores of different sizes impacting primary and secondary drying time (39, 60, 61). 
The modality of freezing can affect the degree of supercooling and ice crystals size, hence 
the resistance of the material to the flow of water vapour during sublimation (Rp) (Figure 
1.7). The degree of supercooling governs the rate of nucleation and thus determines the 
number and size of ice crystals formed, which, in turn, affects the porosity/surface area 
of the lyophilised cake (60). 





Figure 1.7 Schematic illustration of the impact of the cooling rate on the freezing and primary drying 
steps. 
 
As shown in Figure 1.7, high freezing rates induce a high degree of supercooling (low 
nucleation temperature), small ice crystal formation, higher Rp and longer primary drying 
time (shorter secondary drying). Lower freezing rates induce a low degree of supercooling 
(high nucleation temperature) larger ice crystal formation, lower Rp and shorter primary 
drying time (longer secondary drying). The decrease of nucleation temperature by 1 °C 
has been observed to increase primary drying by 3% (60). Therefore, the stochastic 
freezing is highly responsible for vial to vial variability during freeze-drying. 
To reduce the typical intra and inter batch variability and increase homogeneity of the 
freezing step, controlled nucleation can be employed. Controlled nucleation is a process 
that enables nucleation of the vials at the same time and temperature across the batch, 
resulting in a uniform starting point for ice crystals growth. Several technologies and 
methodologies are currently available to perform controlled nucleation during freeze-
drying (61).  




Finally, the optimal soak time at the minimum temperature can be selected considering 
the cake height (generally 1 h per cm) and evaluating the impact of total solute 
concentration. Higher total solute concentrations generally require longer times and lower 
temperatures for complete solidification (42). 
1.1.2.2 Primary drying 
 
Primary drying is the longest phase of the lyophilisation process, it is the step where the 
ice crystals formed during freezing are removed by sublimation. The critical process 
parameters in this step are shelf temperature and chamber pressure that will then define 
the product temperature (44, 62). Product temperature (Tp) is a critical parameter that has 
to be monitored to ensure the success of the manufacturing process (62-64). 
Conventionally, Tp should be maintained below critical temperatures of the product to 
prevent cake defects (e.g. collapse or melting). However, in some cases it has been 
observed that the use of aggressive conditions, resulting in a short-term increase in Tp 
above critical temperatures, does not negatively impact the cosmetic appearance and 
stability of the final product (65-68). Several Process Analytical Technology (PAT) tools 
can be used to monitor product temperature, however, the ones currently used in 
commercial manufacturing show some disadvantages (39, 63, 69).  
The sublimation occurring during primary drying is governed by heat and mass transfer 
events (Figure 1.8). 





Figure 1.8 Schematic illustration of heat and mass transfer processes occurring during sublimation. 
 
The heat transfer coefficient (Kv) is defined as the ratio of the area normalised heat flow 
to the temperature difference between heat source (shelf) and heat sink (product vial) 
(70). The overall Kv is given by the sum of three contributing factors: Kc which is the 
conductive heat transfer from the shelf to the vial, Kr which is the radiative heat transfer 
coefficient and Kg which is the gas convective heat transfer coefficient, given by the gas 
molecule located in the gap between shelf and the bottom of the vial and in the lyo 
chamber (Equation 1.1) (71).  
Equation 1.1: Kv contributors 
Kv= Kc + Kr + Kg                                   
Kg provides the largest contribution and it is highly influenced by chamber pressure, 
unlike the other two contributors (71). Kr is widely reported to cause an increase of the 
overall heat transfer for vials located at the edges, known as ‘edge effect’ (71, 72). Kv 
trends non-linearly as a function of chamber pressure and can vary from freeze-dryer to 
freeze-dryer due to differences in equipment type, configuration and size (39, 47, 73). 
The mass transfer is the mass of water vapour that will be transferred from the product to 
the lyo chamber during sublimation. Mass transfer is controlled by the equipment 
capacity, stoppers, processing conditions and product characteristics (74). During primary 




drying, the product receives heat from the shelf, part of which will be consumed by ice 
sublimation. During mass transfer, an important role is carried out by the Rp. Rp is the 
resistance of the product dry cake to the water vapour flow during sublimation (74). 
Hence, Rp generally increases non-linearly as primary drying proceeds until the ice is 
sublimed and the maximum dry layer thickness is achieved. Rp is strictly linked to the 
ice nucleation and crystal growth (60, 61) (Section 1.1.4.1) as well as the total solute 
concentration. Products having high total solute concentrations tend to have higher Rp 
values (74). Rp plays a key role in determining sublimation rate and product temperature, 
hence primary drying time (70).  
Considering the significant impact of primary drying time on the lyophilisation process 
duration, often the optimisation of the lyophilisation process is focused on reducing and 
optimising this step (75). End point of primary drying can be determined by using 
different methods. The two most common and simple methods include the identification 
of the points where: (1) the Pirani gauge reading matches the capacitance manometer 
(CM), and (2) the product temperature reaches the shelf temperature. The first method is 
generally more accurate and provides information on the end of primary drying for the 
overall batch rather than on the single vial. The Pirani gauge measures the thermal 
conductivity of the gas in the chamber. Considering that during primary drying the 
chamber contains 99% of water vapour, and the thermal conductivity of water vapour is 
1.6 times larger than that one of the nitrogen gas, the Pirani gauge reads higher pressure 
levels while sublimation is occurring. Towards the end of primary drying, when the last 
fractions of ice undergo sublimation, the gas composition in the chamber changes from 
water vapour to nitrogen, and the Pirani pressure decays as a function of time until it 
reaches the same pressure level as the CM (76). At the end of primary drying, the moisture 




content can vary from product to product, but for an amorphous product usually ranges 
between 5 to 20% (42).  
1.1.2.3 Secondary drying 
 
Secondary drying is the final step of the lyophilisation process where the unfrozen water 
is removed through desorption. This step involves increasing the shelf set point under 
vacuum to achieve optimal moisture levels (usually below 1-3%) in the product (49-51). 
High moisture levels can have a negative impact on product stability and storage. In 
amorphous materials, high moisture levels can lower the glass transition temperature 
(Tg), inducing excipient re-crystallisation and phase separation during the product storage 
over the shelf-life (77, 78). Tg is an important CQA parameter, it represents the 
temperature limit below which lyophilised amorphous products should be stored (36, 77, 
78). Many biopharmaceutical products having low Tg require low storage temperature 
conditions (2-8 °C). The necessity for cold chain during storage is a significant cost 
investment for pharmaceutical companies, which contribute to further increasing the costs 
of high value products (e.g. IgGs). High moisture levels can also increase the rate of 
chemical degradation of the protein. However, it has been observed that for some products 
an optimal moisture level is required, and a certain amount of bound water is preferred to 
preserve product stability (36, 79, 80).  
For amorphous products, it is important to select a Tshelf during secondary drying that 
assures a Tp below the Tg. Typically, amorphous products are more difficult to dry than 
crystalline products (42). Furthermore, crystalline products can withstand more drastic 
ramp rates and aggressive shelf temperatures during secondary drying. Usually, 
secondary drying times longer than 6 hours are not required. However, amorphous 
products having higher total solute concentrations may need extra secondary drying time 
(42).  




1.1.3 Primary packaging components 
 
Primary packaging components should be considered as intrinsic and critical elements of 
the lyophilised product (81). Changes in the primary packaging components can impact 
the manufacturing process and the stability of the lyophilised products. In particular, vials 
and rubber stoppers type, materials and treatments can impact the product CQAs. Type I 
glass vials are generally selected for parenteral protein products, and tubing vials are 
preferred over moulded vials (73). Tubing vials show less variability in the glass thickness 
which translates in more constant Kv values than moulded vials (73, 82). Therefore, the 
use of tubing vials can guarantee a less variable drying of the product during 
lyophilisation. Stopper rubber type, presence of silicone, sterilization and dryness can all 
affect the product stability (83-85). Extractable and leachable components (86), as well 
as moisture (83-85) release from the stoppers can compromise product stability and 
quality (81). The effect of stopper moisture and the dynamic of water exchange between 
stoppers and lyophilised products have been reported to significantly impact product 
stability (83-85).  
Currently, the majority of high concentration protein formulations are in a liquid format 
in vials or pre-filled syringes to facilitate the subcutaneous administration (87, 88). 
1.1.4 Scale-up and Technical transfer 
 
The lyophilisation process transfer or scale-up between different freeze-dryers represents 
a significant challenge for pharmaceutical companies. In some cases, differences due to 
geometry (e.g. horizontal vs vertical condenser) or size (e.g. pilot vs commercial scale) 
of the equipment in use can drastically impact the lyophilisation process dynamics, 
increasing the risk of batch failure during transfer or scale-up (47, 48, 60, 89, 90).  For 
this reason, it is good practice to collect information on the heat and mass transfer 




performance relative to the specific equipment (60, 90). In particular, Kv, maximum 
sublimation rate and minimum controllable pressure studies are useful tests that can be 
performed to characterise the equipment, de-risking the technical transfer process. This 
information in combination with QbD approaches can facilitate the process transfer, 
reducing the number of lyophilisation cycles required to build confidence and to address 
data driven decisions for a successful lyophilisation process optimisation. If differences 
in the equipment performance are identified during transfer, operation conditions can be 
modified accordingly to provide a process that provides products with equivalent CQAs. 
Finally, the use of QbD approaches enables the establishment of proven acceptable ranges 
and ensures robustness of the lyophilisation process when variations in the Critical 
Process Parameters (CPPs) occur (deviations) within certain limits.  
1.1.5 Quality by Design in lyophilisation 
 
The term QbD is defined by ICH Q8 as “a systematic approach to development that 
begins with predefined objectives and emphasizes product and process understanding 
and process control based on sound science and quality risk management”. QbD aims to 
achieve the quality of the product by applying a scientific approach where the design 
space is the key element. As per ICH Q8 guidelines, “a design space is the 
multidimensional combination of input variables and process parameters that have been 
demonstrated to provide assurance of quality”. This scientific approach allows 
evaluation of the impact of CPPs on the CQAs of the product, minimising the use of trial 
and error approaches. When a robust design space is built the change of CPPs within a 
proven acceptable range will not negatively impact the product CQAs. During 
lyophilisation process design, the use of QbD is generally applied to the primary drying 
step prediction and optimisation (48, 72, 89, 91-93). Pikal et al. developed a mathematical 
model based on the heat and mass transfer, which allows estimation of Tp and end point 




of the primary drying, accounting for the sublimation flow of the specific product (72). 
This modelling tool aids to select optimal lyo-cycle conditions, while operating safely 
below the critical temperature of the formulation. This approach can also provide the user 
with information regarding the robustness of the cycle performance, which enables 
investigation into the potential effect of process deviations on product quality. However, 
the key element for the success of the prediction is the capability to insert correct input 
parameters (75, 94) 
The input parameters required for development of the design space are reported in 
Appendix, Table A3 and Table A4. Input parameters include mainly formulation and 
container information, Kv and Rp data. Kv and Rp data can be estimated or 
experimentally calculated with the aid of several PAT tools (Section 1.1.6). The most 
common method used to calculate Kv is the gravimetric method (95). Rp can be 
determined by the use of Manometric Temperature Measurement (MTM), or by using 
experimental Tp information obtained from a conservative lyo-cycle where Tp is 
maintained below the formulation critical temperature (74). Performing primary drying 
above the collapse temperature is known to increase Rp due to an increase in viscosity of 
the product and the occurrence of micro-collapse (74, 96). Rp data for some standard 
formulations is available in a general database and can be used in a preliminary stage to 
estimate Rp when product temperature data is not available (94).  
Statistical uncertainty and variability in the Kv and Rp parameters estimation should be 
considered in the building of the design space. For instance, the Kv distribution due to 
differences in the heat transfer of vials located at different positions on the shelf can be a 
significant source of bias, compromising the accuracy of the prediction (93). The model 
and building of a design space have a relevant impact on the development of 
lyophilisation processes for products that cannot withstand aggressive process conditions, 




but less impact on products that can be dried above their critical temperatures. Hence, it 
is advisable to understand the effect of micro or macro collapse on the other product 
CQAs to optimise the process time, avoiding product defects or excessively long primary 
drying steps. Chapter 4 reports the equations required for estimation of Kv, Rp and 
primary drying time.  
Regarding the freezing step, a novel mechanistic model has been proposed to predict the 
ice crystals size distribution during freezing of lyophilised formulations (97). Finally, in 
2013, Sahni and Pikal proposed a modelling approach for the prediction of desorption 
during secondary drying (98). The possibility to model the overall lyophilisation process 
(not only primary drying) would have a relevant impact for lyophilisation scientists 
engaged in the development of lyophilisation cycles.  
1.1.6 Process Analytical Technology Tools  
 
Process analytical technology (PAT) has been defined by the United States Food and 
Drug Administration (FDA) as ‘a mechanism to design, analyse and control 
pharmaceutical manufacturing processes through the measurement of Critical Process 
Parameters (CPP) which affect Critical Quality Attributes (CQA).’ Several PAT tools 
can be used to monitor the lyophilisation process. 
CPPs are ‘process parameters whose variability has an impact on a CQA and therefore 
should be monitored or controlled to insure the process produces the desired quality’ 
(39). During the lyophilisation process, chamber pressure and shelf temperature are the 
main operating process parameters which define the resulting Tp (62). Several PAT tools 
have been used to monitor the lyophilisation process, particularly over the primary drying 
step. Some examples of PAT tools reported in literature are listed in Table 1.2. 




Table 1.2 Summary of the PAT tools used to monitor critical process parameters during the primary 
drying step of the lyophilisation process. 
Critical process parameter 
monitored 
PAT tool Target References 
Chamber pressure (end of 
primary drying) 
Capacitance Manometer Batch (39, 63, 69) 
Pirani gauge (thermal conductivity 
type gauge) 
Batch (39, 63, 69) 
Mass spectrometry Batch (63) 
Product temperature (Kv, Rp, end 




(39, 63, 69) 




(39, 63, 69) 




(39, 63, 64, 
69) 
Pressure rise test (PRT) Batch (63) 
Manometric temperature 
measurement (MTM) 





Infrared Thermography Batch (101) 





Valvless monitoring system (VMS) Batch (39) 
Temperature measurement by 
sublimation rate (TMbySR) 
Batch (39) 




Mass vapour flow rate (Kv, Rp) 
Tunable Diode Laser Absorption 
Spectroscopy (TDLAS) 
Batch (39, 63, 69) 
Heat flux sensors Batch (63) 
 
Primary drying is the longest and most critical phase of the lyophilisation process.  
Therefore, the majority of the existing PAT tools are designed to monitor parameters 
related to this step. In contrast, a small number of PAT tools are available to monitor 
freezing or desorption over the secondary drying step. Some of these PAT tools can be 
used to monitor more than one step. For instance, Through Vial Impedance Spectroscopy 
(TVIS) (105) or infrared camera (106) are two novel technologies which can both be 
employed in the monitoring of the freezing step as well as primary drying in pilot scale 
freeze-dryers. Additionally, the use of Raman spectroscopy has been proposed as a novel 
alternative and non-destructive technique to monitor in-line the freezing step (104) and 
off-line the protein product stability after lyophilisation (107). During the secondary 
drying step, a vial headspace moisture/pressure analyser can be used in-line and off-line 




as a non-destructive technique to monitor container closure integrity and moisture in the 
vial headspace allowing moisture shelf mapping (Chapter 5) (108, 109). Fissore et al. 
proposed the use of an in-line system for monitoring of the secondary drying step. This 
tool couples mathematical models and solvent desorption rate, that is determined by 
measuring the vapour flux in the drying chamber (49).  
The advantage of the use of PAT tools is the possibility to monitor and control the process, 
reducing the risk of batch failure and ensuring final product quality (69). However, some 
disadvantages should be considered: a) difficulties during the PAT tool implementation 
related to scale-up or technical transfer, b) interference of the PAT tool with the monitored 
system, c) use of single vial vs batch monitoring systems and d) use of in-line vs off-line 
tools. An example is provided by the temperature monitoring systems used to measure 
Tp over the lyophilisation process. The most common temperature monitoring tool is the 
thermocouple that provides single vial measurement and is an invasive system. Once 
placed in the vials, thermocouples induce a change in the dynamics of the freezing and 
drying steps, generating bias in the measurement (63, 64). Invasive temperature 
monitoring systems can act as sites of nucleation, inducing lower degree of supercooling, 
larger ice crystals formation and faster primary drying in probed vials relative to the un-
probed vials (63, 64). Additionally, the design of thermocouples used in manufacturing 
and pilot scale equipment can vary impacting the Tp output information (63, 64). 




1.1.7 Product Critical Quality Attributes 
 
Product critical quality attributes (CQA) are defined as a ‘physical, chemical, biological, 
or microbiological property or characteristic that should be within an appropriate limit, 
range, or distribution to ensure the desired product quality’ (39). 
The product CQAs are tested to ensure the quality of lyophilised biopharmaceutical 
products which can vary depending on the product and its manufacturing process. As 
reported in the ICH Q6B - Test Procedures and Acceptance Criteria for 
Biotechnological/Biological Product "Selection of tests to be included in the 
specifications is product specific. Acceptance criteria should be established and justified 
based on data obtained from lots used in preclinical and/or clinical studies, data from 
lots used for demonstration of manufacturing consistency, and data from stability studies, 
and relevant development data’’(110). Product CQAs commonly tested for lyophilised 
drug products are reported in Table 1.3 (110). 






Volume in the container 
Uniformity of dosage units 
Moisture content/ Loss on drying 
Reconstitution time 
Appearance of the lyophilised product 
Appearance of the reconstituted solution 
Identity 
(physicochemical, biological, immunochemical) 
Purity and Impurities 
Potency (physicochemical and biological) 
Quantity 
General testing (e,g. pH, osmolarity) 
Required in some cases 
Additional testing for unique dosage forms 




1.2 Thesis hypothesis 
 
Pre-formulation and formulation development studies, combined with 
statistical/mathematical and QbD tools, can enable rational formulation design to achieve 
optimum protein stability and reduced lyophilisation times for high concentration 
antibody (IgG1) formulations.  
1.2.1 Aim 
 
The aim of this study is to develop a stable lyophilised high concentration IgG1 
formulation intended for subcutaneous use, rending formulation and process development 
more cost effective for pharmaceutical companies and the administration more patient 
compliant. In particular, this work focuses on building new knowledge in the formulation 
and manufacturing process design for high concentration protein formulations. 
1.2.2 Primary objectives 
 
A number of objectives were identified: 
• To compile a systematic quantitative review, analysing formulation strategies of 
commercial parenteral protein formulations in the liquid and lyophilised formats, 
approved in Europe (European Medicine Agency, EMA) between 1995-2018. 
(Chapter 2) 
• To develop an empirical model (based on a DOE) for selection of formulations with 
maximised critical temperatures to facilitate lyophilisation process optimisation. 
(Chapter 3).  
• To optimise the lyophilisation process (reducing time and costs) with the aid of 
different PAT tools for product temperature determination and QbD tools for primary 
drying prediction. (Chapter 4) 




• To analyse the physical/solid state characteristics of the high concentration protein 
formulations designed (Chapter 3) and lyophilised (Chapter 4) over stability at 
different storage temperature conditions, with the aim of eliminating cold chain 
during storage. (Chapter 5). 
• To analyse biophysical stability pre and post lyophilisation of the high concentration 
antibody formulations designed (Chapter 3) and lyophilised (Chapter 4) at different 
storage temperature conditions, with the aim of eliminating cold chain during 
storage. (Chapter 6) 
• To summarise overall findings and to evaluate how this body of work contributes to 
improve current knowledge on the topic. Recommendations for future work are also 
included in this chapter. (Chapter 7) 








Chapter 2: Parenteral protein formulations: An 
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The focus of parenteral protein formulation design is to identify an excipient composition 
that will stabilise proteins against stresses experienced during processing, storage, and 
administration. Excipients also aid reconstitution of lyophilised formulations, maintain 
sterility of multi-dose products, provide isotonicity, and in a small number of cases alter 
pharmacokinetics (111, 112). The majority of parenteral protein formulations consist of 
proteins and excipients in an aqueous-based solution or suspension. Processing conditions 
and external factors such as shifts in pH, changes in temperature, surface interactions and 
extraneous impurities can destabilise proteins, provoking their chemical and physical 
structural degradation (113, 114). In some cases, aqueous formulations of therapeutic 
proteins do not provide adequate stability and therefore, a dried state formulation is a 
favoured, alternative approach which can aid the stability and prolong the shelf-life of 
protein products (115). Lyophilisation, the process of subliming water from frozen 
solutions under low pressure (vacuum), is a widely employed technique for the 
manufacture of dried biological materials (116). However, lyophilisation has the potential 
to cause protein damage due to stresses during both the freezing and drying phases (24, 
113). Hence, an appropriate excipient composition is required to protect proteins from 
stresses experienced during the lyophilisation process.  
The function and behaviour of excipients in protein formulations is widely reported (28, 
117-122). Despite the wide range of formulation information available, it can be 
challenging for a formulation scientist to get an overview of how frequently excipients 
are included in commercial protein products. For example, prior publications focus on the 
function of excipients and provide a range of products as examples of their application. 
What differentiates this overview from previous work is that it builds on earlier literature 
and provides up to date, comprehensive information of the frequency of excipients usage 





in approved protein products. It also presents an analysis of the quantitative excipient 
composition in the majority of the commercial protein products. The compilation of such 
information creates a valuable source for formulation scientists regarding the regulatory 
acceptance of excipients and their prior history in commercial formulations.  
Approval of therapeutic protein products for use within the European Union is via a 
centralised procedure (123). The European Medicines Agency (EMA) publishes a 
European Public Assessment Report (EPAR) for every medicine assessed (approved or 
refused), providing the public with information regarding the product. The EPAR is not 
a single document but a resource containing a set of regulatory documents related to 
authorisation details, product information and assessment history. The EPAR is one of 
the most informative and up to date public sources of information on a large number of 
commercial therapeutic proteins. The overview presented is a summary of the wealth of 
the formulation data available in the EPARs in relation to approved parenteral protein 
formulations. Specifically, data was gathered and analysed to provide a breakdown of 
products according to protein type, formulation approach (aqueous-based liquid or 
lyophilised formulations), the most frequently included excipients classified in functional 
categories, with a more detailed look at antibody formulations.  
In reviewing EPARs’ data, the split of protein formulations between the liquid and dried 
(lyophilised) state was investigated and the types of excipients incorporated in both 
formulation approaches (liquid or lyophilised) are discussed. Qualitative and quantitative 
composition of protein formulations can be influenced by the process selected for 
manufacturing products in a certain dosage form (liquid or lyophilised). The overview 
provides details of the excipient concentrations employed in approved protein products 
in the European Union (EMA). Due to the limited data related to the excipient quantitative 
composition in the EPARs, this information has been supplemented by using FDA 





sources (124) and product information documents published by the Marketing 
Authorisation Holder (125). The excipient quantitative composition is provided for 215 
out of 264 protein products and 88 out of 94 antibody products approved in the European 
Union.  
The final part of the overview focuses specifically on monoclonal antibody (Mab) 
products, since Mabs are currently the largest class of therapeutic proteins (1, 3, 5, 14). 
Mab doses required for the treatment of chronic diseases are relatively high (usually 50–
200 mg) compared to the majority of the other therapeutic proteins (126). Intravenous 
infusion administration is mostly used for the delivery of a number of these products. 
However, an alternate treatment approach is to formulate Mabs at high concentrations to 
enable administration of the required dose in smaller volumes (1–2 mL) subcutaneously. 
The selection of the appropriate excipient composition is required to address challenges 
when designing high concentration protein formulations (14, 127). 
2.2 Methodology 
 
A review of the EPARs available on the EMA website was conducted for all parenteral 
protein products authorised centrally in the European Union between 1995 and 2018 (up 
to June 2018) (126). For each of these products, the following information was collected: 
commercial name, active pharmaceutical ingredient (API) and related quantitative 
composition, class of therapeutic protein, therapeutic area, dosage form, route of 
administration, excipient composition, date of issue of marketing authorisation and 
marketing authorisation holder (pharmaceutical company). Information was compiled in 
a Microsoft Excel database (included in supplementary information). The accuracy of 
data transferred to the data base was assured by two researchers checking 100% of the 
data entries against the EPARs.  





Formulations were divided into two groups: liquid (L) and lyophilised (LYO), based on 
their manufacturing process detailed in the EPARs. Commercial products having the 
same name but different excipient composition, different formulation approaches (e.g. 
liquid versus lyophilised) or a different liquid formulations’ format (e.g. concentrate, 
solution or suspension) were considered as distinct products in this overview.  
All excipients were categorised considering their potential roles in protein formulations 
and were assigned to one of seven functional categories. In the case of multifunctional 
excipients, they were listed in one category but referred to in the discussion under all 
relevant categories. Excipients can possess diverse roles when added at different 
concentrations or to different formulation approaches. This multifunctional nature of 
excipients influenced their classification in this publication. For example, amino-acids 
were designated as a single category with a range of functions (buffers, stabilisers, bulking 
agents). Non-amino acids stabilisers/bulking agents category comprise excipients (mainly 
carbohydrates) that in the liquid dosage form serve as stabilisers. However, some of these 
excipients in the lyophilised dosage form, have the potential to act also as bulking agents. 
Furthermore, as formulation data does not specify the excipients’ solid form (amorphous 
or crystalline) it was not possible to separate the stabilising and bulking functions of some 
excipients (amino acids and carbohydrates) in lyophilised formulations. Therefore, the 
following seven categories were designated (1) non-amino acids buffers (2) amino acids 
buffers/stabilisers/bulking agents; (3) non-amino acids stabilisers/bulking agents; (4) 
surfactants; (5) preservatives; (6) tonicifiers and (7) other excipients.  
The ‘other excipients’ category consisted of excipients present in a relatively low number 
of products, this included complexing agents, antioxidants, solubilising agents and 
excipients exclusively present in specific types of formulations, for example zinc salts in 
insulin products. The hypothesis and assumptions regarding the role of these excipients 





in a specific product were stated only in presence of available information (124, 126, 128, 
129) or individual specific references which are detailed in Section 2.3.2.8.  
The analysis of the percentage and frequency at which individual excipients were 
included in the products was conducted using IBM SPSS Statistics v.23 software. 
Percentage of products containing a specific excipient or excipient category is calculated 
as percentage within the type of dosage form (liquid or lyophilised).  
Quantitative composition of protein products is also reported in this overview as a 
guideline for the range of protein and excipients concentrations employed in marketed 
formulations. This information was gathered from accredited sources: FDA label (FDA) 
(124) and product information document (Marketing Authorisation Holder) (125), when 
data was not provided in the EPAR’s scientific discussion (Assessment history, EMA) 
(130). These primary information sources are dynamic databases; hence this overview is 
a snapshot of the marketed products information available in the specific timeframe. 
Furthermore, to guarantee accuracy of the dataset, only information that could be verified 
against the primary sources was included in this overview. Again, the accuracy of data 
transferred was assured by two researchers checking 100% of the products’ information 
against these sources. It is important to note that information listed in this overview relates 
only to products approved by the EMA. Other formulations with the same product name 
may be approved in other jurisdictions, for example, products with different strengths or 
excipient compositions.  
Analysis of monoclonal antibody products was also conducted to show the relationship 
between concentration of protein administered and route of delivery. 
  





2.3 Results and Discussion 
 
2.3.1 Approved protein formulations 
 
EPAR data showed that approximately 440 parenteral products were approved by the 
EMA via its centralised procedure in the period 1995–2018 (June). More than half of 
these products (n=264) contained therapeutic proteins and a greater number of them were 
formulated as liquid dosage forms (66%; n=174), compared to lyophilised forms (34%; 
n=90). Figure 2.1 shows that the number of liquid parenteral protein formulations is 
consistently higher than the number of lyophilised formulations approved in the 
timeframe studied. Since 2013, approximately 20 parenteral protein products have been 
approved per year.  
 
Figure 2.1 Trend of liquid and lyophilised parenteral protein products approved per year by the 
EMA between 1995 and 2018 (June) (*Last updated: 18/06/ 2018). 
 
Therapeutic proteins included in liquid and lyophilised products, were divided into their 
functional classes, Figure 2.2a and Figure 2.2b. Antibodies (36%; n=94) and hormones 





(27%; n=71), represent the two main classes, and are more commonly formulated as 
liquid formulations (antibodies: n=69 and hormones: n=61) compared to lyophilised 
formulations (antibodies: n=25 and hormones: n=10). Insulin and its analogues are the 
most frequent therapeutics in the class of hormone products (n=26 out of 61), and they 
are formulated exclusively as liquid dosage forms (solutions for infusion or injection, and 
suspensions for injection). In contrast, coagulation factors are manufactured only as 
lyophilised formulations (n=24) and represent the second largest class of therapeutic 
proteins in this dosage form following antibodies.







Figure 2.2 Classes of therapeutic proteins included in liquid and lyophilised parenteral products. (a) 
Pie chart of the total number of products; (b) Pie charts showing the split between liquid and 
lyophilised products. *‘Other’ class includes types of therapeutic proteins present in a percentage of 
commercial products <3% (analgesic peptide, antiangiogenic agent, anticoagulant, antiplatelet, 









2.3.2 Excipients included in approved protein formulations 
 
2.3.2.1 Excipient categories 
 
Excipients were subdivided into seven categories: non-amino acids buffers; amino-acids 
buffers/stabilisers/bulking agents; non-amino acids stabilisers/bulking agents; 
surfactants; preservatives; tonicifiers and other excipients as detailed in Section 2.2. The 
percentages of liquid and lyophilised products containing excipients which fall into each 
of these categories are shown in Figure 2.3. 
 
Figure 2.3 The percentage of liquid and lyophilised parenteral protein products that contain 
excipients from each of the excipient categories: Non-amino acids BUFF (buffers); Amino acids 
BUFF/S/BA (buffers/stabilisers/bulking agents); Non-amino acids S/BA (stabilisers/bulking agents); 
Surfactants; Preservatives; Tonicifiers and Other excipients. Note: The function of these excipients as 
bulking agents is only relevant for lyophilised products *‘Other excipients’ category consists of complexing 
agents, antioxidants, solubilising agents and excipients specific to individual formulations. 
 
Most categories of excipients are frequently employed in both liquid and lyophilised 
products, whereas others, such as preservatives, are more specific to one formulation 
approach (e.g. multi-dose liquid formulations).  
The majority of the formulations: liquid (70%; n=122) and lyophilised (61%; n=55) 
contain non-amino acids buffers. However, amino acids are present in a large number of 





products (L: 39%; n=68; LYO: 51%; n=46) and can have different functions as buffering 
agents or stabilisers/bulking agents depending on the concentration incorporated. A small 
number of products are formulated in the absence of buffering agents. This may be due 
to the ability of the protein to maintain the critical pH, especially if formulated at high 
concentrations (e.g. FLEBOGAMMA DIF® (human normal immunoglobulin)) (131).  
Non-amino acids stabilisers are present in a large number of liquid products (64%, 
n=111). Excipients included in the non-amino acids’ stabilisers/bulking agents’ category 
are also incorporated in most of the lyophilised products (93%, n=84). Surfactants are 
present in a similar percentage of liquid (65%; n=113) and lyophilised (62%; n=56) 
formulations. Preservatives are included in liquid (29%, n=50) and lyophilised (6%, n=5) 
products. As expected, all multi-dose products (n=53) contain preservatives. Multi-dose 
products comprise 20% of all products (liquid and lyophilised) and are more commonly 
formulated in the liquid dosage form (n=48). All lyophilised formulations intended for 
multiple use contain preservatives in the diluent for reconstitution and none in the 
lyophilised product. The reason for including preservatives directly in the diluent for 
reconstitution is to minimise any possible preservative-protein interactions (114, 132). 
Antibodies are exclusively formulated in a single dosage form, whereas insulin in a 
multiple dosage form. Tonicifiers are incorporated in a high percentage of both liquid 
(36%; n=62) and lyophilised (42%; n=38) formulations to achieve the iso-osmolarity 
recommendations for parenteral administration (133-135). Excipient classified in the 
‘other excipients’ category was present in a similar percentage of liquid (27%; n=47) and 
lyophilised (22%; n=20) products.  
Table 2.1 summarises the most common excipients included in liquid and lyophilised 
products for each functional category. This table also shows the concentration ranges 





employed for each of these excipients in the liquid and lyophilised protein products 
analysed.  
 





Table 2.1 More common individual excipients classified into functional categories and listed by 
descending frequency of use in liquid and lyophilised parenteral protein products (percentage and 
number of formulations containing each excipient and range of excipient concentrations included in 
approved products). 
Excipient class Liquid Lyophilised 
Non-amino acids 
Buffering agents 
Sodium phosphate (33%; 
n=58) 
(0.2-14.8 mg/mL) 
Sodium phosphate (32%; 
n=29) 
(0.2-14.4 mg/mL) 
Sodium acetate (19%; 
n=33) 
(0.4-6.8 mg/mL) 
Sodium citrate (20%; n=18) 
(1.1-34.8 mg/mL) 
Sodium citrate (17%; n=29) 
(0.5-14.7 mg/mL) 





Histidine (16%, n=27) 
(0.9-4.3 mg/mL) 
Histidine (34%; n=31) 
(0.7-8.9 mg/mL) 
Methionine (12%; n=21) 
(0.1-3 mg/mL) 
Glycine (13%; n=12) 
(0.2-25 mg/mL) 
Glycine (9%; n=15) 
(0.1-18.8 mg/mL) 
Methionine (6%; n=5) 
(0.06-0.5 mg/mL) 
Arginine (8%; n=14) 
(4.4-42.1 mg/mL) 




Glycerol (17%; n=29) 
(16-20 mg/mL) 
Sucrose (59%; n=53) 
(1.9-160 mg/mL) 
Sucrose (16%; n=28) 
(10-200 mg/mL) 
Mannitol (33%; n=30) 
(10.6-80 mg/mL) 
Mannitol (14%; n=24) 
(1.9-54.6 mg/mL) 
Trehalose (10%; n=9) 
(8-70 mg/mL) 
Sorbitol (10%; n=17) 
(20-50 mg/mL) 
Human albumin (7%; n=6) 
(8-15 mg/mL) 
Surfactants 
Polysorbate 80 (32%; 
n=55) 
(0.01-2 mg/mL) 
Polysorbate 80 (41%; n=37) 
(0.05-0.7 mg/mL) 
Polysorbate 20 (26%; 
n=45) 
(0.01-2 mg/mL) 
Polysorbate 20 (18%; n=16) 
(0.04-0.4 mg/mL) 
Poloxamer 188 (7%; n=12) 
(0.1-8 mg/mL) 
Poloxamer 188 (3%; n=3) 
(1-1.2 mg/mL) 
Preservatives* 
Metacresol (19%; n=33) 
(1.5-3.2 mg/mL) 
Benzyl alcohol (4%; n=4) 
(9-14.9 mg/mL) 
Phenol (14%; n=24) 
(0.8-5.7 mg/mL) 
Benzalkonium chloride (1%; 
n=1) 
Benzyl alcohol (3%; n=6) 
(9-10 mg/mL) 
Metacresol (1%; n=1) 
(3.2 mg/mL) 
Tonicifiers 
Sodium chloride (36%; 
n=62) 
(0.6-11.7 mg/mL) 
Sodium chloride (42%; n=38) 
(0.3-27 mg/mL) 




*Preservatives in lyophilised products are added to the diluent for reconstitution 
Note: the function of these excipients as bulking agents is only relevant for lyophilised products 





Non-amino acids buffers are usually included in a range of concentrations between 0.2 
and 14.8 mg/mL (usual ionic strength: 5–25 mM). However, ATRYN® (antithrombin 
alfa) contains sodium citrate at a higher concentration of 135 mM (34.8 mg/mL). Amino 
acids can have different functions; hence, they can be used in a wide range of 
concentrations (0.1 and 52 mg/mL) within the formulations. The usual range of 
concentrations at which amino acids are employed is between 0.1 and 25 mg/mL, with an 
ionic strength of 5–260 mM. However, arginine is added in higher concentrations 
compared to other amino acids, acting mainly as a stabiliser. For example, METALYSE® 
(tenecteplase) contains arginine at a concentration of 52 mg/mL to increase the solubility 
of the protein, as reported in the product EPAR’s scientific discussion (136). Histidine at 
low concentrations between 0.7 and 8.9 mg/mL is included in the majority of the products, 
serving mainly as a buffer. Histidine and arginine are frequently used in their 
hydrochloride salt form in protein products. Glycine is often employed as a 
stabiliser/bulking agent besides its role as a buffering agent at concentrations between 0.1 
and 25 mg/mL, whereas methionine at low concentrations (0.06–3 mg/mL) is usually 
selected for its antioxidant properties. Non-amino acids stabilisers and bulking agents are 
incorporated at concentrations up to 200 mg/mL to maintain the required molar ratio with 
the protein. Surfactants are generally present in a different range of concentrations in 
liquid (0.01–2 mg/mL) and lyophilised (0.04–1.2 mg/mL) products. However, the liquid 
formulation ORENCIA® (abatacept), with a high concentration of the fusion protein (125 
mg/mL), contains 8 mg/mL of Poloxamer 188. Preservatives are employed in 
concentrations between 0.7 and 14.9 mg/mL. Sodium chloride and potassium chloride are 
included as tonicifiers and/or stabilisers in a variable range of concentrations between 0.2 
and 27 mg/mL.  





The following sections provide greater details and discussions regarding individual 
excipients divided into each functional category. 
2.3.2.2 Non-amino acids buffers 
 
Buffers are required to adjust and maintain the pH to a value at which the specific protein 
has maximal stability. The optimum pH value is selected considering the protein’s 
isoelectric point (pI) as a critical physical parameter that can affect protein solubility, 
aggregation and degradation (137). Furthermore, the selected pH needs to be in a 
physiological range (pH6-7.4) in order to avoid irritation, pain or extravasation during 
injection into the patients. For intramuscular and subcutaneous administration the 
acceptable pH range is between pH 4 and 9 (138). Of the protein products where pH is 
reported, the values range from pH 3.1 for JETREA® (ocriplasmin) to pH 8.15 for 
XULTOPHY® (insulin degludec), which are respectively administered through 
intravitreal and subcutaneous routes.  
The percentage of approved liquid and lyophilised parenteral products containing non-
amino acids buffers are shown in Figure 2.4.  






Figure 2.4 The percentage of approved liquid and lyophilised parenteral protein products containing 
individual non-amino acids buffers. 
 
The most common buffers (excluding amino acids) employed in liquid protein 
formulations are sodium phosphate (33%; n=58), sodium acetate (19%; n=33) and sodium 
citrate (17%; n=29). Sodium phosphate (32%, n=29), and sodium citrate (20%; n=18) are 
also frequently added to lyophilised protein products (120). However, acetate buffer was 
found not to be incorporated in any lyophilised products identified as part of this 
overview. Acetic  acid is volatile and can be converted to a gaseous state and hence be 
lost from the formulation during lyophilisation (139, 140). Sodium phosphate buffers 
employed in commercial products are usually composed of two salt forms: sodium 
dihydrogen monohydrate and disodium dihydrate. The different sodium phosphate 
components were grouped together under the name of sodium phosphate in this overview.  
Despite their wide use as buffers, sodium phosphate salts present some drawbacks, 
especially when included in formulations intended to be lyophilised. Highly concentrated 
buffer systems can crystallize and provoke changes in pH during freezing (139). Sodium 





phosphate is prone to crystallize during freezing, leading to a pH shift of up to four units. 
Furthermore, sodium phosphate crystallisation and precipitation are severely influenced 
by salt components solubility and concentration, temperature, cooling rate, volume of 
solution and initial pH value (25, 141). The presence of other compounds can influence 
buffer crystallisation, precipitation and consequently cause pH shifts which can accelerate 
drug degradation in frozen solutions. For example, crystallizable solutes, such as glycine, 
mannitol or sodium chloride can modify ion activity, facilitating crystallisation of buffers; 
while non-crystallizable excipients such as sucrose or trehalose can inhibit buffer 
crystallisation (139). The citrate salts remain in an amorphous state upon freezing and 
drying, minimizing pH shifts, compared to succinates and tartrates (131, 142).  
A concept that should also be taken into account during pre-formulation studies is that 
the pH of the solution before drying has an influence on the rate of chemical reactivity in 
the resulting dried material (142). In lyophilised formulations, buffers tend to depress 
critical temperatures for the lyophilisation process; glass transition of the maximally 
freeze-concentrated solution (Tg’) and collapse temperature (Tc). However, buffering 
agents are usually used in low concentrations (5–25 mM) (143). TRIS buffer which is 
included in a small number of liquid (3%; n=6) and lyophilised (8%; n=7) formulations 
has been shown to release formaldehyde in peptide formulations stored at 70°C. However, 
this does not occur at the lower temperatures normally employed for formulation 
processing or storage (142).  
Individual acids and bases can also be incorporated as pH modifiers to adjust the pH to a 
target value. Sodium hydroxide (L: 46%; n=80; LYO: 20%; n=18), hydrochloric acid (L: 
36%; n=62; LYO: 11%; n=10) and phosphoric acid (L: 3%; n=5; LYO: 6%; n=5) are 
frequently added to liquid and lyophilised formulations, to modify their pH to a desired 
value and/or to create a salt form in combination with other buffer components.  





Key considerations: The choice of the optimal buffer system for a specific formulation 
needs to be conducted by performing compatibility studies between the excipient and the 
specific protein. However, some general rules need to be considered, especially for 
lyophilised protein products. Salts that can provoke significant pH shifts during freezing 
should be used with caution (e.g. sodium phosphate, sodium acetate). Despite reported 
disadvantages, sodium phosphate is present in a high number of liquid and lyophilised 
products. Most of the commercial lyophilised products contain amino acids (histidine) or 
salts with low pH shift tendency (sodium citrate) as buffer systems. The absence of buffers 
in protein formulations can be considered when this does not negatively impact the quality 
and stability of the product. 
2.3.2.3 Amino acids buffers/stabilisers/bulking agents 
 
Amino acids play several roles in parenteral protein formulations as buffers, stabilisers or 
bulking agents. They can influence tonicity of the formulation and some have antioxidant 
properties (144-147). The solid state (amorphous or crystalline) and concentration of an 
amino acid can determine its role in a specific product. Amino acids use as excipients in 
biopharmaceutical products has increased in recent years, due to their multi-functionality 
(108 products (2007–2018, June) vs 54 products (1995–2007) contain amino acids). 
Amino acids tend to stabilise proteins by hydration or direct interactions (145). However, 
the mechanism of interaction between the different amino acids with proteins is 
complicated and not always completely understood. Furthermore, amino acids have a 
complex chemistry (acidic or basic, multiple functional groups) and can be included in 
formulation as different salt forms; all these factors can further impact the type of protein-
amino acid interactions. Most of the amino acids are included in formulations in their salt 
form, in order to increase their solubility. The effect of the counter ion, can also impact 
the stability of the protein (148).  





As shown in Figure 2.5 the most commonly employed amino acids in liquid and 
lyophilised commercial products are histidine (L: 16%; n=27; LYO: 34%; n=31), 
methionine (L: 12%; n=21; LYO: 6%; n=5) and glycine (L: 9%; n=15; LYO: 13%; n=12), 
followed by arginine (L: 8%; n=14; LYO: 4%; n=4).  
 
Figure 2.5 The percentage of approved liquid and lyophilised parenteral protein products containing 
individual amino acids buffers/stabilisers/bulking agents. Note: The function of these excipients as 
bulking agents is only relevant for lyophilised products. 
 
Histidine as a buffer is reported to provide maximal stability (149), provoking minimal 
pH shifts during freezing (40). Histidine, is a multi-functional excipient, capable in some 
cases of reducing protein aggregation and functioning as cryo/lyo-protectant during the 
lyophilisation process in addition to acting as a buffer (150, 151). Al-Hussein et al. 
revealed how the role of histidine as a stabiliser was particularly important when 
formulated in combination with sugars and when maintained in the amorphous state 
(146). The concentration at which the excipient is used in different formulations 
determine its main role, i.e. as a stabiliser/bulking agent when present in high 
concentrations or as a buffer in low concentrations. Furthermore, histidine has antioxidant 





properties, it can act as scavenger of hydroxy radicals in solution (144, 145). Methionine 
is present in a high number of liquid and lyophilised products; this excipient can be 
selected for its antioxidant properties (20, 145). Methionine is added to commercial 
products often in combination with other amino acids (e.g. histidine or arginine). Glycine 
is present in lyophilised products where it can act as a bulking agent, in addition to its 
potential buffering properties in liquid and lyophilised formulations (145).  
The capability of positively charged amino acids to particularly enhance the stability of 
protein formulations and suppress aggregation is reported (152). Arginine is present in a 
relatively low number of products. However, its trend of use has increased between 2014 
and 2018. Amongst the 18 products containing arginine, 10 were approved since 2014. 
Arginine and its salt forms have been shown to be capable of reducing protein 
aggregation, increasing protein solubility and reducing viscosity of protein solutions in 
some cases (145, 153, 154). This effect is particularly important when formulating 
proteins at high concentrations. However, the mechanism of interaction between arginine 
and proteins is not completely understood. Trout et al. (155-157) proposed a hypothesis 
according to which arginine molecules self-associate in clusters. These amino acidic 
clusters create weak hydrophobic interactions (hydrogen, electrostatic, cation- or Van der 
Waals) with guanidinium and aromatic groups of the protein, crowding out protein–
protein interactions and avoiding aggregates formation. Furthermore, arginine and 
glutamic acid mixtures are shown to have a synergistic effect in increasing the solubility 
of proteins; this is due to the formation of additional hydrogen bonds with the protein in 
the presence of both excipients (158).  
Other amino acids such as alanine, isoleucine, leucine, lysine, phenylalanine, proline, 
threonine and valine are added to a small number of commercial products; they can 
contribute to the stability of the protein in formulation through specific interactions (20, 





145). Arginine, histidine and lysine are reported to be amorphous in the solid state, while 
all the other amino acids are observed to be in a crystalline form after lyophilisation (147, 
159). Concentrations of amorphous amino acids in formulations intended to be 
lyophilised should be carefully selected, since they tend to suppress critical temperatures 
(Tg′ and Tc) for lyophilisation process, increasing time and processing costs (148). 
Key considerations: Amino acids are a varied class of excipients with multi-functional 
roles and mechanisms, which are not yet completely understood especially when 
formulated in the dried state. The role of these excipients in protein formulation can be 
altered by adjusting the concentrations employed. From the analysis of this database, the 
trend of use of amino acids in protein formulations has increased in recent years probably 
due to their multi-functionality. In particular, the effect of combining different amino 
acids can provide a synergistic effect. Furthermore, some amino acids (basic amino acids) 
have properties that could be noteworthy when formulating proteins at high 
concentrations (e.g. to increase solubility, to reduce aggregation and viscosity) (145, 152-
154, 160).





2.3.2.4 Non-amino acids stabiliser/bulking agents 
 
The percentage of approved liquid and lyophilised parenteral products containing 
individual stabilisers and bulking agents are shown in Figure 2.6.  
 
Figure 2.6 The percentage of approved liquid and lyophilised parenteral protein products containing 
individual non-amino acids stabilisers/bulking agents. Note: The function of these excipients as bulking 
agents is only relevant for lyophilised products. 
 
The excipients included in this category are predominantly carbohydrates that can 
function as stabilisers in liquid and lyophilised protein products. Additionally, some of 
these excipients can act as bulking agents, maintaining the structure of lyophilised cakes 
(e.g. mannitol) (142, 161). In this case, the solid state of the excipient within the 
formulation determines its role. For example, mannitol which tends to crystallise is used 
as a bulking agent, while sucrose, which maintains its amorphous state, acts mainly as a 
stabiliser in lyophilised products. Due to the lack of this solid-state information in the 
EPAR data, it was difficult to determine the specific role of these excipients in commercial 
products. For this reason, stabilisers have been combined with bulking agents in a single 
category. The list of excipients that have been referenced as bulking agents (excluding 





amino acids) is broad, consisting of human albumin, maltose, mannitol, sorbitol, sucrose 
and trehalose (138, 142, 144, 162-164). However, sucrose and trehalose are 
predominately incorporated in lyophilised products as stabilisers in an amorphous state, 
rather than bulking agents in their crystalline state.  
Three different hypotheses have been proposed to explain the mechanism by which 
excipients are able to physically stabilise proteins (vitrification, exclusion and water 
replacement theories) (45, 58, 165). For many formulations the stabilisation may be due 
to the cumulative effect of these three different mechanisms. Excipients contribute to 
protein stabilisation by a range of mechanisms including direct interactions, minimising 
protein-protein interaction and aggregation, and stabilising the folded state of the protein 
(166-168).  
Bulking agents are employed in lyophilised formulations of low dose (high potency) 
drugs that do not have the necessary bulk to support their own structure (e.g. total solid 
content < 2% (w/v)) (142, 161). While protein integrity and stability are not necessarily 
related to the cake structural defects, requirements for an intact cake appearance tend to 
be observed for commercial lyophilised products (65, 169). A review by Patel et al. (169) 
establishes some guidelines of what is acceptable from a product quality and regulatory 
perspective in terms of visual cake appearance. The presence of a crystalline compound 
in formulation can also reduce the reconstitution time of lyophilised products containing 
high concentrations of protein (37).  
The most common stabilisers included in liquid formulations are glycerol (17%; n=29), 
sucrose (16%; n=28), and mannitol (14%; n=24). Due to the increased requirement for 
physical stabilisation of the protein during the lyophilisation process, non-amino acids 
stabilisers/bulking agents are added to the 93% (n=84) of the lyophilised formulations. 
Non-amino acids stabilisers/bulking agents most frequently present in lyophilised 





products are sucrose (59%; n=53), mannitol (33%, n=30) and in a lower number of 
products trehalose (10%; n=9) and human albumin (7%; n=6). Glycerol is exclusively 
included in liquid products where it can have multiple roles; this excipient is a co-
solvent/solubilising agent, which can serve as a tonicifier as well. Absence of glycerol in 
lyophilised commercial products may be attributed to its plasticising effect on the 
product’s Tg and to the stability issues observed in some formulations, where the increase 
in protein mobility provokes deamidation (58). Sucrose can act as a cryo/lyo-protectant 
in lyophilised formulations; it is maintained in an amorphous state after lyophilisation 
with moisture contents lower than 2.5% (58). On the contrary, mannitol is widely present 
in lyophilised products as a bulking agent due to its capability to crystallize and support 
the lyophilised cake.  
Sugars and polyols are frequently used as stabilisers (cryo/lyo protectants) and bulking 
agents in lyophilised products. However, carbohydrates with low Tg′ values, such as 
sorbitol (Tg′=−45°C) (170) can increase lyophilisation process time. This explains the 
absence of sorbitol as an excipient in lyophilised commercial formulations. Furthermore, 
sorbitol can crystallize over time and this needs to be considered in formulating a product 
intended to be lyophilised (170).  
Despite several reported advantages, trehalose use is not widespread amongst commercial 
products compared to other sugars (L:6%; n=10; LYO: 10%; n=9). However, eight new 
products containing trehalose were approved between 2017 and 2018. Trehalose has good 
aqueous solubility, low hygroscopicity, high hydration number (due to its hydrophilicity), 
good hydrolytic stability in extreme pH and upon betaglycosidase action. This sugar has 
a higher Tg compared to other carbohydrates; Tg value in presence of 0.3% residual water 
content was reported to be approximately 111°C for trehalose, while it is approximately 
65°C for sucrose (45, 142, 165). However, the following reasons may limit trehalose use 





as an excipient. Firstly, business reasons can determine a company’s choice of excipient; 
trehalose is more expensive than other stabilising sugars, such as the more commonly 
employed sucrose (171). Where comparative stability can be achieved with sucrose, 
logistic and business rationale would influence excipient choice. Secondly, the use of 
trehalose as stabiliser in some cases was observed to be less effective in comparison to 
sucrose. Jovanović et al. (172) reported significant changes in the tertiary structure of 
lysozyme and myoglobin in formulations containing trehalose. Finally, trehalose can be 
present in formulation as an heterogenous system formed by different crystalline phases. 
This polymorphism renders its behaviour in formulation difficult to predict, with a 
potential impact on stability (172, 173). The transformation paths that trehalose can 
undergo depend on several factors, including the solid state (amorphous or crystalline) 
and the dosage form (liquid or solid) as well as the dehydration process and residual 
moisture levels in the product (173-175). The use of trehalose could be preferred over 
other carbohydrates if there is a significant improvement in terms of product stability or 
process efficiency.  
Reducing sugars (e.g. lactose and maltose) should be avoided due to potential interactions 
with amino acid side chains, which can cause chemical alteration of the proteins (Maillard 
reaction or glycation) (58). Indeed, maltose is present in only one lyophilised commercial 
product (ORENCIA® (abatacept)) at a concentration of 50 mg/mL and at a ratio of 2:1 
maltose to abatacept in the lyophilised form prior to reconstitution (124). Maltose is 
reported on the EPAR’s scientific discussion to be used as a stabiliser/bulking agent at 
the concentration in formulation (176). This sugar is included in the ORENCIA® 
(abatacept) lyophilised product intended to be administered intravenously but replaced by 
sucrose in the corresponding subcutaneous liquid product. It is important to note that the 
Maillard reaction is favoured in alkaline or acidic conditions, and that the pH of this 





product after reconstitution is maintained neutral (pH 7.2–7.8). Trace level reducing 
sugars can also be found in non-reducing excipients such as mannitol, maltitol and 
sucrose. Hence, care should be taken regarding the quality of the excipients selected (58, 
177).  
Recrystallisation of sugars and polyols during manufacture and storage should be 
avoided, because conversion between amorphous and crystalline states can compromise 
the protein stability. Mannitol at high concentrations can provoke vial breakage due to 
recrystallisation during the lyophilisation process (primary drying phase) and storage 
(58). For these reasons, the introduction of an annealing step in the lyophilisation cycle 
is required when crystalline components are present in protein formulations. In some 
formulations, different sugars/ polyols are used in combination, so one excipient behaves 
as a stabiliser and the other as a bulking agent, for example ENBREL® (etanercept) 
contains sucrose and mannitol. The former is capable of stabilising the protein, whereas 
the latter prevents the collapse of the cake. Pikal et al. (178) reported similar examples of 
formulations containing glycine as a stabiliser and mannitol as a bulking agent. The main 
advantage in the employment of a mixture of amorphous and crystalline compounds is 
the possibility to reduce the lyophilisation cycle time, conducting the primary drying 
above the Tg’ value of the amorphous phase (179). The recommended molar ratio of 
protein to stabiliser is 360:1 (weight ratio 1:1), whereas it is usually higher for bulking 
agents (40, 143, 161, 180).  
Human albumin can have a number of functions in parenteral formulations, as a stabiliser 
(138, 144), bulking agent and tonicifier (138), but it is not employed in recent products 
possibly due to its potential risk of introducing contaminants (e.g. viruses) (138). Dextran 
40 is included in one lyophilised antibody-drug conjugate product MYLOTARG® 





(gentuzumab ozogamicin), approved in 2018. Dextran at concentrations of 9.1 mg/mL is 
reported to act as a bulking agent (EPAR’s scientific discussion) (181).  
Key considerations: The physical state of the excipient and the dosage form (liquid or 
lyophilised) need to be evaluated in the selection of a stabiliser/bulking agent. Sorbitol 
and glycerol can be used in liquid formulations, but they are not recommended in 
lyophilised products. Reducing sugars should be avoided in both liquid and lyophilised 
products because of the possibility to undergo Maillard reaction, altering the chemistry 
and the activity of the protein. Mannitol and sucrose are widely used especially in 
lyophilised commercial products. Mannitol as a bulking agent is in a crystalline form, 
hence the introduction of an annealing step in the lyophilisation process is required. 
Trehalose is a promising excipient, but its employment is limited partially due to its 
relative high costs. 
2.3.2.5 Surfactants  
 
Surfactants in both liquid and lyophilised formulations stabilise the protein, increasing its 
solubility and minimising interface interactions (182). Surfactants stabilise proteins by 
the following mechanisms; a) direct interactions of the surfactant molecules with 
hydrophobic domains exposed on the protein surface and b) interfacial competition, i.e. 
surfactant occupancy of the surface is more thermodynamically favoured compared to the 
protein occupancy (182). The use of surfactants in lyophilised products reduces the 
surface tension at the ice-water interface, promotes protein refolding and prevents 
aggregation (33, 45). High concentration protein formulations require surfactants in order 
to improve solubility of the protein and overcome problems related to their high tendency 
to form aggregates. Surfactants can also protect highly concentrated proteins from 





mechanical agitation and manipulation (e.g. during syringeability) and reduce the 
reconstitution time of lyophilised products (28, 31).  
A relatively small number of surfactants are included in the liquid and lyophilised 
products. The main excipients are polysorbate 80 (L: 32%, n=55; LYO: 41%, n=37), 
polysorbate 20 (L: 26%, n=45; LYO: 18%, n=16) and poloxamer 188 (L: 7%, n=12; 
LYO: 3%, n=3). Several of both formulation types (L: 35%; n=61; LYO: 38%; n=34) do 
not contain any surfactants, most of which are insulin-based products. The reason for the 
absence of surfactants in these commercial products was investigated. However, no clear 
trend was observed when evaluating products by year of approval, class of therapeutic 
protein or dosage form. The majority of surfactants included in protein formulations are 
non-ionic. Non-ionic surfactants are preferred over ionic surfactants which can denature 
proteins (182); they are also selected for their low toxicity and reduced sensitivity to the 
presence of electrolytes (183). Non-ionic surfactants are normally employed in a 
concentration range between 0.0003 and 0.3% (w/v) (45). Polysorbates are composed of 
fatty acid esters of polyoxyethylene sorbitan monolaurate (polysorbate 20) and 
polyoxyethylene sorbitan monooleate (polysorbate 80). The main disadvantage of 
polysorbates is their ability to undergo hydrolysis and autoxidation of the side-chains, 
resulting in hydrogen peroxide formation and development of short chain acids (e.g. 
formic acid). These sub-products can compromise the stability of a biopharmaceutical 
formulation (e.g. increasing the oxidation rate of proteins) and the safety of the product 
if accumulated in high amounts (182-184). The concentration of polysorbates in a pre-
formulation stage is selected considering: a) critical micelle concentration (CMC) and b) 
the possibility of degradation through the manufacturing process or during storage of the 
product.  





The concentration of surfactant needs to be carefully determined at the pre-formulation 
stage because of these disadvantages. An alternative surfactant is poloxamer 188, a 
triblock copolymer, included in a small number of liquid and lyophilised protein products 
(182). In comparison to polysorbates, poloxamer 188 inhibits protein adsorption through 
a different mechanism; which is independent from the interface affinity and allows 
formation of protein surfactant complexes (185). The mechanism by which surfactants 
reduce protein adsorption can also impact the concentration used in formulation, which 
does not always depend exclusively on the CMC (185). Poloxamer 171 was added to 
INSUMAN® solution for infusion (400 IU/mL) or injection (100 IU/mL) in the new 
formulation (EPAR updated 04/06/2018).  
Key considerations: The most commonly employed surfactants are polysorbates. 
However, the impact of the formation of degradation sub/products on protein stability 
should be evaluated at the pre-formulation stage. If their employment is required, the 
minimum functional concentration should be included and the impact of their variability 
on product and process stability be assessed. Poloxamers represent an alternative to the 
polysorbates.  
2.3.2.6 Preservatives  
 
Parenteral liquid products in multi-dose vials require the presence of a preservative to 
minimise microbial contamination. One of the main drawbacks of antimicrobial 
preservatives is their significant volatility and reactivity. Furthermore, many examples of 
interactions between various preservatives and drugs, excipients, packaging and filter 
materials are reported in literature (58, 132, 186). Preservatives are usually used in low 
amounts (0.002–1% (w/v)) (132), however, concentrations above 1% (w/v) have been 
noted in commercial products. Metacresol, phenol, benzyl alcohol and benzalkonium 
chloride were identified as the main preservatives included in protein products. 





Preservatives are mainly incorporated in multi-dose products (L: n=48; LYO: n=5) and 
in multi-dose lyophilised products they are always added to the solvent for reconstitution. 
Metacresol (L: 19%, n=33; LYO: 1%, n=1) and phenol (L: 14%, n=24; LYO: 0%) are the 
most frequently used preservatives, they are included respectively in 69% and 50% of the 
liquid multi-dose products. Metacresol is more active against gram +ve than gram −ve 
bacteria (144).  
Phenol is the most common preservative in liquid insulin-based formulations and is active 
against a broader spectrum of microorganisms including viruses and mycobacteria. 
Phenol activity increases in acidic and concentrated solutions as well as at higher 
temperature. It has been reported that monoclonal antibody formulations containing 
phenol can lead to soluble and insoluble aggregates formation (114, 138, 144). Benzyl 
alcohol is present in four liquid multiple use products (8% of the multi-dose liquid 
products). However, it is also added to two liquid single use products (PEGASYS® 
(peginterferonalfa-2a) and REBIF® (interferon beta-1a)), where it acts as stabiliser to 
prevent oxidation (EPAR’s scientific discussion) (187). Benzyl alcohol is also added to 
four lyophilised formulations (80% of the multi-dose lyophilised products). 
Benzalkonium chloride (L:1%, n=1; LYO:1%, n=1) is a quaternary ammonium 
compound active against gram +ve and gram −ve bacteria. Both products containing 
benzalkonium chloride are intended for multiple use.  
Key considerations: Metacresol and phenol are the most common preservatives employed 
in liquid commercial products. The use of preservatives is particularly required in multi-
dose preparations. Metacresol, benzyl alcohol and benzalkonium chloride were observed 
to be added to the diluent for reconstitution of a low number of lyophilised products (all 
for multiple use). 







Tonicifiers are added to protein formulations to create isotonic solutions for parenteral 
administration. The delivery of a non-isotonic solution through a parenteral route of 
administration can cause damage to the tissue and pain at the site of administration. 
Osmolality values between 280 and 300 mOsm/Kg and <600 mOsm/Kg for intravenous 
and subcutaneous administration respectively represent the osmolality limitations in 
developing parenteral protein formulations (135). The usual range of osmolality observed 
in commercial protein products is between 210 and 440 mOsm/Kg (126). The 
achievement of iso-osmolar biopharmaceutical products is particularly challenging for 
high concentration protein formulations due to the high amount of protein and the overall 
high solute concentration. Sodium chloride (NaCl) and potassium chloride (KCl) are the 
two main tonicifiers, however all formulation components can contribute to the product 
tonicity. NaCl is used in a relatively high percentage of liquid (36%; n=62) and 
lyophilised (42%; n=38) commercial products and is added to formulations, especially in 
the liquid form, also as a stabiliser. Sodium chloride was reported to reduce the viscosity 
of a reconstituted high concentration protein formulation (31) and to have a stabilising 
effect on insulin based formulations (188). This excipient was also observed to inhibit 
mannitol crystallisation in frozen solutions (189). However, the use of NaCl is not optimal 
for lyophilised formulations, due to the ability of water and NaCl to form an eutectic 
mixture at −21°C that can enhance protein mobility (138, 174). This could be the 
justification for six lyophilised products, including BETAFERON® (interferon beta-1b) 
and ALPROLIX® (eftrenonacog alfa), where in sodium chloride is added to the diluent 
provided for reconstitution rather than to the lyophilised product (190). KCl is exclusively 
present in a low number of liquid formulations (L: 1%, n=2). The inclusion of sugars, 
polyols, amino acids and salts all increase the tonicity of a protein formulation. Hence, 





excipients reported in Sections 2.3.2.3 and 2.3.2.4 contribute to the tonicity of the product. 
Furthermore, the impact of these excipients on the ionic strength of the formulation 
should be evaluated, since a high ionic strength can compromise the protein stability, 
promoting protein aggregation (7).  
Key considerations: Achieving iso-osmolarity is recommended for products intended to 
be administered through parenteral routes. Tonicity of a product can be adjusted using 
NaCl or KCl, but also by using specific concentrations of sugars, polyols and amino acids 
in formulation. NaCl is present in a high number of lyophilised products, however care 
should be taken during lyophilisation process design due to its suppression effect on the 
eutectic temperature of the formulation. 
2.3.2.8 Other excipients  
 
The ‘other excipients’ category contains mainly complexing agents, antioxidants and 
solubilising agents. All these excipients have stabilising properties, but are not included 
in the main category stabilisers/ bulking agents for two reasons: (1) they are not bulking 
agents (usually used in low concentrations); (2) they are present in a low number of 
products and/or they are stabilising agents via specific mechanisms. The percentages of 
approved liquid and lyophilised parenteral products containing ‘other excipients’ are 
listed along with their main functions in Table 2.2 (138, 144, 188, 191-197). 





Table 2.2 Examples of other excipients with specific functions included in liquid and lyophilised 
parenteral protein products. 
Excipient Function Liquid Lyophilised Reference 
Calcium chloride Complexing agent; 
preservative 
3%; n=5 19%; n=17 (138, 144) 
EDTA  Complexing agent 
(chelating agent) 
3%; n=6 0%; n=0 (144) 
Glutathione Antioxidant 0%; n=0 2%; n=2 (191) 
Nicotinamide Antioxidant; 
solubilizing agent 
1%; n=1 0%; n=0 (144) 
Pentetic acid Complexing agent 
(chelating agent) 
2%; n=3 0%; n=0 (144) 
Protamine sulphate* Complexing agent to 
prolong insulin activity 




enhancer following SC 
administration 
2%; n=3 0%; n=0 (195, 196) 
Urea Stabiliser (dissolving 
aggregates) 
1%; n=1 1%; n=1 (194) 
Zinc acetate* 
Zinc chloride* 
Zinc oxide * 
Complexing agent to 














Liposomal targeting 0%; n=0 1%; n=1 (197) 
*Specific for products containing insulin 
 
Edetic acid or edetate salt (EDTA) is used as a complexing agent in liquid formulations 
(L: 3%, n=6;). EDTA can form complexes (chelates) with metal ions which are removed 
from the solution in a process defined as sequestering. Heavy metals have the capability 
to catalyse autoxidation, so their removal can be required for stabilisation purpose. 
Usually employed EDTA concentrations are between 0.005 and 0.1% (w/v) (144). EDTA 
also possess antioxidant and antimicrobial properties and it can be used in combination 
with other antioxidants and preservatives for a synergistic effect (144). Calcium chloride 
(L: 3%; n=5; LYO: 19%; n=17) is usually employed as a complexing agent in lyophilised 
products containing coagulation factors. Coagulation factors is a class of therapeutic 
proteins whose activity and stability is promoted in presence of calcium ions (138).  
Antioxidants minimise oxidative reactions of the API or excipients over the shelf-life of 
the product. Glutathione is an antioxidant found exclusively in two lyophilised products, 





ADVATE® (octocog alfa) and ADYNOVI® (rurioctocog alfa pegol), both based on 
coagulation factors. Glutathione behaves as a reducing agent creating disulphide bonds 
with cysteine residues of proteins, preventing their oxidation. This process is aided by the 
thiol groups of glutathione which are oxidised forming glutathione disulphide (GSSG) 
(198-200).  
Nicotinamide is included in one recent liquid product, FIASP® (insulin aspart). This 
excipient is reported to reduce the self-association of insulin, promoting the rapid 
absorption of the monomeric form, which results in a faster action. Protamine sulphate 
(L: 5%, n=9) is a specific excipient employed exclusively in liquid insulin products to 
prolong the action of the therapeutic protein. Zinc acetate (L: 3% n=5), zinc chloride (L: 
10% n=17) and zinc oxide (L: 3% n=5) are also additives used specifically in liquid 
formulations based on insulin. The presence of zinc ions in the formulation at specific 
concentrations promote the association of insulin molecules in hexamers, increasing the 
protein stability and prolonging its activity (188).  
Finally, recombinant human hyaluronidase (rHuPH20) is a novel excipient that enhances 
protein bioavailability following subcutaneous administration. It modifies and creates 
conduits in the interstitial matrix to promote dispersion of molecules including proteins 
(196). This excipient, exclusively employed in three liquid antibody products intended to 
be administered subcutaneously, is reported to reduce administration times in comparison 
to the corresponding intravenous products (201).  
Key considerations: The employment of ‘other excipients’ can be due to the necessity to 
further improve the performance of the product, overcoming specific issues. Their 
inclusion in formulations should be evaluated case by case. 
  





2.3.2.9 Additional considerations in excipient selection  
 
Data analysis showed how qualitative and/or quantitative composition can vary for 
protein products according to different factors: (1) formulation approach (liquid or 
lyophilised); (2) route of administration; (3) API concentration; (4) primary packaging 
container; (5) different formats of liquid formulations (concentrate vs solution). 
Commercial examples are provided for each of the listed factors. BENLYSTA® 
(belimumab), COSENTYX® (secukinumab), ENBREL® (etanercept) and XOLAIR® 
(omalizumab) are all examples in which the excipient composition differs between the 
liquid and lyophilised product. In particular, a replacement of stabilisers (amino acids or 
trehalose) with sucrose in the lyophilised form was observed in BENLYSTA® 
(belimumab), COSENTYX® (secukinumab) and XOLAIR® (omalizumab). In ENBREL® 
(etanercept), the sodium phosphate salt included in the liquid form is replaced by the 
TRIS salt in the lyophilised form. Mannitol is also added, in combination with sucrose, 
to the lyophilised product. HERCEPTIN® (trastuzumab) contains methionine and 
rHuPH20, which are not present in the lyophilised product. The route of administration 
of a specific product can also impact the choice of the excipients; MABTHERA® 
(rituximab) is an antibody product whose subcutaneous formulation contains rHuPH20. 
This excipient is excluded from the product for intravenous use for reasons related to its 
function and discussed in Section 2.3.2.8. The different API concentrations can have 
varied qualitative and quantitative excipient compositions, this is the case of HUMIRA® 
(adalimumab) and OMNITROPE® (somatropin). Furthermore, LANTUS® (insulin 
glargine) and TOUJEO® (insulin glargine) liquid products do not contain polysorbate 20 
in the cartridges; however, the surfactant is present in the vials. Some excipients can be 
added to specific types of liquid formulations, for instance, STELARA® (ustekinumab) 
concentrate for solution for IV infusion (20 mg/mL) contains EDTA, which is not 





included in the highly concentrated (80 mg/mL) subcutaneous liquid solution. Therefore, 
excipients should be carefully selected considering several factors with the aim of 
improving the stability of a target/final product with specific characteristics.  
Regarding lyophilised products, the addition of specific excipients to the diluent for 
reconstitution may improve stability of the product during its life span between 
reconstitution and administration. As discussed before, sodium chloride or preservatives 
can be included directly in the diluent for reconstitution. Furthermore, REFIXIA® 
(nonacog beta pegol) contains 4.2 mL of 10 mM histidine solution in a prefilled syringe 
as diluent for reconstitution which was observed to improve the stability of the final 
product (202). BLINCYTO® (blinatumomab) includes a stabiliser solution (containing 
lysine, citric acid, polysorbate 80 and sodium hydroxide) to prevent adsorption of 
blinatumomab to the surfaces of administration; hence, it is added to the IV infusion bag 
(203). 
2.3.3 Approved antibody products 
 
2.3.3.1 Antibody concentration and relationship with the route of 
administration 
 
The number of antibody products approved up to June 2018 was 94 (L: 73%, n=69; LYO: 
27%, n=25). Figure 2.7 shows the trend in the number of liquid and lyophilised parenteral 
antibody products approved per year from 1998, when the first antibody product was 
approved, to June 2018. 






Figure 2.7 Trend of liquid and lyophilised parenteral antibody products approved per year by the 
EMA between 1995 and 2018 (June) (*Last updated: 18/06/ 2018). 
 
Liquid formulations are more common than lyophilised formulations (119) and the 
number of marketed products per year has significantly increased in 2017. The most 
common class of antibodies in approved products is IgG1 (L: 70% n=48; LYO: 84% 
n=21). A lower number of liquid products contain IgG4 (L: 10% n=7), human normal 
IgG (L: 9% n=6), and IgG2 (L: 7% n=5) as API. Two liquid products contain Fab 
fragments (PRAXBIND® (idarucizumab) and CIMZIA® (certolizumab pegol)) and one 
liquid product contains an IgG2/4 (SOLIRIS® (eculizumab)). Lyophilised products are 
predominately based on IgG1 with three products containing IgG4. Only two bispecific 
antibody products are currently approved by the EMA. One HEMLIBRA® (emicizumab) 
is formulated as a liquid and the second BLINCYTO® (blinatumomab) as a lyophilised 
product. The four approved antibody-drug conjugates (ADC) are all in a lyophilised 
dosage form. No particular trend was observed in the use of specific excipients for the 
different classes of antibody. However, human normal immunoglobulin products tend to 
have a low number of excipients in their formulations (1 or 2).  





Figure 2.8 shows the antibody concentration (mg/mL) in liquid products before dilution 
and in lyophilised products following reconstitution. Approximately half of these 
products (L: 48%; LYO: 68%) contain antibodies at a concentration ≤ 50mg/mL.  
 
Figure 2.8 Range of therapeutic concentrations (mg/mL) of liquid and lyophilised parenteral 
antibody products. *for lyophilised formulations intended after reconstitution. 
 
Figure 2.9 reports the amount of therapeutic protein per vial (mg/vial) for lyophilised 
products. Information regarding the fill volume of the vials before lyophilisation was not 
provided in the EPAR data, therefore it is not possible to determine the initial 
concentration of protein or the total solute concentration prior to lyophilisation. However, 
a higher percentage of products contain protein in amounts ≥ 100mg/vial.  






Figure 2.9 Amount of antibody per vial (mg/vial) for lyophilised parenteral antibody products. 
 
Analysis of products’ protein concentration (lyophilised products after reconstitution) 
reveals a clear relationship with the route of administration, Figure 2.10. More than half 
of the commercial antibody products are intended to be administered intravenously 
(60%). Antibody formulations with high concentrations of protein (>50 mg/mL) are more 
commonly administered subcutaneously. The antibody concentrations in formulation 
depends on the therapeutic effect and the route of administration selected to deliver the 
dose. For example, LUCENTIS® (ranibizumab), a product for the treatment of macular 
degeneration and edema, myopia and diabetes complications, is formulated at a relatively 
low concentration (10 mg/mL) and is intended to be administered by intravitreal route 
(204).  






Figure 2.10 Relationship between ranges of antibody concentrations (mg/mL) and route of 
administration. *for lyophilised formulations intended after reconstitution. 
 
2.3.3.2 Qualitative and quantitative excipient composition  
 
The categories of excipients included in liquid and lyophilised antibody products are 
shown in Figure 2.11. Antibody formulations contain non-amino acids buffers in 
approximately half of both liquid (54%; n=37) and lyophilised (56%; n=14) commercial 
products. Amino acids are also added to approximately 50% of the products in both 
dosage forms (L: 54%; n=37; LYO: 52%; n=13). A high number of liquid formulations 
contain non-amino acids stabilisers (L: 59%, n=41), whereas all lyophilised products 
contain non-amino acids stabilisers/bulking agents (LYO: 100%, n=25). Most of the 
liquid and lyophilised products include surfactants (L: 87%, n=60; LYO: 88%, n=22). 
Preservatives are not present in any antibody formulations, which are always provided in 
a single use dosage form. Sodium chloride and potassium chloride are more frequently 
added to liquid products (L:36%, n=25) where they can act as tonicifiers and/or stabilisers. 
Excipients classified as ‘other excipients’ are only included in a small number of liquid 
products (13%; n=9).  






Figure 2.11 The percentage of liquid and lyophilised parenteral antibody products that contain 
excipients from each of the excipient categories: Non-amino acids BUFF (buffers); Amino acids 
BUFF/S/BA (buffers/stabilisers/bulking agents); Non-amino acids S/BA (stabilisers/bulking agents); 
Surfactants; Preservatives; Tonicifiers and Other excipients. Note: The function of these excipients as 
bulking agents is only relevant for lyophilised products *‘Other excipients’ category consists of complexing 
agents, antioxidants, solubilising agents and excipients specific to individual formulations. 
 
Figure 2.12 shows the percentage of liquid and lyophilised antibody formulations that 
contain individual excipients. Amongst non-amino acids buffers the most commonly 
employed excipients are: sodium citrate (L: 20%, n=14; LYO: 20%, n=5) and sodium 
phosphate (L: 12%, n=8; LYO: 28%, n=7). As for protein products, sodium acetate (L: 
22%, n=15) is observed to be included exclusively in liquid products. Histidine (L: 39%; 
n=27; LYO: 40%; n=10) is the most common amino acid added to liquid and lyophilised 
antibody products, followed by the amino acid glycine (L: 12%; n=8; LYO: 8%; n=2). 
Arginine is more frequently used in the liquid forms (10%; n=7) than the lyophilised 
forms (4%; n=1). Methionine is included exclusively in liquid products (9%; n=6).  
Sucrose is the most common non-amino acid stabiliser and is present in most of the 
lyophilised products (L: 20%, n=14; LYO: 72%, n=18). Sorbitol is included exclusively 
in liquid products (10%; n=7). Surfactants employed comprise polysorbate 80 (L: 55%, 
n=38; LYO: 64%, n=16), polysorbate 20 (L: 29%, n=20; LYO: 24%, n=6) and to a lesser 
extent poloxamer 188 (L: 3%, n=2; LYO: 0%). Sodium chloride is present in a high 





number of liquid products (L:36%, n=25) and only three lyophilised products with low 
concentrations of antibodies, two of which are ADC. Finally, excipients classified as 
‘other excipients’ and employed in antibody formulations include chelating agents 
(EDTA and pentetic acid), calcium chloride as complexing agent and rHuPH20. rHuPH20 
is exclusively present in MABTHERA® (rituximab), HERCEPTIN® (trastuzumab) and 
HYQVIA® (human normal immunoglobulin), all liquid products based on antibodies.






Figure 2.12 The percentage of liquid and lyophilised parenteral antibody products that contain 
individual excipients from each of the excipient categories: Non-amino acids BUFF (buffers); Amino 
acids BUFF/S/BA (buffers/stabilisers/bulking agents); Non-amino acids S/BA (stabilisers/ bulking 
agents); (SURF) Surfactants; (T) Tonicifiers; (OE*) Other excipients. Note: The function of these 
excipients as bulking agents is only relevant for lyophilised products * (OE) ‘Other excipients’ category 
consists of complexing agents, antioxidants, solubilising agents and excipients specific to individual 
formulations. 
 
The quantitative composition of 88 out of 94 liquid and lyophilised antibody commercial 
products was investigated consulting accredited sources and summarised in Table 2.3 





Table 2.3 Quantitative composition of individual excipients included in 88 approved liquid and lyophilised parenteral antibody products, listed by ascending values of 
concentration (124-126, 130). (Continue to next page) 
Excipient name Excipient quantitative composition of approved LIQUID antibody products Excipient quantitative composition of approved 
LYOPHILISED antibody products 
Potassium phosphate  
(Non-amino acids BUFF)1 
LEMTRADA® (alemtuzumab) 0.2 mg/mL  SIMULECT® (basiliximab) 1.44 mg/mL 
Sodium acetate 
(Non-amino acids BUFF) 1 
 
AMGEVITA® (adalimumab) 0.6 mg/mL acetic acid; BAVENCIO® (avelumab) 0.6 mg/mL; 
SOLYMBIC® (adalimumab) 0.6 mg/mL acetic acid; TECENTRIQ® (atezolizumab) 0.83 
mg/mL acetic acid; DUPIXENT® (dupilumab) 1 mg/mL; REPATHA® (evolocumab) 1.2 
mg/mL; CIMZIA® (certolizumab pegol) 1.36 mg/mL PROLIA® (denosumab) 17 mM (1.4 
mg/mL); XGEVA® (denosumab) 18 mM (1.5 mg/mL); OCREVUS® (ocrelizumab) 20 mM 
(EMA); 2.14 mg/mL, 0.25 acetic acid (FDA); CINQAERO® (reslizumab) 2.45 mg/mL; 0.12 
mg/mL acetic acid; PRAXBIND® (idarucizumab) 2.95 mg/mL, 0.20 mg/mL acetic acid; 
DARZALEX® (daratumumab) 2.96 mg/mL, 0.18 mg/mL acetic acid; CYLTEZO® 
(adalimumab) 3 mg/mL; 0.16 mg/mL acetic acid, ARZERRA® (ofatumumab) 6.8 mg/mL; 
VECTIBIX® (panitumumab) 6.8 mg/mL 
None 
Sodium citrate 
(Non-amino acids BUFF) 1 
HUMIRA® (adalimumab, 50 mg/mL) 1.3 mg/mL citric acid, 0.3 mg/mL; ERBITUX® 
(cetuximab) 10 mM (1,92 mg/mL) citric acid; PORTRAZZA® (necitumumab) 10 mM (EMA), 
2.55 mg/mL, 0.26 mg/mL citric acid (FDA); ZINPLAVA® (bezlotoxumab) 4.75 mg/mL; 0.8 
mg/mL citric acid, TALTZ® (ixekizumab) 5.11 mg/mL, 0.51 mg/mL citric acid; OPDIVO® 
(nivolumab) 5.88 mg/mL; BLITZIMA® (rituximab) 25 mM (7.35 mg/mL) tri-sodium dihydrate; 
RITEMVIA® (rituximab) 25 mM (7.35 mg/mL) tri-sodium dihydrate; RITUZENA® 
(rituximab) 25 mM (7.35 mg/mL) tri-sodium dihydrate; TRUXIMA® (rituximab) 25 mM (7.35 
mg/mL) tri-sodium dihydrate; MABTHERA® (rituximab, 10 mg/mL) 7.35 mg/mL 
BLINCYTO® (blinatumomab) 1.20 mg/mL citric acid; 
EMPLICITI® (etoluzumab) 1.38 mg/mL; 0.20 mg/mL citric 
acid; BENLYSTA® (belimumab) 2.7 mg/mL, 0.16 mg/mL 
citric acid; ADCETRIS® (brentuximab vedotin) 20 mM*** 
(EMA); 5.6 mg/mL, 0.21 mg/mL citric acid (FDA)) 
Sodium phosphate 
(Non-amino acids BUFF) 1 
TYSABRI® (natalizumab) 1.13 mg/mL monobasic monohydrate; 0.48 mg/mL dibasic 
heptahydrate; LEMTRADA® (alemtuzumab) 1.15 mg/mL dibasic dihydrate; HUMIRA® 
(adalimumab, 50 mg/mL) 1.53 mg/mL dibasic dihydrate, 0.85 mg/mL monobasic dihydrate; 
HYQVIA® (human normal Ig) 1.78 mg/mL dibasic; SOLIRIS® (eculizumab) 1.78 mg/mL 
dibasic, 0.46 mg/mL monobasic; AVASTIN® (bevacizumab) 51 mM (EMA), 5.8 mg/mL 
monobasic monohydrate, 1.2 mg/mL dibasic anhydrous (FDA); MVASI® (bevacizumab) 5.8 
mg/mL monobasic monohydrate, 1.2 mg/mL dibasic anhydrous; ROACTEMRA® (tocilizumab, 
20 mg/mL) 15 mM* 
SIMULECT® (basiliximab) 0.20 mg/mL; FLIXABI® 
(inflixabi) 0.56 mg/mL monobasic monohydrate, 0.26 mg/mL 
dibasic heptahydrate; MYLOTARG® (gemtuzumab 
ozogamicin) 0.6 mg/mL dibasic anhydrous, 0.1 mg/mL 
monobasic monohydrate; INFLECTRA® (infliximab) 0.61 
mg/mL dibasic dihydrate; 0.22 mg/mL monobasic 
monohydrate; REMSIMA® (infliximab) 0.61 mg/mL dibasic 
dihydrate, 0.22 mg/mL monobasic monohydrate; 
REMICADE® (infliximab) 0.61 mg/mL dibasic  dihydrate, 
0.22 mg/mL monobasic monohydrate; NUCALA® 
(mepolizumab) 7.14 mg/mL dibasic heptahydrate 
Sodium succinate 
(Non-amino acids BUFF) 1 





Table 2.3 Quantitative composition of individual excipients included in 88 approved liquid and lyophilised parenteral antibody products, listed by ascending values of 
concentration. (Continued) 
Excipient name Excipient quantitative composition of approved LIQUID antibody products Excipient quantitative composition of approved 
LYOPHILISED antibody products 
Tris 
(Non-amino acids BUFF) 1 
YERVOY® (ipilimumab) 3.15 mg/mL HCl BESPONSA® (inotuzumab ozogamicin) 2.4 mg/mL 
Arginine 
(Amino acids BUFF/S/BA) 2 
DUPIXENT® (dupilumab) 5.25 mg/mL HCl monohydrate; BENLYSTA® (belimumab) 5.3 
mg/mL HCl monohydrate; KEVZARA® (sarilumab) 7.84 mg/mL; ARZERRA® (ofatumumab) 
10 mg/mL; HEMLIBRA® (emicizumab) 150 mM (26.13 mg/mL); XOLAIR® (omalizumab) 
42.1 mg/mL HCl monohydrate  
ENTYVIO® (vedolizumab) 125 mM (26.34 mg/mL) HCl 
monohydrate 
Glycine 
(Amino acids BUFF/S/BA) 2 
SYNAGIS® (palivizumab) 0.1 mg/mL; ERBITUX® (cetuximab) 100 mM (7.5 mg/mL); 
LARTRUVO® (olaratumab) 7.5 mg/mL; CYRAMZA® (ramucirumab) 133 mM (9.98 
mg/mL); PORTRAZZA® (necitumumab) 133 mM (9.98 mg/mL); KIOVIG® (human normal 
Ig) 250 mM (18.77 mg/mL); HyQVIA® (human normal Ig) 250 mM (18.77 mg/mL)  
SYNAGIS® (palivizumab) 0.2 mg/mL; SIMULECT® 
(basiliximab) 8 mg/mL 
Glutamic acid 
(Amino acids BUFF/S/BA) 2 
KYNTHEUM® (brodalumab) 4.33 mg/mL None 
Histidine 
(Amino acids BUFF/S/BA) 2 
SIMPONI® (golimumab) 0.87 mg/mL; PRALUENT® (alirocumab, 75 mg/mL) 8 mM (1.24 
mg/mL); PRALUENT® (alirocumab, 100 mg/mL) 6 mM (0.93 mg/mL); STELARA® 
(ustekinumab, 90 mg/mL) 1 mg/mL; STELARA® (ustekinumab, 5 mg/mL) 1.04 mg/mL HCl 
monohydrate, 0.77 mg/mL,; BENLYSTA® (belimumab) 1.2 mg/mL HCl monohydrate, 0.65 
mg/mL; CYRAMZA® (ramucirumab) 10 mM (EMA), 1.22 mg/mL HCl monohydrate, 0.65 
mg/mL (FDA); FASENRA® (benralizumab) 1.4 mg/mL, 2.3 mg/mL HCl monohydrate; 
TREMFYA® (guselkumab) 1.5 mg/mL HCl monohydrate, 0.6 mg/mL; KEYTRUDA® 
(pembrolizumab) 1.55 mg/mL; CRYSVITA® (burosumab) 1.55 mg/mL; LARTRUVO® 
(olaratumab) 1.7 mg/mL HCl monohydrate, 0.3 mg/mL; ILARIS® (canakinumab) 2.1 mg/mL, 
1.3 mg/mL HCl monohydrate; XOLAIR® (omalizumab) 2.34 mg/mL HCl monohydrate, 1.37 
mg/mL; COSENTYX® (secukinumab) 20 mM (3.1 mg/mL); DUPIXENT® (dupilumab) 3.1 
mg/mL; HEMLIBRA® (emicizumab) 20 mM (3.1 mg/mL); QARZIBA® (dinutuximab beta) 
20 mM (3.1 mg/mL); TECENTRIQ® (atezolizumab) 20 mM (3.1 mg/mL); KEVZARA® 
(sarilumab) 3.25 mg/mL; MABTHERA® (rituximab, 120 mg/mL) 3.47 mg/mL HCl 
monohydrate, 0.53 mg/mL;  SYNAGIS® (palivizumab) 3,9 mg/mL; PERJETA® (pertuzumab) 
20 mM (4.28 mg/mL) acetate; LUCENTIS® (ranibizumab) 10 mM**; GAZYVARO® 
(obinutuzumab) 20 mM**; HERCEPTIN® (trastuzumab) 20 mM** 
HERCEPTIN® (trastuzumab) 0.48 mg/mL HCl 
monohydrate, 0.31 mg/mL; HERZUMA® (trastuzumab) 
0.48 mg/mL HCl monohydrate, 0.31 mg/mL; KANJINTI® 
(trastuzumab) 0.48 mg/mL HCl monohydrate, 0.31 mg/mL; 
ONTRUZANT® (trastuzumab) 0.48 mg/mL HCl 
monohydrate, 0.31 mg/mL; SYLVANT® (siltuximab) 0.74 
mg/mL; KEYTRUDA® (pembrolizumab) 1.55 mg/mL; 
XOLAIR® (omalizumab) 2 mg/mL HCl monohydrate, 1.3 
mg/mL;  ILARIS® (canakinumab) 2.8 mg/mL, 1.7 mg/mL 
HCl monohydrate; COSENTYX® (secukinumab) 30 mM 
(4.66 mg/mL); SYNAGIS® (palivizumab) 7.3 mg/mL; 
ENTYVIO® (vedolizumab) 50 mM (EMA), 4.6 mg/mL, 4.28 





(Amino acids BUFF/S/BA) 2 






Table 2.3 Quantitative composition of individual excipients included in 88 approved liquid and lyophilised parenteral antibody products, listed by ascending values of 
concentration. (Continued) 
Excipient name Excipient quantitative composition of approved LIQUID antibody products Excipient quantitative composition of approved 
LYOPHILISED antibody products 
Methionine 
(Amino acids BUFF/S/BA) 2 
STELARA® (ustekinumab, 5 mg/mL) 0.4 mg/mL; COSENTYX® (secukinumab) 5 mM (0.75 
mg/mL); HERCEPTIN® (trastuzumab) 10 mM (1.49 mg/mL); CRYSVITA® (burosumab) 
1.49 mg/mL;  MABTHERA® (rituximab, 120 mg/mL) 1.49 mg/mL  
None 
Proline 
(Amino acids BUFF/S/BA) 2 
KYNTHEUM® (brodalumab) 24 mg/mL; REPATHA® (evolocumab) 25 mg/mL; 
PRIVIGEN® (human normal Ig) 250 mM (28.78 mg/mL); HIZENTRA® (human normal Ig) 
250 mM (28.78 mg/mL)  
None 
Dextran 
(Non-amino acids S/BA) 3 
None MYLOTARG® (gentuzumab ozogamicin) 9.1 mg/mL 
Human albumin 
(Non-amino acids S/BA) 3 
 
HYQVIA® (human normal Ig) 1 mg/mL None 
Mannitol 
(Non-amino acids S/BA) 3 
PORTRAZZA® (necitumumab) 50 mM (9.1 mg/mL); YERVOY® (ipilimumab) 10 mg/mL; 
HUMIRA® (adalimumab, 50 mg/mL) 12 mg/mL; LARTRUVO® (olaratumab) 13.7 mg/mL; 
DARZALEX® (daratumumab) 25.5 mg/mL; OPDIVO® (nivolumab) 30 mg/mL; HUMIRA® 
(adalimumab, 100 mg/mL) 42 mg/mL; ILARIS® (canakinumab) 49.2 mg/mL; BAVENCIO® 
(avelumab) 51 mg/mL 
SIMULECT® (basiliximab) 16 mg/mL; SYNAGIS® 
(palivizumab) 56.3 mg/mL 
Sorbitol 
(Non-amino acids S/BA) 3 
PRAXBIND® (idarucizumab) 40.08 mg/mL; SIMPONI® (golimumab) 41 mg/mL; 
CRYSVITA® (burosumab) 45.91 mg/mL;  XGEVA® (denosumab) 46 mg/mL; PROLIA® 
(denosumab) 47 mg/mL; FLEBOGAMMA DIF® (human normal Ig, 50 mg/mL) 50 mg/mL 
None 
Sucrose 
(Non-amino acids S/BA) 3 
PERJETA® (pertuzumab) 120 mM (41.08 mg/mL); TECENTRIQ® (atezolizumab) 120 mM 
(41.08 mg/mL); DUPIXENT® (dupilumab) 50 mg/mL; KEVZARA® (sarilumab) 50 mg/mL; 
QARZIBA® (dinutuximab beta) 50 mg/mL; ROACTEMRA® (tocilizumab, 20 mg/mL) 50 
mg/mL; CINQAERO® (reslizumab) 70 mg/mL; KEYTRUDA® (pembrolizumab) 70 mg/mL; 
STELARA® (ustekinumab, 90 mg/mL) 76 mg/mL; TREMFYA® (guselkumab) 79 mg/mL 
STELARA® (ustekinumab, 5 mg/mL) 85 mg/mL; AMGEVITA® (adalimumab) 90 mg/mL; 
SOLYMBIC® (adalimumab) 90 mg/mL; PRALUENT® (alirocumab) 100 mg/mL 
SIMULECT® (basiliximab) 4 mg/mL; MYLOTARG® 
(gemtuzumab ozogamicin) 15.5 mg/mL; SYLVANT® 
(siltuximab) 33.8 mg/mL; EMPLICITI® (etoluzumab) 42.5 
mg/mL; BESPONSA® (inotuzumab ozogamicin) 50 mg/mL; 
FLIXABI® (infliximab) 50 mg/mL; INFLECTRA® 
(infliximab) 50 mg/mL; REMICADE® (infliximab) 50 
mg/mL; REMSIMA® (infliximab) 50 mg/mL; KADCYLA® 
(trastuzumab emtansine) 60 mg/mL; KEYTRUDA 
(pembrolizumab) 70 mg/mL; BENLYSTA® (belimumab) 80 
mg/mL; ILARIS® (canakinumab) 92.4 mg/mL;  
COSENTYX® (secukinumab) 270 mM (EMA), 92.4 mg/mL 
(FDA); ENTYVIO® (vedolizumab) 100 mg/mL; XOLAIR® 





Table 2.3 Quantitative composition of individual excipients included in 88 approved liquid and lyophilised parenteral antibody products, listed by ascending values of 
concentration. (Continued) 
Excipient name Excipient quantitative composition of approved LIQUID antibody products Excipient quantitative composition of approved 
LYOPHILISED antibody products 
Trehalose 
(Non-amino acids S/BA) 3 
OCREVUS® (ocrelizumab) 106 mM (EMA), 40 mg/mL (FDA); AVASTIN® (bevacizumab) 
60 mg/mL; MVASI® (bevacizumab) 60 mg/mL; COSENTYX® (secukinumab) 200 mM 
(EMA), 75.67 mg/mL (FDA); HERCEPTIN® (trastuzumab) 210 mM (71.88 mg/mL); 
MABTHERA® (rituximab, 120 mg/mL) 79,45 mg/mL; CYLTEZO® (adalimumab) 81.25 
mg/mL; GAZYVARO® (obinutuzumab) 240 mM (82.15 mg/mL); FASENRA® 
(benralizumab) 95 mg/mL; LUCENTIS® (ranibizumab) 100 mg/mL 
HERCEPTIN® (trastuzumab) 19.05 mg/mL; KANJINTI® 
(trastuzumab) 19.05 mg/mL; ONTRUZANT® 
(trastuzumab) 19.05 mg/mL; BLINCYTO® 
(blinatumomab) 34.11 mg/mL; ADCETRIS® (brentuximab 
vedotin) 63 mg/mL (EMA), 70 mg/mL (FDA) 
Polysorbate 80 
(Surfactants)  
HIZENTRA® (human normal Ig) 0.02 mg/mL (EMA), 0.008-0.03 mg/mL (FDA);  
STELARA® (ustekinumab, 90 mg/mL) 0.04 mg/mL; BENLYSTA® (belimumab) 0.1 mg/mL; 
ERBITUX® (cetuximab) 0.1 mg/mL; YERVOY® (ipilimumab) 0.1 mg/mL;  LEMTRADA® 
(alemtuzumab) 0.1 mg/mL; CYRAMZA® (ramucirumab) 0.1 mg/mL;  REPATHA® 
(evolocumab) 0.1 mg/mL; PORTRAZZA® (necitumumab) 0.1 mg/mL; SIMPONI® 
(golimumab)  0.16 mg/mL; ARZERRA® (ofatumumab) 0.2 mg/mL; COSENTYX® 
(secukinumab) 0.2 mg/mL; KEYTRUDA® (pembrolizumab) 0.2 mg/mL; OPDIVO® 
(nivolumab) 0.2 mg/mL; TYSABRI® (natalizumab) 0.2 mg/mL;  SOLIRIS® (eculizumab) 
0.22 mg/mL; ZINPLAVA® (bezlotoxumab) 0.25 mg/mL; TALTZ® (ixekizumab) 0.3 mg/mL; 
ILARIS® (canakinumab) 0.4 mg/mL; STELARA® (ustekinumab, 5 mg/mL) 0.4 mg/mL; 
CRYSVITA® (burosumab) 0.5 mg/mL;  ROACTEMRA® (tocilizumab, 20 mg/mL) 0.5 
mg/mL; TREMFYA® (guselkumab) 0.5 mg/mL; MABTHERA® (rituximab, 120 mg/mL) 0.6 
mg/mL; MABTHERA® (rituximab, 10 mg/mL) 0.7 mg/mL; BLITZIMA® (rituximab) 0.7 
mg/mL; RITEMVIA® (rituximab) 0.7 mg/mL; RITUZENA® (rituximab) 0.7 mg/mL; 
TRUXIMA® (rituximab) 0.7 mg/mL; AMGEVITA® (adalimumab) 1 mg/mL; CYLTEZO® 
(adalimumab) 1 mg/mL;  HUMIRA® (adalimumab, 50 mg/mL) 1 mg/mL; HUMIRA® 
(adalimumab, 100 mg/mL) 1 mg/mL; SOLYMBIC® (adalimumab) 1 mg/mL; DUPIXENT® 
(dupilumab) 2 mg/mL 
FLIXABI® (infliximab) 0.05 mg/mL; INFLECTRA® 
(infliximab) 0.05 mg/m; REMICADE® (infliximab) 0.05 
mg/mL; REMSIMA® (infliximab) 0.05 mg/mL; 
BESPONSA® (inotuzumab ozogamicin) 0.1 mg/mL; 
SYLVANT® (siltuximab) 0.16 mg/mL; ADCETRIS® 
(brentuximab vedotin) 0.2 mg/mL; KEYTRUDA® 
(pembrolizumab) 0.2 mg/mL; BLINCYTO® 
(blinatumomab) 0.23 mg/mL; EMPLICITI® (etoluzumab) 
0.28 mg/mL; BENLYSTA® (belimumab) 0.4 mg/mL; 
ILARIS® (canakinumab) 0.6 mg/mL; ENTYVIO® 
(vedolizumab) 0.6 mg/mL; COSENTYX® (secukinumab) 




FASENRA® (benralizumab) 0.06 mg/mL; LUCENTIS® (ranibizumab) 0.1 mg/mL; 
KYNTHEUM® (brodalumab) 0.1 mg/mL;  PROLIA® (denosumab) 0.1 mg/mL; 
PRALUENT® (alirocumab) 0.1 mg/mL; QARZIBA® (dinutuximab beta) 0.1 mg/mL; 
XGEVA® (denosumab) 0.1 mg/mL; OCREVUS® (ocrelizumab) 0.2 mg/mL; PERJETA® 
(pertuzumab) 0.2 mg/mL;  PRAXBIND® (idarucizumab) 0.2 mg/mL; LARTRUVO® 
(olaratumab) 0.2 mg/mL; AVASTIN® (bevacizumab) 0.4 mg/mL; DARZALEX® 
(daratumumab) 0.4 mg/mL;  HERCEPTIN® (trastuzumab) 0.4 mg/mL; TECENTRIQ® 
(atezolizumab) 0.4 mg/mL; MVASI® (bevacizumab) 0.4 mg/mL; XOLAIR® (omalizumab) 
0.4 mg/mL; BAVENCIO® (avelumab) 0.5 mg/mL KEVZARA® (sarilumab) 2 mg/mL  
HERCEPTIN® (trastuzumab) 0.08 mg/mL; HERZUMA® 
(trastuzumab) 0.08 mg/mL; KANJINTI® (trastuzumab) 
0.08 mg/mL; ONTRUZANT® (trastuzumab) 0.08 mg/mL; 
KADCYLA® (trastuzumab emtansine) 0.2 mg/mL; 




Table 2.3 Quantitative composition of individual excipients included in 88 approved liquid and lyophilised parenteral antibody products, listed by ascending values of 
concentration. (Continued) 
Excipient name Excipient quantitative composition of approved LIQUID antibody products Excipient quantitative composition of approved 
LYOPHILISED antibody products 
Poloxamer 188 
(Surfactants)  
GAZYVARO® (obinutuzumab) 0.2 mg/mL; HEMLIBRA® (emicizumab) 0.2-0.5 mg/mL None 
Potassium chloride 
(Tonicifiers)  
LEMTRADA® (alemtuzumab) 0.2 mg/mL None 
Sodium chloride 
(Tonicifiers)  
PORTRAZZA® (necitumumab) 40 mM (2.34 mg/mL);  LARTRUVO® (olaratumab) 2.9 
mg/mL; OPDIVO® (nivolumab) 2.92 mg/mL; ARZERRA® (ofatumumab) 2.98 mg/mL; 
DARZALEX® (daratumumab) 3.5 mg/mL; CYRAMZA® (ramucirumab) (75 mM) 4.38 
mg/mL; VECTIBIX® (panitumumab) 5.8 mg/mL; ERBITUX® (cetuximab) 100 mM (5.84 
mg/mL); YERVOY® (ipilimumab) 5.85 mg/mL; HUMIRA® (adalimumab, 50 mg/mL) 6.18 
mg/mL; BENLYSTA® (belimumab) 6.7 mg/mL; CIMZIA® (certolizumab pegol) 7.31 mg/mL;  
LEMTRADA® (alemtuzumab) 8 mg/mL; TYSABRI® (natalizumab) 8.2 mg/mL; HYQVIA® 
(human normal Ig) 8.5 mg/mL; SOLIRIS® (eculizumab) 8.77 mg/mL; ZINPLAVA® 
(bezlotoxumab) 8.77 mg/mL; MABTHERA® (rituximab, 10 mg/mL) 9 mg/mL; TRUXIMA® 
(rituximab) 154 mM (9 mg/mL); BLITZIMA® (rituximab) 154 mM (9 mg/mL); RITEMVIA® 
(rituximab) 154 mM (9 mg/mL); RITUZENA® (rituximab) 154 mM (9 mg/mL); TALTZ® 
(ixekizumab) 11.69 mg/mL 
SIMULECT® (basiliximab) 0.32 mg/mL; BESPONSA® 
(inotuzumab ozogamicin) 0.6 mg/mL MYLOTARG® 
(gemtuzumab ozogamicin) 5.8 mg/mL 
Calcium chloride 
(Other excipients) 
HYQVIA® (human normal Ig) 0.4 mg/mL None 
EDTA 
(Other excipients)  
STELARA® (ustekinumab, 5 mg/mL) 0.02 mg/mL; ARZERRA® (ofatumumab) 0.02 mg/mL; 
LEMTRADA® (alemtuzumab) 0.02 mg/mL; HYQVIA® (human normal Ig) 1 mg/mL 
None 
Pentetic acid 
(Other excipients)  
OPDIVO® (nivolumab) 0.01 mg/mL; ZINPLAVA® (bezlotoxumab) 0.01 mg/mL; YERVOY® 




(Other excipients)  
MABTHERA (rituximab, 120 mg/mL) 2000 units/mL; HERCEPTIN® (trastuzumab) 2000 
units/mL; HYQVIA® (human normal Ig) 160 units/mL 
None 
Note: The function of these excipients as bulking agents is only relevant for lyophilised products.  
a- Disodium phosphate dodecahydrate/Sodium dihydrogen phosphate dihydrate. 
b-  Histidine/Histidine-HCl.  
c-  Sodium citrate/Citric acid. 
d- Non-amino acids BUFF (buffers). 
e- Amino acids BUFF/S/BA (buffers/stabilisers/bulking agents).  
f- Non-amino acids S/BA (stabilisers/bulking agents). 
 






Some of the products for which the quantitative composition was not available are 
biosimilars to other reference products. Biosimilars in some cases can have the same 
qualitative and/or quantitative excipient composition. For example, MVASI® 
(bevacizumab) is a biosimilar, having the same formulation of the reference product 
AVASTIN® (bevacizumab) (206). On MVASI®’s scientific discussion (EMA) it is 
reported: ‘The finished product was developed to have the same formulation, route of 
administration, dosage form and strength as the reference product Avastin’ (207). 
Furthermore, some biosimilars possess identical excipient composition (e.g. rituximab 
biosimilars: RITUZENA®, RITEMVIA® and BLITZIMA®) and have been approved by 
the EMA following a multiple marketing authorisation application (208).  
The pH values at which listed antibody formulations were buffered are in a range between 
pH 4.6 and 8.2. The trend observed in the use of excipients for antibody formulations 
matches with the results obtained for protein formulations, probably because antibodies 
form the main class of therapeutic proteins. Hence, additional information is reported 
below only for other excipients added to antibody products and not discussed in previous 
sections. For example, proline (24–28.78 mg/mL) is reported in the EPAR’s scientific 
discussion of some liquid antibody products to be a viscosity and tonicity modifier or a 
stabiliser (209, 210). EDTA and pentetic acid are added as chelating agents only to liquid 
products at concentrations usually in a range between 0.02 and 1 mg/mL and 0.01–0.04 
mg/mL, respectively. Calcium chloride is reported to be at concentrations of 0.4 mg/mL 
in the antibody product HYQVIA® (human normal Ig). Finally, rHUPH20 is added at 
concentrations of 2000 units/mL in MABTHERA® (rituximab) and HERCEPTIN® 
(trastuzumab). However, in HYQVIA® (human normal Ig) rHUPH20 (160 units/mL) is 
provided in a separate vial containing other excipients and added to the antibody product 
prior to administration. 







The information summarised in this overview aims to update formulation scientists on 
the trends of excipients’ use in approved protein products, aiding them in the selection of 
excipients for the development of new formulations. The data presented details the most 
common excipients included in liquid and lyophilised formulations classified into 
functional categories, focusing in particular on antibody products. The discussion also 
provides information and key considerations in the use of specific excipients, analysing 
their role and rationale of use in protein formulations with different dosage form (liquid 
or lyophilised). A shortcoming of the EPARs data is the limited quantitative 
compositional information on approved products. However, this information was 
collected for most of the protein formulations using other publicly available sources (FDA 
and Marketing Authorisation Holder). Of note from this overview is the low number of 
‘novel’ excipients introduced within the products approved over the period analysed. This 
may be due to many factors; such as the employment of an usual ‘platform approach’ 
formulation strategy (28), the regulatory requirements of approving new excipients for 
parenteral formulations (166), as well as companies’ marketing/commercial reasons that 
can drive the choice of one excipient over another (28, 211). 
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3.1  Introduction 
 
As discussed in Chapter 1, each formulation has a critical temperature below which it 
needs to be frozen and dried for complete solidification and prevention of 
physical/structural collapses that can compromise the quality of the product (52, 53). 
Critical temperatures include glass transition of the maximally freeze concentrated 
solution (Tg’) and collapse temperature (Tc) in the case of the amorphous fraction, and 
eutectic temperature (Teu) in the case of the crystalline fraction. Critical temperature 
values are related to the formulation components, their physical nature (amorphous or 
crystalline) and their ratio in the mixture. Typically a difference of 1°C to 3°C has been 
reported between Tg’ and Tc of a protein formulation (Tc > Tg′) (52, 55) however, at 
higher protein concentrations this difference can progressively increase up to 10°C (32). 
Furthermore, the temperature range between the onset collapse temperature (Toc) and the 
full collapse temperature (Tfc) could also widen as protein concentration increases (32, 
212). The first step in lyophilisation process design of a protein formulation is the 
determination of the thermal properties of its frozen solution, specifically its critical 
temperatures.  
Critical temperatures determination is commonly conducted by performing differential 
scanning calorimetry (DSC) to determine Tg′ and freeze-drying microscopy (FDM) to 
determine Tc and Teu. Additionally, a broad number of alternative techniques are 
currently available to determine these parameters, including dynamic mechanical analysis 
(DMA), electrical impedance (EI)/differential thermal analysis (DTA) and optical 
coherence tomography freeze-drying microscopy (OCT-FDM) (54, 213-217). 
Previously, Meister and Gieseler reported unconventional collapse events in formulations 
analysed by FDM and showed how a careful evaluation of the critical temperatures needs 
to be conducted to avoid bias in their measurement. In addition, Meister and Gieseler 
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recommended a new collapse classification and the need for further examples in literature 
to provide a full understanding of unconventional collapse events (212).  
An optimised formulation intended to be lyophilised can be considered as a formulation 
with maximum critical temperatures and preserved protein stability following processing, 
storage and reconstitution. The possibility to lyophilise materials at high shelf 
temperatures is particularly valuable considering that each degree increased on the 
product temperature during primary drying, can produce a 13% reduction in drying time 
(72, 212). It is reported that formulations containing high concentration of proteins tend 
to have high critical temperatures (32, 65). This effect of the protein concentration on 
critical temperatures promotes the development of efficient lyophilisation cycles at higher 
shelf temperatures, with a product temperature maintained below Tg′ and/or Tc, and a 
significant reduction in time and costs of processing. However, for formulations with high 
protein concentrations, the high total solute concentration can negatively impact the 
freezing process (prolonging the time for complete material solidification), drying process 
(resulting in high product dry layer resistance) and drastically increase the viscosity and 
osmolality of the liquid or reconstituted protein formulations. High concentration protein 
formulations tend to exhibit relatively high viscosities, that can negatively impact protein 
aggregation, syringeability and injection into the patient (30).  
In pharmaceutical freeze-drying, Quality by Design (QbD) is widely proposed to inform 
the rational design of formulations and process parameters, minimising the use of iterative 
trial and error approaches (42, 92, 218-220). The two most common theoretical models 
for prediction of Tg′ of amorphous mixtures are the Fox-Flory and Gordon-Taylor 
equations (221). However, these models are limited in their prediction of Tg′, since they 
do not consider the intermolecular interactions, such as hydrogen bonds occurring (222, 
223), the variations in the conformational entropy (224), the size and shape or free 
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volumes of the molecules in the mixture (225). Weng et al. showed the inability of the 
conventional Gordon and Taylor equation to predict Tg for any of the protein/sugar 
mixtures analysed in their study (221).  
The aim of this study was to aid formulation selection by predicting and maximising 
critical temperatures, and to investigate the effect of each formulation component on the 
critical temperatures. As an alternative to theoretical models, empirical models generated 
from mixture design of experiments (DOEs) were employed to predict both critical 
temperatures (Tg′ and Tc). While theoretical and mathematical models have been used to 
predict Tg and Tg’ (148, 221) to our knowledge this is the first time that models for Tc 
prediction are reported in literature. Critical temperatures were analysed for formulations 
with a wide range of protein concentrations (1 to 10% w/v) and total solute concentrations 
(10, 15 and 20% w/v). The models were generated for formulations containing BSA, and 
subsequently verified with equivalent IgG1 formulations. The excipients included in 
formulations studied were sucrose and arginine/arginine-HCl (arg/arg-HCl). Sucrose was 
selected because it is the most commonly employed cryo/lyo-protectant, and arg/arg-HCl 
as its use has increased in recent years in commercialised, lyophilised protein products 
(Chapter 2). Sucrose is an amorphous disaccharide capable of stabilising the protein by 
forming H-bonds and replacing water (replacement theory) or by forming a rigid 
amorphous matrix (vitrification theory) which reduces mobility and degradation of the 
protein (226). Arginine was selected as excipient for its multifunctional role, since it can 
act as protein aggregation suppressor, viscosity and solubility enhancer as well as pH 
modifier (152, 227-232). In particular, protein stability was observed to increase when 
arginine is included in formulation in the presence of the chloride counter ion (148). The 
mechanism by which arginine contributes to reducing protein aggregation is not 
completely understood. The main hypothesis involves the occurrence of preferential 
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interactions between the guanidinium groups of arginine with the aromatic groups (π-
electrons) of the amino acids in the protein (155, 233). Extensive studies have been 
conducted on the role of arginine as an aggregation suppressor in solution, but very little 
has been published on its role in lyophilised products (234-236).   
3.2 Materials 
 
Heat shock fractionated BSA (Sigma Aldrich, Ireland) with a purity ≥ 98% and Mw of 
66 KDa was used. The humanized anti-IL8 IgG1 was produced by Chinese hamster ovary 
cell lines (CHO cells) in NIBRT (Ireland) and purchased as a frozen solution (−80°C) in 
tris buffer 50mM, pH7. The Mw of humanized IgG1 was ~140–150 KDa (characterisation 
conducted by SE-HPLC and SDS-Page). Sucrose and arginine were both purchased from 
Sigma Aldrich, Ireland. Hydrochloric acid (HCl) 37% (Acros Organics, Fisher Scientific, 
Ireland), diluted with ultrapure water (Type I, MilliQ) to 1M and 5M solutions, was used 
to adjust pH to desired values and to form the arg/arg-HCl salt. Polysorbate 80 (Sigma 
Aldrich, Ireland) was included in formulations as a surfactant. Ultrapure water (Type I, 
MilliQ) was used for preparation of the formulations. Syringe filters 0.2μm, PTFE 
membrane and 13mm diameter (VWR International, North American, USA) were used to 
filter excipient solutions prior to protein formulation under aseptic conditions. 
Formulation concentrations expressed in percentages are always considered as % (w/v) 
in this thesis.
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3.3.1 Pre-formulation studies 
 
In advance of developing the empirical models based on a DOE approach, pre-
formulation studies were conducted to determine any formulation constraints. 
3.3.1.1 Tg′ and crystallisation events determination of placebo 
solutions  
 
Placebo solutions with 10% (w/v) total solute concentration were prepared using a range 
of arginine:sucrose ratios (5:0, 4:1, 3:2, 2:3, 1:4, 0:5) dissolved in ultrapure water. Sucrose 
(292 mM) and arginine stock solutions (574 mM) were prepared and HCl was used to 
titrate the arginine stock solution to pH5, pH6, and pH7. Equivalent formulations were 
prepared in absence of HCl to study the effect of the counter ion on Tg′ and crystallisation 
of arginine. Formulations were analysed by DSC (Q2000, TA Instrument, Inc., Delaware, 
USA), once volumes of 20μL were transferred into Tzero aluminium pans and 
hermetically sealed. Tg′ analysis was performed by freezing the samples to −80°C and 
reheating them to +5°C at a rate of 2°C/min with a temperature modulation of ± 1°C every 
60s. For crystallisation detection, samples were cooled to −80°C, heated to −10°C and 
held at his temperature for 60 min, then re-cooled to −60°C and re-heated to +5°Cat a rate 
of 2°C/min and a modulation of ± 1°C every 60s. Data was processed by using the 
Universal Analysis Software (version 4.5A).  
DSC experiments were performed in triplicate. Two-way ANOVA and Tukey’s multiple 
comparison tests were conducted to investigate the effect of arginine and HCl on the Tg′ 
of placebo solutions.
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3.3.1.2 Viscosity of BSA formulations   
 
The effect of BSA and arginine concentrations on formulation viscosity was investigated 
at 25°C and in a wide range of shear rates 100–10,000 s−1 using the Fluidicam TM RHEO 
(Formulaction, Inc., Toulouse, France). A glass chip with a channel gap of 50 µm and a 
sample size of 1.5 mL were employed during the analysis. An aqueous dye solution with 
a viscosity of 0.95 cP was used as a reference. Two groups of formulations were analysed; 
(1) formulations with a fixed ratio of protein:sucrose:arg/arg-HCl (P1:S0.8:A0.2) and 
increased protein concentration (5 to 40% w/v) to observe the effect of protein 
concentration, and (2) formulations having a fixed protein concentration (10% w/v) and 
total solute concentration (20% w/v), but varied sucrose: arg/arg-HCl ratios (S1:A0, 
S0.8:A0.2, S0.6:A0.4, S0.4:A0.6, S0.2:A0.8) to observe the effect of arg/arg-HCl. Two 
replicates for each formulation were analysed. 
3.3.2 Formulation studies 
 
3.3.2.1 Empirical models development  
 
A mixture DOE was developed by using Minitab®18 Software with the aim to select the 
ratio of formulation components and to predict critical temperatures for formulations 
included in the design space. An extreme vertices mixture design of experiments with 
three components and augmented degree two design (in presence of centre and axial 
points) was selected.  
An individual DOE was constructed for four formulation sets with fixed total solute 
concentrations and protein concentration ranges (Table 3.1). Formulation constraints 
were applied and a total number of 49 BSA formulations with different ratios of 
protein:sucrose:arg/argHCl were characterised to generate the empirical models.  
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Table 3.1 DOE name, formulation constraints applied and number of runs for each DOE set. 










10%-Low 10 1-5 1-9 0-8 13 
15%- Low 15 1-5 1-14 0-13 13 
15%-High 15 5-14 1-10 0-9 10 
20%-High 20 5-15 1-15 0-14 13 
 
The constraints were selected considering the high concentration of protein desired and 
the necessity to include sucrose as cryo/lyo-protectant in all formulations. Detailed 
composition of the 49 BSA formulations is reported in the Results (Section 3.4.3). 
3.3.2.2 Empirical models analysis and verification  
 
Statistical analysis of the empirical models based on DOEs was performed by using 
Minitab®18 Software with the aim of predicting critical temperatures for formulations 
included in the design space, and thereby selecting the ratio of formulation components 
to achieve maximised critical temperatures. The advantage to select formulations with 
maximised critical temperatures is to facilitate the development of shorter and more cost 
effective lyophilisation cycles, conducted at more aggressive conditions. The model 
employed was based on a regression equation with more than one term (Equation 3.1) 
Equation 3.1: Polynomial equation for building the regression model 
y = b0 + b1X1 + b2X2 + ... + bkXk 
where: y is the response variable, b0 is the constant (intercept), b1,b2, …,bk are the 
regression coefficients (slope) for the different terms (X1, X2, …,Xk). This  was  used for 
prediction of the responses by introducing the regression coefficient of each component 
into the equation (Minitab®18 Software). Subsequently, a response optimiser control, 
provided by the software, was used to select formulations by maximizing the responses 
(critical temperatures). The DOE model was then verified by predicting Tg′ and Tc of 
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additional optimal formulations included in the design space and correlating the predicted 
critical temperatures with the measured values (Tg′ and Tc). Verification of the model 
15%-High was not performed since the model could not be developed and used for 
prediction (Section 3.4.3). The additional optimal formulations used for verification 
include 25 observations for BSA formulations (3 formulations analysed in triplicate and 
8 formulations analysed in duplicate), and 9 observations for IgG1 formulations (3 
formulations analysed in triplicate) (Table 3.2).
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1 2.0 8.0 0.0 10.0 
2 2.0 6.4 1.6 10.0 
3 5.0 5.0 0.0 10.0 











5 5.0 10.0 0.0 15.0 











7 5.0 15.0 0.0 20.0 
8 5.0 12.0 3.0 20.0 
9* 10.0 10.0 0.0 20.0 
10* 10.0 8.0 2.0 20.0 
11* 10.0 6.0 4.0 20.0 
 
 
*All formulations (F) contained BSA as protein and were analysed in duplicates except for 
formulations 9, 10 and 11 20% (w/v)-High that were prepared including either BSA or IgG1 as 
proteins and were analysed in triplicates; Polysorbate 80 is added to the protein formulations at 
concentrations of 0.05% (w/v) and is not considered in the total solute concentration.  
3.3.2.3 Fox-Flory equation  
 
Theoretical Tg’ for all formulations was also estimated by using the Fox-Flory equation 
(Equation 3.2). 












                    
where Tg1, Tg 2, Tg 3 and w1,w2,w3 are Tg' and weight fractions of the components 1, 2 
and 3, respectively. The Tg′ value of the excipient components (sucrose Tg′–32°C and 
arg/arg-HCl Tg′=−44°C) in aqueous solution was determined by DSC, whereas a 
previously reported Tg’ value was used for the protein BSA (237, 238). 
Chapter 3 – Application of a mixture DOE for the prediction of formulations critical 




3.3.2.4 Preparation of BSA formulations  
 
BSA formulations were prepared by dissolution of the protein in the excipient solutions. 
Excipient solutions were obtained by dilution of the sucrose and arginine stocks (20% 
w/v). For the stock solutions, the desired mass of excipients was dissolved in ultrapure 
water. The arginine stock solution (1148 mM) was titrated to pH7 ± 0.3 using 1 M HCl. 
3.3.2.5 Preparation of IgG1 formulations  
 
The IgG1 was formulated at the desired concentration by performing ultracentrifugation 
using AMICON ultra-15 centrifugal filter units (Merck, Darmstadt, Germany). The IgG1 
at an initial concentration of 0.5% (w/v) was concentrated to a final concentration of 20% 
(w/v). The concentration and buffer exchange were conducted by performing three runs 
of ultracentrifugation (Rotanta 460R, Hettich, Germany) at 3800 rpm (30 min per run). 
The protein was then formulated by dilution 1:1 with the excipient solution (pH6) to 
obtain a final protein concentration of 10% (w/v).  pI of the IgG1 was determined to be > 
7 (as per NIBRT information). 
Polysorbate 80 at fixed concentration of 0.05% (w/v) was added to the final formulations 
by dilution from the stock solution 1% (w/v). Polysorbate 80 is not considered in the total 
solute concentration of the formulations.
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3.3.2.6 Tg′ determination  
 
Tg′ of the formulations was measured using DSC (Q2000, TA Instrument Inc., Delaware, 
USA). Formulation volumes of 20μL were transferred into Tzero aluminium pans, and 
hermetically sealed.  
DSC analysis were performed by cooling the samples to −60°C and re-heating them to 
+5°C at a ramp rate of 5°C/min. Data was processed by using the Universal Analysis 
Software (version 4.5A). Tg′ values were measured as midpoint temperature of the 
thermal event showed in the reversing heat flow thermogram (Supplementary 
Information (SI), Figure 1). 
3.3.2.7 Tc determination  
 
Tc was determined by carrying out FDM analysis (Lyostat 3, equipped with a Zeiss Axio 
imager, A1 microscope and a Linksis32 Software, Linkam Scientific Instrument, 
Biopharma Process Systems Ltd, Winchester, UK). All samples were cooled at a freezing 
rate of 10°C/min to −40°C. After 10 min of isothermal equilibration, a vacuum (0.1 mbar) 
was applied to initiate the sublimation. Once the drying front was approximately 1–2 
inches on the monitor, the temperature was increased at a ramp rate of 0.5°C/min under 
vacuum until the full collapse of the material was reached.  
Pictures were captured at 5s intervals during drying. The collapse temperature was 
reported as Toc which is the first observable loss of material structure, and Tfc which 
indicates the complete loss of material structure, both occurring during the drying step.  
All formulations included in the DOEs used to verify the empirical models were analysed 
using the selected DSC and FDM protocols. 
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3.4.1 Tg′ and crystallisation of placebo solutions 
 
The Tg′ of placebo solutions containing sucrose and arginine at a range of ratios and fixed 
total solute concentration (10% w/v) was analysed to investigate the effect of excipient 
components on the critical temperatures in absence of the protein. As shown in Figure 
3.1 arginine has a significant plasticising effect on the Tg′ of sucrose solutions (p <0.0001 
ANOVA, Tukey’s multiple comparison). This effect was enhanced in the presence of HCl 
(pH 5-7), which significantly decreased the Tg’ of the corresponding formulations 
containing arginine in absence of the counter ion (max ΔTg′=6.26°C). The plasticising 
effect of arg/arg-HCl follows a linear trend, however, the same trend was not observed in 
absence of HCl. The Tg′ of analysed formulations was not affected by pH at the range 
(pH5-7) investigated.  
 
Figure 3.1 Plasticising effect of arginine and HCl counter ion on the Tg′ of sucrose solutions. Arginine 
and HCl counter ion both have a significant plasticising effect on the Tg′ of placebo formulations with 
varied sucrose:arginine ratios and a fixed total solute concentration (10% w/v) (n=3). 
 
No significant difference in the Tg′ values and absence of crystallisation were observed 
by DSC analysis following annealing (SI, Figure 2). 
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3.4.2 Viscosity of BSA formulations 
 
Viscosity is one of the main limitations encountered when formulating proteins at high 
concentrations. Hence, it is necessary to investigate the effect of both protein and arg/arg-
HCl concentration on the viscosity of high concentration BSA formulations studied 
herein. Figure 3.2a shows an increase in viscosity with increase in protein concentration, 
in particular for protein concentrations higher than 20% (w/v). For this reason, our study 
was focused on formulations with protein concentrations constrained between 1 and 15% 
(w/v). Figure 3.2b shows the effect of the increased amount of arg/arg-HCl on viscosity 
of formulations with fixed protein concentration (10% w/v) and total solute concentration 
(20% w/v). As previously reported arg/arg-HCl reduced viscosity (154), however, for 
fomulations studied this effect was significant up to arginine concentrations of 4% (w/v). 
Additionally, an increase in viscosity was observed for formulations with higher total 






Figure 3.2 Viscosity of BSA formulations. (a) Effect of protein concentration on viscosity for formulations with fixed Protein: Sucrose: Arg/Arg-HCl ratio (P1:S0.8:A0.2) 
and increased protein concentration (5–40% w/v); (b) Effect of Arg/Arg-HCl on viscosity for formulations with fixed protein (10% w/v) and total solute concentration 
(20% w/v), increased Arg/Arg-HCl concentration (0–8% w/v) and reduced sucrose concentration (10–2% w/v); (c) Effect of solute concentration (10%, 15%, 20% w/v) 
for formulations with fixed protein concentration and increased total solute concentration with and without Arg/Arg-HCl in ratios (P1:S0.8:A0.2 or P1:S1) (n=2).
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3.4.3 Empirical models development 
 
Tg′ and Toc were determined for the formulations included in each DOE set (Table 3.1) 
with the aim of building an empirical model for each total solute concentration. Detailed 
formulation composition and corresponding critical temperature values are provided for 
each DOE set in Table 3.3.  
Table 3.3 Predicted and measured critical temperatures of formulations used to develop the 
empirical model for each DOE set. 
10% (w/v)-Low 











1 2.0 6.5 1.5 -30.4 -30.0 -30.6 -29.2 -29.0 
2 4.0 2.5 3.5 -28.7 -28.1 -27.9 -26.9 -26.0 
3 5.0 3.0 2.0 -25.0 -24.1 -24.5 -23.1 -22.1 
4 2.0 2.5 5.5 -35.5 -34.7 -33.8 -34.2 -32.5 
5 5.0 1.0 4.0 -24.0 -26.5 -24.6 -22.2 -22.8 
6 3.0 1.0 6.0 -31.0 -33.2 -31.1 -29.4 -29.6 
7 4.0 4.5 1.5 -26.1 -25.7 -26.6 -23.2 -24.1 
8 1.0 9.0 0.0 -30.8 -30.3 -30.6 -29.9 -29.9 
9 5.0 5.0 0.0 -22.4 -21.7 -22.3 -18.4 -18.6 
10 3.0 7.0 0.0 -26.9 -26.0 -26.7 -24.6 -24.0 
11 1.0 5.0 4.0 -34.2 -35.1 -34.4 -33.3 -33.6 
12 3.0 4.0 3.0 -28.7 -29.6 -30.1 -26.7 -28.4 
13 1.0 1.0 8.0 -37.1 -39.9 -37.6 -36.0 -36.5 
 
15% (w/v)-Low 











1 4.0 3.8 7.3 -34.4 -32.5 -33.6 -32.3 -31.1 
2 3.0 12.0 0.0 -30.1 -28.2 -29.7 -27.5 -27.1 
3 2.0 10.3 2.8 -32.1 -31.8 -32.1 -30.0 -30.0 
4 5.0 5.5 4.5 -31.6 -28.9 -32.0 -28.7 -29.1 
5 2.0 3.8 9.3 -36.3 -37.0 -35.7 -34.6 -34.0 
6 4.0 8.3 2.8 -31.6 -28.9 -31.5 -28.6 -28.8 
7 3.0 6.5 5.5 -32.9 -32.5 -33.6 -30.6 -31.3 
8 3.0 1.0 11.0 -34.6 -36.9 -35.3 -32.3 -33.2 
9 5.0 10.0 0.0 -28.1 -25.3 -28.3 -25.9 -25.9 
10 5.0 1.0 9.0 -32.4 -32.5 -32.2 -30.0 -29.9 
11 1.0 1.0 13.0 -38.8 -41.4 -38.7 -36.9 -36.8 
12 1.0 7.5 6.5 -34.2 -36.2 -34.3 -33.1 -33.2 
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13 1.0 14.0 0.0 -30.9 -31.0 -31.0 -28.3 -28.3 
 
15% (w/v)-High 











1 14.0 1.0 0.0 ND -12.4 ND NM NM 
2 5.0 1.0 9.0 -32.5 -32.5 ND NM NM 
3 8.0 4.0 3.0 -24.5 -23.4 ND NM NM 
4 5.0 10.0 0.0 -28.6 -25.3 ND NM NM 
5 11.0 2.5 1.5 ND -17.9 ND NM NM 
6 6.5 2.5 6.0 -27.6 -27.9 ND NM NM 
7 6.5 7.0 1.5 -24.6 -24.4 ND NM NM 
8 5.0 5.5 4.5 -31.6 -28.9 ND NM NM 
9 9.5 5.5 0.0 ND -18.9 ND NM NM 
10 9.5 1.0 4.5 -22.5 -22.5 ND NM NM 
 
20% (w/v)-High 












1 10.0 1.0 9.0 -30.4 -27.1 -30.7 -28.0 -28.6 
2 15.0 1.0 4.0 ND -18.8 -23.9 -18.7 -18.3 
3 5.0 15.0 0.0 -29.2 -27.1 -29.3 -26.5 -26.6 
4 12.5 3.3 4.3 -27.5 -21.6 -26.6 -24.2 -22.6 
5 10.0 10.0 0.0 -25.2 -21.7 -25.1 -20.4 -20.5 
6 10.0 5.5 4.5 -28.3 -24.4 -28.9 -24.2 -26.0 
7 7.5 3.3 9.3 -33.2 -29.9 -32.8 -30.7 -31.0 
8 5.0 8.0 7.0 -32.6 -31.3 -32.7 -31.0 -30.8 
9 7.5 10.3 2.3 -29.5 -25.8 -29.0 -26.6 -26.2 
10 12.5 5.3 2.3 -24.6 -20.4 -25.2 -21.9 -20.4 
11 15.0 5.0 0.0 ND -16.4 -20.7 -12.7 -13.1 
12 15.0 3.0 2.0 ND -17.6 -22.7 -14.9 -16.2 
13 5.0 1.0 14.0 -35.7 -35.5 -35.7 -33.6 -33.3 
 
P= Protein (BSA), S= Sucrose, A= Arg/Arg-HCl. ND not detected and NM not measured. Not detected 
indicates the incapability to detect the event, NM indicates that the analysis was not performed 
 
For six formulations it was not possible to experimentally determine the Tg′ (3 
formulations in DOE 15%-High and 3 in DOE 20%High). As a result, for the DOE 15%-
High, an empirical model could not be generated and used to predict Tg′ of formulations 
within the design space. For the DOE 15%-High, some of the formulations selected to 
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build the model contain high protein concentration and low excipient concentrations with 
consequently high Tg′ values, which can overlap with the melting region in the 
thermogram (Figure 3.3). However, the undetected values for the DOE 20%-High did 
not impact the capability to build and verify the model. The possibility to develop the 
DOE 20%-High model, regardless of missing values, was due to the higher number of 
runs (13 instead of 10). In addition, the composition of the formulations with missing 
values in the DOE 20%-High design space is limited to a restricted region.  
Since the empirical model for the DOE set 15%-High could not be built due to the 
inability to detect Tg′ values for certain formulations, the Toc model for corresponding 
formulations was not further developed.  
Examples of the limitations observed in determining Tg′ of high concentration protein 
formulations (14–15% (w/v), Tg′ > –22°C) is presented in Figure 3.3. This behaviour 
was also observed for a number of formulations with lower protein concentrations (9.5 
and 11% (w/v) combined with excipients at specific ratios). In all these cases the predicted 
Tg′ determined using the Fox-Flory equation was higher than −19°C. 
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Figure 3.3 Examples of the limitations observed in determining Tg′ of high concentration protein 
formulations. The effect of protein concentration on the overlapping of Tg′ and melting of the protein 
depressed by the presence of excipients. Tg′ of formulations with different protein concentration 2–
15% (w/v) are shown: Formulation A: BSA 2% (w/v), Sucrose 6.5% (w/v), Arg/Arg-HCl 1.5% (w/ 
v); Formulation B: BSA 5% (w/v), Sucrose 12% (w/ v); Arg/Arg-HCl 3% (w/v); Formulation C: BSA 
10% (w/v), Sucrose 8% (w/v), Arg/Arg-HCl 2% (w/v); Formulation D: BSA 12.5% (w/v), Sucrose 
5.3% (w/v), Arg/Arg-HCl 2.3% (w/v), Formulation E: BSA 15% (w/v), Sucrose 3% (w/v), Arg/Arg-
HCl 2% (w/v). 
 
For formulations investigated across the DOE sets an unconventional collapse behaviour 
(e.g. microcollapses or fissures) was observed. Hence, the classification of the collapse 
events was conducted observing three different phases of structural loss, i.e. onset 
collapse (Toc), microcollapse (Tmc) and full collapse (Tfc). Figure 3.4 shows all the 
possible events occurring during the collapse of high concentration protein formulations. 
During FDM analysis the heating rate was increased (20°C/min) with the aim of showing 
all the collapse events in a single picture. Figure 3.4 is exclusively included to summarize 
the type of events occurring, but not to collect temperature data for any of the 
formulations, since the high heating rate was considered suboptimal for accurate 
measurement.  
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Figure 3.4 Representative FDM image of the collapse events observed for high concentration protein 
formulations. (1) Drying front; (2) Onset collapse (Toc), (3) Microcollapse (Tmc); (4) Full collapse 
(Tfc). Drying rate of 20°C/min was selected in order to show all the events occurring in a single image, but 
no quantitative information of the real temperature was extrapolated from this picture. 
 
For some of the formulations analysed the interval between Toc and Tfc was found to be 
large (0.20–5.86°C). The effect of protein and arg/arg-HCl concentration on the collapse 
behaviour is shown in Figure 3.5. Microcollapse events were usually observed for high 
concentration protein formulations (≥5% (w/v)), whereas they were less frequent in 
formulations with increased arg/arg-HCl concentration, which showed a more 
conventional collapse behaviour.  
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Figure 3.5 Effect of arginine/arginine-HCl and protein concentration on the collapse behaviour of 
high concentration protein formulations. (a) Formulation A: BSA 5% (w/v), Sucrose 5% (w/v); (b) 
Formulation B: BSA 5% (w/v), Sucrose 12% (w/v), Arg/Arg-HCl 3% (w/v); (c) Formulation C: BSA 
10% (w/v), Sucrose 10% (w/v); 5d) Formulation D: BSA 2% (w/v), Sucrose 6.4% (w/v), Arg/Arg-
HCl 1.6% (w/v). Toc (yellow), Tfc (orange/red).  
 
Data used to inform the empirical models were observed to be normally distributed 
(Anderson-Darling test, p > 0.05), and in absence of outliers (Grubbs’ Test, p > 0.05). 
The type of model established was a linear regression model (analysis of variance, p < 
0.05). It is considered that the absence of large residuals (within 2 and −2) and the normal 
distribution of the residual plots make the model adequate for prediction (SI, Figure 3). 
A summary of the statistical parameters that explain the suitability of the model for the 
three DOE sets analysed is shown in Table 3.4. 
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Table 3.4 Summary of the statistical parameters required to assess the suitability of the empirical 
models generated from the different DOE sets. 
Response DOE R2 (%) R2 (adj.) (%) SD* 
Tg’ 
Low-10% 97.17 94.33 1.07 
Low-15% 97.40 94.81 0.63 
High-20% 98.21 94.63 0.81 
Toc 
Low-10% 97.10 94.20 1.25 
Low-15% 96.99 93.99 0.75 
High-20% 97.62 95.24 1.36 
The predicted sum of squares (PRESS) ranges between 9.36 and 59.59. Analysis of variance, linear regression model 
p <0.05. SD* represents the standard deviation of the distance between the data values and the fitted values; SD was 
measured in the units of the response. 
 
Firstly, the models described the effect of each formulation component on the critical 
temperatures expressed by the regression coefficients once incorporated in the general 
equation (Equation 3.1). The three formulation components have an additive effect with 
no level of interactions (p >0.05). Several regression coefficients are available for the 
three different DOEs considering the responses (Tg′ and Toc), the formulation 
components and the ratio between protein and excipient, which varies with the total solute 
concentration. 
Regression coefficients of each DOE model are reported in Table 3.5. In all cases, 
regression coefficients for the Toc model were higher than those for the Tg′ model. Hence, 
the Toc was always higher than the Tg′ for corresponding formulations, as expected. 
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Table 3.5 Regression coefficients of the three formulation components in amounts. 
Response DOE P S A P-S* P-A* S-A* P-S-A* 
Tg’ 
Low-10% -0.90 -3.24 -4.23 -0.06 -0.07 -0.04 -0.06 
Low-15% -1.34 -2.11 -2.78 -0.01 0.05 0.04 -0.03 
High-20% -0.81 -1.67 -2.00 -0.01 -0.03 0.04 -0.01 
Toc 
Low-10% -0.77 -3.31 -4.13 -0.07 -0.09 -0.06 -0.08 
Low-15% -1.29 -1.93 -2.63 0.00 0.06 0.00 -0.01 
High-20% -0.21 -1.56 -1.66 -0.03 -0.10 0.04 -0.01 
P=Protein (BSA), S=Sucrose, A=Arg/Arg-HCl. * P values of the coefficients for all the formulation components 
interaction were > 0.05. 
 
The contribution of protein and excipients to the responses was clearly observed in the 
Cox-response plots (Figure 3.6a-c) where each line describes the component impact on 
critical temperatures, once compared to a reference composition blend. In all DOE data 
sets the formulation components follow the same trend. Increased protein concentration 
has a positive effect on the Tg′, whereas sucrose and arg/ arg-HCl both decrease the 
responses in a concentration dependent manner. However, arg/arg-HCl had a more 





Figure 3.6 Cox response plots of the empirical models generated for critical temperatures prediction. (a) 10%(w/v) total solute concentration, (b) 15%(w/v) total solute 
concentration; (c) 20%(w/v) total solute concentration. Cox response plots show the effect of formulation components on the response Tg′. Cox response plots for the 
response Toc are reported in the supplementary information since they follow the same trend as for the response Tg′. 
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The mixture contour plots ( 
Figure 3.7a-c) indicate the composition of the formulations (black dots) used to build 
the model and the critical temperature intervals (coloured bands) of formulations 
included in the design space. A response optimisation command was applied to each 
model with the aim of selecting formulation compositions with maximised critical 
temperatures. Constraints to the temperature range were applied to identify the region of 
the design space in which these formulations are more likely to be located ( 
Figure 3.7d-f). The rational choice of the constraints applied was conducted based on 
preliminary results (Tg′ and Toc) obtained for the analysed formulations and considering 
formulations with Tg′ values between −20 to −30°C and Toc values between −15 to 
−28°C.  
Cox response and mixture contour plots for the Toc response followed the same trend as 






Figure 3.7 Plots of the empirical models generated by mixture DOEs for critical temperatures prediction and optimisation. (a–c) mixture contour plots; (d-f) contour 
plots of the overlaid responses for formulations with different total solute concentrations: 10% (w/v), 15% (w/v) and 20% (w/v). Mixture contour plots show black dots 
which indicate formulations provided by the software to build the design space, black lines to identify constraints used in the design and coloured bands to specify the 
formulation regions at specific Tg′ intervals; Contour plots of overlaid responses (Tg′ and Tc) identify the region selected by performing a response optimisation. Mixture 
contour plots for the response Toc are reported in the supplementary information since they follow the same trend as for the response Tg′. 
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3.4.4 Empirical models verification 
 
Additional two constraints were applied to select specific formulations in the narrowed 
region of the design space for model verification: (1) low concentrations of arg/arg-HCl 
(<4%) were chosen due to the plasticising effect of this excipient and the minimal 
reduction in viscosity above this concentration (Figure 3.2), protein concentrations (2 –
15% w/v) were included in formulations since this was the concentration range of interest.  
Considering applied constraints, 11 formulations were selected to validate the models. 
Figure 3.8 shows the composition of the 11 formulations, and their corresponding Tg′, 
Toc and Tfc. Formulations with equivalent protein concentrations showed reduced critical 
temperatures as the total solute concentration increased. Furthermore, as protein 
concentration increases, an obvious difference between Tg′ < Toc < Tfc was observed. The 
maximum difference in temperature observed between Tg′ and Toc, Toc and Tfc, and Tg′ 
and Tfc was 5.9°C, 5.0°C, and 8.9°C, respectively. Critical temperature values of the 
additional formulations are detailed in SI, Table 1. 
 
Figure 3.8 Critical temperatures of 11 formulations selected. Formulations are ordered by ascending 
values of protein concentration and total solute concentration. Tfc (°C), Toc (°C) and Tg′ (°C) are 
reported for the 11 formulations selected and used to verify the empirical models (n=2). 
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In order to obtain the highest protein concentration in formulation and maximised critical 
temperatures, formulations with BSA concentrations of 10% w/v were selected. 
Consequently, formulations having 10% w/v of the protein IgG1 were also analysed. 
 It was observed that the difference in critical temperatures of equivalent BSA and IgG1 
formulations was not statistically significant (Figure 3.9). Hence, the empirical model 
20%-High based on the BSA formulations was also verified for the IgG1 formulations. 
 
Figure 3.9 The effect of the type of protein (BSA and IgG1) on the critical temperatures of high 
concentration protein formulations. Critical temperatures of equivalent formulations with different 
type of protein are not significantly different (Two-way ANOVA, Tukey’s multiple comparison, n=3). 
Formulations contain 10% w/v protein (IgG1 or BSA), S=Sucrose, A=Arg/Arg-HCl. Difference in the 
Mean of Tg′ and Toc for formulations showed in the figure ranges between 2.88°C and 4.81°C. 
 
The model verification was conducted by detecting Tg′ and Toc for the additional BSA 
and IgG1 formulations. Figure 3.10 shows how the additional data points fall within the 
95% prediction interval (PI) for each model. In particular, Figure 3.10e and f display the 
capability of the DOE 20%-High model to accurately predict critical temperatures for the 
IgG1 formulations. Therefore, the model built on the BSA formulations can be used to 
predict critical temperatures of equivalent IgG1 formulations.  
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Furthermore, the empirical models provided were found to be more accurate in predicting 
Tg′ relative to the theoretical Fox-Flory model (i.e. R2 values were always lower and 95% 
PI larger for the Fox-Flory model), as shown in Figure 3.10a, c and e. 
 
Figure 3.10 Verification of the three DOEs and the Fox-Flory models by using BSA and IgG1 
formulations. (a) Tg’ and (b) Toc for DOE 10%-Low, n=8 observations (BSA); (c) Tg′ and (d) Toc 
for DOE 15%-Low, n=4 observations (BSA); (e) Tg′ and (f) Toc for DOE 20%-High, n=22 
observations (n=13 BSA and n=9 IgG1). Black dots represent values of critical temperatures for 
formulations used to build the empirical models. Black line is the fit of the empirical regression 
models generated. Coloured dots represent critical temperatures of formulations used to verify the 
empirical models. Grey triangles and line represent the Fox-Flory model. 
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Initial studies were conducted on placebo solutions containing the selected excipients of 
interest, arginine and sucrose to analyse their impact on Tg′. Previously, Startzel et al. 
investigated the impact of arginine, pH and arginine counter ion on the Tg′ and Tc of 
sucrose rich formulations (148). The impact of arginine counter ions on protein stability 
was evaluated, showing the greatest stability for formulations containing arg/arg-HCl 
(148). Additionally, Tischer et al. demonstrated that L-ArgHCl increases the solubility of 
both, the native and the unfolded protein, which is linked to a reduction of the free energy 
of the protein species in solution (239). The capability of arg-HCl to increase protein 
solubility was previously explained by a shift of a series pre-equilibria towards 
dissociation, which results in a reduction of the concentration of nucleation seeds without 
impacting the overall mechanism of aggregation (239). Consequently, in this study, the 
effect of the chloride salt form of arginine was investigated along with the impact of 
sucrose and protein on the critical temperatures. In agreement with Startzel et al., our 
findings show that the use of arginine at high concentrations in formulations represents a 
limitation due to its plasticising effect on the critical temperatures (240). As previously 
reported, both excipients (sucrose and arg/arg-HCl) were observed to be in the amorphous 
state and to remain predominantly amorphous following annealing (148). The amorphous 
nature of both excipients induces a significant reduction of the formulation critical 
temperatures. However, this effect is counterbalanced by the high concentration of protein 
in formulations, which tend to increase critical temperatures.  
In addition, arg/arg-HCl is widely reported to reduce viscosity of protein formulations, 
by acting as a salt and reducing the occurrence of protein-protein electrostatic interactions 
(154, 160). However, because of its plasticising effect, its concentration should be limited 
in protein formulations intended to be lyophilised. Therefore, arg/arg-HCl concentration 
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should be optimised to minimise its impact on Tg′ and maximise its positive effect on 
formulation viscosity. The rheological behaviour of high concentration protein 
formulations analysed in this study was in agreement with previous publications (154, 
160). Protein had a major effect on formulation viscosity when included at high 
concentrations. However, this effect would be influenced by the total solute concentration, 
and the protein: excipient ratio. In this study, viscosity was determined for BSA 
formulations, which can show a similar trend, but different rheological behaviour and 
viscosity values than the corresponding IgG1 formulations (241). Hence, in an attempt to 
balance the positive effect on viscosity and the negative effect as plasticizer, results from 
this study show that the use of arg/arg-HCl is recommended at low concentrations 1–4% 
(w/v) for high concentration protein formulations.  
Critical temperatures were determined for formulations provided by each DOE set, 
however six formulations provided by the DOEs have undetected values for Tg′ (Table 
3.3). DSC is the most common method used to determine Tg′ of protein formulations, 
however, in some cases detection of the thermal event can be challenging. This drawback 
shows the necessity to explore the use of alternative techniques based on different 
physical principles to detect high Tg′ values, characteristic for high concentration protein 
formulations. For instance, DMA and DTA/Impedance can be two valid options, since 
they are based on mechanical and electrical inputs respectively, and therefore can provide 
information which are not exclusively based on thermal changes in the material (54, 215).  
Regarding the FDM analysis, most published studies refer to the onset collapse (Toc) as 
collapse temperature (Tc). Toc is the event which precedes the full collapse, and it is the 
safest point to consider as critical during lyophilisation process optimisation (52, 212). 
For some of the formulations studied the material undergoes collapse of a small region, 
and then proceeds until the region of full collapse is reached a few degrees later. This 
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event is denoted as microcollapse in this study (Figure 3.4). The trend observed in Figure 
3.5, highlights how this unconventional collapse behaviour was less frequent in 
formulations with high concentration of arg/arg-HCl. This effect might be due to the 
capability of arg/arg-HCl to reduce the viscosity (and increase solubility) of protein 
formulations facilitating the freezing and drying step, and provoking more conventional 
collapses at lower temperature values.  
Additionally, high concentration protein formulations present a high total solute 
concentration and dry layer resistance that can provoke structural losses of the material 
during drying before a real collapse event occurs (212). This might explain the reason 
why high concentration protein formulations can often be lyophilised above their critical 
temperatures with no impact on the physical collapse of the cake. Hence, the conventional 
classification of the collapse events should be revised for these formulations, and the 
collapse temperature might be more accurately reported as a range of temperature rather 
than a single value. Furthermore, the high dry layer resistance of high concentration 
protein formulations can affect significantly both the freezing and drying process. FDM 
analysis of Tc can be difficult to perform for formulations with high total solute 
concentrations (15 or 20% w/v). Some of the formulations with high total solute 
concentration became ‘very dark’ after freezing, making it difficult to adjust the light and 
the focus of the FDM camera. The same formulations during drying can lose their 
structure (microcollapses or fissures) at lower temperatures than their actual collapse.  
The importance of the freezing protocol used in the FDM analysis and its impact on the 
collapse temperature behaviour have been reported by Meister and Gieseler (212). High 
freezing rates may generate a less homogenous matrix determining more variability in the 
velocity of sublimation and different observation times for the viscous flow. The high 
freezing rates can also increase the dry layer resistance provoking breakages of the 
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material before the occurrence of the actual collapse (212). Hence, for samples showing 
this behaviour the use of slower cooling rates might be more appropriate. In order to 
address these limitations and exclude any variability in determining Tc, the collapse 
information included in the DOEs are exclusively related to the Toc of the formulations 
and other structure losses are not considered at this stage in the models. The differences 
between Tg′, Toc and Tfc for high concentration protein formulations (Figure 3.8) justify 
the necessity to establish which Tc should be considered in a process development stage, 
since the large difference observed can have a significant impact on the primary drying 
time of an optimised lyo-cycle.  
The capability of an empirical model to predict Toc was slightly lower compared to the 
model for Tg′ prediction (larger standard deviation from the fit, Table 3.4). This could be 
due to the fact that the FDM used to detect Toc is a microscopy technique based on the 
visual observation of the operator, which generates a inherent variability. An alternative 
and novel method to overcome these difficulties in FDM data interpretation could be the 
use of a Thermal Analysis by Surface Characterization (TASC) software (Biopharma 
Technology Ltd., Winchester, UK) (242). This software addition to the Lyostat 
equipment (FDM, Biopharma Technology Ltd., Winchester, UK) can increase data 
accuracy and reproducibility, reducing operator error and providing a quantitative 
interpretation of the collapse events (242). The TASC software analyses changes in the 
successive images by monitoring brightness and colour of each pixel in the region of 
interest. Hence, it produces a normalised TASC trace overlay to the data graph and shows 
a change in the line based on the degree of collapse.  
Finally, the difference in sample morphology, thickness and dry layer resistance between 
the FDM stage and the vial in the freeze-dryer might also have a significant impact on the 
Tc. The OCT-FDM is an alternative technique that can be used to detect Tc directly in 
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the vials, reducing bias in the measurement related to the sample size, preparation and 
treatment (216, 217).  
Despite a similar trend across the different DOEs for each solute content and response, 
the contribution of each component varies considering its concentration in formulation, 
the total solute concentration and the ratio between the protein and excipients. For 
instance, for the DOE 15%-Low in which protein concentration is maintained between 1 
and 5% (w/v) and the total solute concentration is 15% (w/v), the effect of protein is 
minimal if compared to the depressing effect of excipients (in high amounts, maximum 
10% w/v). Additionally, as shown in the Cox-response plots (Figure 3.6a-c), the effect 
of protein at concentrations 1–5% is more significant for the DOE 10%-Low (lower 
excipient amounts) than the DOE 15%-Low (higher excipient amounts), hence, the 
protein:excipient ratio as well as the ratio between excipients has a significant impact on 
critical temperatures. The possibility to use the model to investigate the effect of different 
formulation components on the critical temperatures may be of particular interest for 
excipients with unknown behaviour.  
Results shown in Figure 3.9 support the concept that the concentration of protein rather 
than the type of protein affects the formulations critical temperatures. This finding is 
supported by previous unpublished data generated in our group on the thermal 
characterisation of high concentration protein formulations. The previous work showed 
that formulation critical temperatures for three types of proteins (BSA, Lysozyme and γ-
globulin) at high concentrations had comparable thermal characteristics regardless of the 
protein type and molecular weight. The use of less expensive model proteins, such as 
BSA, to build an empirical model for predicting IgG1 formulation critical temperatures 
makes the process development of costly protein formulations more effective and less 
time consuming. The empirical models give the possibility to pharmaceutical companies 
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to construct a database of their commercial products and predict their critical temperatures 
in a preliminary process development stage, aiding also re-formulation of specific 
products when required. The creation of empirical models capable of predicting critical 
temperatures for specific formulations platforms could facilitate the lyophilisation 
process design and optimisation.  
The theoretical Fox-Flory, Gordon and Taylor and Kwei (221) equations are very useful 
methods to calculate Tg′ values of specific formulations prior to their empirical 
determination in a preformulation stage. However, these theoretical models are limited in 
terms of applicability and accuracy. The Fox-Flory equation is based on a weighted 
averaged relationship, whereas the Gordon and Taylor equation considers an unequal 
distribution of the components including their density in the equation. If the densities of 
the components are equal the Gordon-Taylor can be simplified to the Fox-Flory equation. 
However, neither equation considers the intermolecular interactions occurring in the 
mixture blend or the plasticising effect of water on Tg′. On the contrary, the Kwei model 
implements the Gordon and Taylor equation by including an additional factor (q) in the 
equation which counts for the intermolecular interactions in the mixture (221). Hence, the 
Kwei model is more realistic and can complement the routinely used Fox-Flory and 
Gordon and Taylor models, improving their accuracy (221). However, the factor q is not 
easily obtainable for some components, especially proteins, which can have different sites 
of interaction. For this reason, the Kwei model was not applied to this study. The 
limitations observed in these theoretical/ mathematical models can be overcome by 
empirical/statistical models. The empirical models generated from the DOEs intrinsicly 
consider factors contributing to the responses (e.g intermolecular interactions) in the 
specific mixture, providing outcomes with a reduced level of uncertainty. Some 
Chapter 3 – Application of a mixture DOE for the prediction of formulations critical 




excipients can create preferential interactions (e.g sucrose: H-bonds, arginine: aromatic 
groups-guanidinium group) with the proteins which can impact the Tg′ regression.  
Previously, a similar and successful approach was employed to generate a model for 
prediction of flow behaviour of pharmaceutical blends (243). These models establish the 
type of regression (linear, cubic or quadratic) for the specific system and return regression 
coefficients that once applied to the equation provide the best fit. The empirical models 
presented in this study follow a linear regression, but they can also be applied to mixtures 
containing components with a higher level of interaction, that can be accurately described 
by a different type of regression. For the first time, empirical models are reported to 
predict not only the Tg′, but also the Toc of protein formulations. This is an important step 
considering the large interval that can elapse between these two critical temperatures 
when high concentration protein formulations are analysed. The reliability of the model 
depends on the capability to accurately determine the responses for specific mixtures. 
Hence, techniques and constraints need to be rationally selected to support a successful 
prediction model. 
The main contribution of this manuscript to the current knowledge in the field are related 
to the possibilities: (1) to predict both critical temperatures by using the empirical model, 
(2) to aid formulation selection or reformulation when required, understanding the impact 
of excipients with unknown behaviour, (3) to build the model by using inexpensive model 
proteins and estimate critical temperatures of expensive high concentration protein 
formulations such as IgG1. Furthermore, the manuscript highlights the difficulty in 
determining critical temperatures for high concentration protein formulations in some 
cases and opens a discussion about the necessity to identify new techniques for the 
determination of these parameters.  
Chapter 3 – Application of a mixture DOE for the prediction of formulations critical 
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The manuscript provides learnings in relation to arg/arg-HCl which has a depressing 
effect on the critical temperatures, but it has a positive effect on viscosity and solubility. 
Hence, the use of the empirical models in presence of rational constraints can aid the 
selection of optimal concentrations of this excipient in formulations. Additionally, the 
presence of arg/arg-HCl affects the way in which the material freezes and dries, reducing 
the occurrence of unconventional collapse events (fissures/ microcollapses) observed in 
some cases for high concentration protein formulations. This effect of arg/arg-HCl may 
be attributed to the known capability of this excipient to increase solubility and reduce 
viscosity of high concentration protein formulations. 
3.6 Conclusions 
The empirical models generated in this study were capable of establishing the effect of 
each formulation component on Tg′ and Toc. Critical temperatures of formulations 
included in the design space were succesfully predicted and the models represent useful 
tools to select high concentration protein formulations with detectable maximised critical 
temperatures. The empirical models showed a more accurate prediction of Tg′ if 
compared to the conventional Fox-Flory equation. In addition, this is the first time that an 
empirical model has been reported to predict Toc. The types of protein studied in 
formulations (BSA vs. IgG1) did not impact the critical temperatures of equivalent 
formulations. Hence, models built using BSA formulations can be successfully applied 
to predict critical temperatures of equivalent IgG1 formulations, making the formulation 
selection and lyophilisation process design more cost effective and less time consuming.  
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The aim of this thesis was to design a stable, lyophilised, high concentration antibody 
(IgG1) formulation using a Quality by Design (QbD) approach. In this chapter, the impact 
of the thesis key findings on the current knowledge in the field is discussed and 
interpreted. In addition, the strengths and limitations of the thesis are summarised. To 
conclude, recommendations for future work are also provided. 
7.2 Interpretation and implications of the thesis findings 
 
The development of high concentration antibody formulations is a key topic of interest 
for pharmaceutical companies and healthcare providers. The protein market is currently 
moving from the IV administration of low concentration/high volume products to the 
more patient compliant SC administration of high concentration/low volume products. As 
discussed in Chapter 2, the majority of these formulations are currently commercialised 
in a liquid format, however, lyophilisation is the process of choice to enhance stability 
and prolong shelf-life of pharmaceutical products. Therefore, the design of stable high 
concentration antibody formulations intended for lyophilisation represents a novel and 
noteworthy research topic. This thesis provides a comprehensive overview of the overall 
process to follow for the design of high concentration protein formulations, including 
formulation selection (Chapter 2 and 3), lyophilisation cycle development (Chapter 4), 
physical stability (Chapter 5) and biophysical stability (Chapter 6).  
The value of this research is that it contributes substantially to the field providing 
recommendations and insights on the design of lyophilised high concentration antibody 
formulations. In particular, this thesis is a comprehensive and detailed study of the process 
flow required to develop and optimise high concentration protein formulations in the 
lyophilised state. The work explores formulation, lyophilisation and stability which are 




the three key areas in the development of lyophilised products, employing rationale and 
systematic approaches with the use of QbD strategies (Figure 7.1). 
 
Figure 7.1 Flow diagram showing the workflow of the thesis incorporating the Quality by Design 
approaches (QbD) applied to each step. 
 




Lyophilisation of high value products can be expensive and time consuming for 
pharmaceutical companies. Therefore, the employment of systematic strategies to reduce 
the number of trials and errors is a high impact contribution to the development of 
biopharmaceutical products. In this regard, this thesis is a crucial starting point and opens 
new avenues for future work in the field of lyophilisation of high concentration IgG 
formulations. 
In this thesis QbD approaches contributed to aid three essential steps of the work: a) 
formulation selection (Chapter 3), b) lyophilisation cycle development and optimisation 
(Chapter 4), and c) physical solid state (Chapter 5).  
7.2.1 Formulation selection and design 
 
As a first step, the selection of excipients was conducted by studying the formulation 
composition of 264 parenteral protein formulations approved in the European Union 
(Chapter 2). Sucrose was included in formulations investigated since it is the most 
common stabiliser in lyophilised products (Chapter 2). On the contrary, arg/arg-HCl, 
included in a low number of commercial products, was selected for its multi-functional 
role and series of properties that can enhance stability of high concentration protein 
formulations (154, 233, 235, 236). Arg/arg-HCl is reported in literature to reduce protein 
aggregation (155, 230, 232, 292), reduce solution viscosity (154, 277) and enhance 
protein solubility (229, 239). These properties are critical for high concentration protein 
formulations, which tend to show high viscosity and aggregation profiles (13, 30). 
Despite its tendency to reduce formulation critical temperatures (Chapter 3), arg/arg-HCl 
was observed to be a valuable excipient in the design of high concentration protein 
formulations. Results show the capability of arg/arg-HCl to reduce viscosity of protein 
formulations (Chapter 3), light induced aggregation of high concentration protein 
formulations (Chapter 6) and in the solid state to reduce specific surface area, providing 




a more elegant cake appearance in comparison to equivalent sucrose rich formulations 
(Chapter 5). Therefore, the first key finding concerns the use of arg/arg-HCl as excipient. 
Arg/arg-HCl at specific concentrations (≤ 4% w/v for selected formulations) can 
positively contribute to the development of high concentration protein formulations in the 
liquid and lyophilised formats. 
The second main contribution is related to the use of high concentration of protein in 
formulations. The challenges encountered during the development of high concentration 
protein formulations have been widely reported in literature (13, 28, 37). However, 
several advantages have also been identified when formulating proteins at high 
concentrations. The high protein concentration tends to increase formulation critical 
temperatures (Chapter 3) allowing the execution of shorter lyophilisation cycles at more 
aggressive conditions. In Chapter 5, the high concentration of protein was shown to 
inhibit excipient crystallisation in the solid state material when exposed to elevated 
relative humidity conditions (up to 70% RH at 25oC) and during storage with and without 
cold chain. Additionally, the protein at high concentrations can act as bulking agent (32) 
and buffering agent (291, 293), contributing to its own stability within the formulation 
and allowing design of less complex formulations with a lower number of excipients.  
As a novel aspect in our study, the high protein concentration (100 mg/mL) was 
formulated in a ratio 1:1 with the excipients. The ratio 1:1 between protein and excipients 
involves a high total solute concentration (200 mg/mL) of the formulations pre 
lyophilisation. Generally, total solute concentrations ≤10% are selected in lyophilisation 
and a ratio 1:1 between protein and cryo/lyo protectant is recommended to guarantee 
complete protein stabilisation during lyophilisation (40, 138). For high concentration 
protein formulations, the high total solute concentration is an additional challenge. A 
conventional approach is to formulate the protein at lower concentration pre-




lyophilisation and to reconstitute the lyophilised powder in a smaller volume of diluent 
to achieve the target higher concentration. In this study, an extremely high protein 
concentration and consequent high total solute concentration pre lyophilisation have been 
successfully lyophilised (Chapter 4) without negatively impacting the biophysical 
stability of the protein (Chapter 6).  
The proposed hypothesis is that the ratio 1:1 between protein and excipients contribute to 
ensure protein stability. A key aspect of these formulations was that they displayed a 
completely amorphous nature when analysed by pXRD. The high total solute 
concentration aided the creation of a glassy matrix where the amorphous formulation was 
capable to reduce protein mobility ensuring prolonged stability and preventing excipient 
crystallisation (Chapter 5 and 6). Generally, amorphous formulations tend to be less stable 
than crystalline formulations. Amorphous materials can undergo phase transitions over 
storage impacting protein stability (57). The principal advantage of the selected protein 
formulations is the capability of the protein at high concentrations to prevent excipient 
crystallisation, providing a stable lyophilised formulation. The lyophilised formulations 
were observed to remain stable in presence and absence of cold chain storage and after 
exposure to high humidity conditions. The possibility to eliminate the requirement for 
cold chain storage further reduces the costs for shipping and storage of these formulations 
(43, 294).  
The high protein and total solute concentration, however, can negatively impact the 
lyophilisation process by increasing the cryo concentration effect (295, 296), favouring 
phase separation (295, 296) and increasing product dry layer resistance (Rp), hence 
primary drying time (297). However, the effect of the increased Rp was mitigated by the 
low fill volume which contributed to the achievement of short lyophilisation cycles 
(Chapter 4). Cryo concentration and phase separation were not a focus of this study, 




however, IgG1 formulations were observed to be stable pre and post lyophilisation, 
showing that freezing and drying steps did not negatively impact the biophysical stability 
of the formulated IgG1 (Chapter 6).  
The biophysical stability of the IgG formulations was studied at stressed conditions post 
lyophilisation, thermal stress and photo induced aggregation were investigated (Chapter 
6). The thermal stress experiments show a thermal unfolding (~ 75 °C) of the protein 
measured by DSC in line with changes of the tertiary structure monitored by CD. In this 
thesis, DSC was the only technique used to monitor biophysical stability that did not 
require sample dilution and was performed at the initial formulation concentration (100 
mg/mL). The limited number of techniques available to monitor biophysical stability at 
high protein concentration is a key challenge in the development of high concentration 
protein formulations (13). This highlights the requirement for the identification and 
development of novel techniques to study high concentration protein formulations.   
7.2.2 Lyophilisation process design 
 
Regarding the lyophilisation process, the freezing step was initially optimised. It was 
observed that lower freezing temperature, slower ramp and prolonged freezing improved 
the cake appearance of the product. Therefore, process parameters (Chapter 4) were 
selected to provide the optimal cake appearance (Chapter 5). 
During primary drying, the effect of the high Rp was counterbalanced by the low fill 
volume, allowing the development of lyophilisation cycles with short primary drying 
times (11-12h conservative cycle, 5h aggressive cycle, Chapter 4). The possibility to 
successfully lyophilise high concentration protein formulations with relatively short 
lyophilisation cycles is the third significant contribution to this study. Considering that 
lyophilisation is generally a time consuming and expensive process (40, 42), the 




possibility to reduce total cycle times is a key objective for pharmaceutical companies. In 
this study, the lyo-cycle development was conducted with the use of a lyomodelling tool 
for estimation of the primary drying step (product temperature, time and sublimation 
flow) (72) (Chapter 4).  
The lyomodelling QbD tool was informed with input parameters extrapolated from three 
process analytical technology (PAT) tools used to monitor product temperature as critical 
process parameter (CPP). The combination of QbD and PAT tools, was selected as a 
favoured strategy to better understand the lyophilisation process and estimate primary 
drying. This approach enables the development of a lyophilisation cycle and construction 
of a design space around the cycle to evaluate and ensure process robustness, when CPPs 
are modified in a certain range (72, 248). The use of lyomodelling is therefore particularly 
useful during the development stage, where the prediction tool can minimise the number 
of pilot, engineering and validation cycles required to target the optimal cycle parameters. 
However, to ensure accurate output information, precise input parameters should be used 
to inform the model. Input parameters include formulation and vials configuration, heat 
transfer coefficient (Kv) and Rp parameters. Kv and Rp can be mathematically calculated 
using measured product temperature and the accuracy of their determination critically 
affects the accuracy of the model (71, 72, 248). In Chapter 4, a thorough comparison of 
three commonly used product temperature monitoring systems (63, 64) was conducted. 
For the first time, Kv and Rp for each system were experimentally calculated, compared 
and used as inputs in the model. Differences in the design, operating principle and ease 
of use can all impact the selection of one PAT tool over another. Understanding existing 
differences between the operation and applications of these tools represents a key 
learning.  




7.2.3 Other QbD approaches 
 
In addition to the lyomodelling tool, two additionally novel QbD approaches have been 
employed in this thesis: the empirical model for formulation critical temperatures 
prediction (Chapter 3) and the correlation models between both headspace residual 
moisture and product residual moisture, and product residual moisture and Tg (Chapter 
5). The use of QbD approaches enabled formulation and process development saving 
costs and time and reducing the number of iterative experiments. 
The main advantage of developing an empirical model for formulation critical 
temperatures prediction is the capability of this model to accurately estimate not only Tg’ 
but also Tc of formulations included in a design space. The correlation model  established 
between vial headspace water vapour and product moisture provided a non-destructive 
method to accurately estimate product residual moisture. This model enables analysis of 
100% of the batch retaining samples, which can be critical during the development stage 
when API supply can be limited.  
It is important to note that the significant correlation established between product residual 
moisture and Tg was linked to the stability of selected amorphous formulations (phase 
transitions such as recrystallisation is inhibited for these formulations). Phase transitions 
can potentially disrupt the robustness of the model due to a change in equilibrium 
moisture uptake by the formulation. However, for the formulation developed in this 
thesis, when vial headspace moisture was determined by performing a single, non-
destructive technique, then product moisture and Tg could be accurately predicted.  
For these QbD approaches, a model protein BSA was used to develop the models, which 
were then successfully verified using equivalent IgG1 formulations. The possibility to use 
model proteins to conduct preliminary studies and estimate the formulation behaviour is 




a cost effective strategy. This strategy becomes particularly important for high value 
products (e.g. IgG formulations). Limited availability and high costs of these materials 
can represent a challenge in a formulation development stage, especially during 
lyophilisation of high concentration protein formulations, where a large amount of 
material is required. In particular, in this thesis, the model protein BSA was effectively 
employed in the estimation of critical temperatures and physical stability which were 
shown to be similar for equivalent IgG1 formulations. On the contrary, biophysical 
stability which is strictly protein dependent was evaluated on the protein formulation 
containing the target protein, IgG1.  
7.2.4 Primary packaging configuration  
 
Primary packaging configuration and components should be considered as integral parts 
of the formulation that can contribute to the processing and stability of a lyophilised 
formulation. Therefore, the type, size of vials and the stoppers (83-85) should be 
appropriately selected and processed ensuring sterilisation and dryness. In this study, 5 
mL tubing vials were used for several reasons: a) to enhance equipment capacity- a larger 
number of smaller vials can be lyophilised in the same cycle determining higher 
productivity; b) the low fill volume selected (1.1 mL) could be accommodated in 5 mL 
vials (<50% of the vial fill volume); c) the use of tubing vials which are generally less 
variable than moulded vials and provide more accurate Kv parameters. The use of a low 
fill volume was also observed to be a successful formulation strategy. The low fill volume 
allowed a 1:1 dilution to achieve short reconstitution times (37) and to obtain short 
lyophilisation cycles mitigating the effect of high product dry layer resistance. 
  




7.3 Advantages and disadvantages of key aspects investigated  
 
Table 7.1 summarises the advantages and disadvantages of the key aspects studied in 
the thesis and discussed in Section 7.2.  
Table 7.1 Summary of advantages and disadvantages of key aspects studied in the thesis. 
Key aspect Advantages Disadvantages 
Use of arg/arg-
HCl as excipient 
• Reduction of light induced 
aggregation 
• Reduction of viscosity 
• Reduction of specific surface area 
• Improvement of product cake 
appearance 




• Inhibition of excipients 
crystallisation 
• Bulking agent 
• Buffering agent 
• High tendency to aggregate is 
protein dependent 
• High viscosity  
High total solute 
concentration 
• Solid and rigid cake structure 
(reduced mobility) 
• Lower hygroscopicity 
• High product dry layer resistance 
• Longer freezing (at lower soak 
temperature, slow ramp, prolonged 
time) 
• Longer primary drying 
• Longer reconstitution time 
Use of model 
protein 
• More cost effective formulation 
and process development 
• Not representative of the biophysical 





• At specific ratios, absence of 
excipients recrystallisation even 
when formulations are exposed to 
drastic humidity conditions 
• More extensive stability 
investigation required 
No requirement 
for cold chain 
storage 
• Reduced costs 
• Products can be stored at 
temperatures ≥ 25 °C (High Tg) 
• More studies required to establish 
the limitations of storage conditions 
(temperature, time) 
Use of 5 mL vials • Higher production capacity • More difficult to handle 
Use of low fill 
volume 
• Shorter reconstitution time  
• Shorter lyophilisation cycles 
(counterbalancing the high 
product dry layer resistance) 
• Higher protein concentration pre 
lyophilisation (dilution 1:1) 
• Larger headspace containing water 
vapour that could potentially be 
transferred to the product increasing 
residual moisture over time (dryness 
of the stoppers is important) 
QbD approaches 
& PAT tools 
• Reduced number of trials and 
errors 
• Improved process understanding 
• Accurate input information to avoid 
bias in the estimation 
7.4 Summary of key findings 
The overall aim of this thesis was to provide insights into the development of high 
concentration antibody formulations in the lyophilised state and to obtain a formulation 
capable to protect the IgG from stresses experienced during concentration, formulation, 




lyophilisation process and storage. The selection of the appropriate formulation 
components at critical concentrations was essential for the achievement of a stable 
lyophilised formulation.  
The main novel aspect was the possibility to lyophilise formulations with high 
concentrations of IgG1 (100 mg/mL) and consequent high total solute concentrations 
(200 mg/mL), finding formulation and process strategies able to avoid impairment of the 
product quality and stability. As outcome of this study, the key findings to consider in 
formulating lyophilised high concentration of IgGs are summarised as follows: 
I. Arg/arg-HCl was shown to be an excipient extremely useful in the formulation of 
high concentration protein formulations since it reduces light induced aggregation 
and viscosity in the liquid state, and reduces specific surface area, improving the 
cake appearance of lyophilised products. In contrast, arg/arg-HCl at high 
concentrations can significantly depress critical temperatures for lyophilisation 
process, however, this effect of arg/arg-HCl can be mitigated by the high 
concentration of protein which increases the critical temperatures. Therefore, it is 
particularly important to identify the optimal ratio protein: excipient to use in 
formulation.  
 
II. The empirical model (based on DOE) was an essential tool to aid selection of the 
excipient ratio and to predict and optimise critical temperatures.  
 
III. The primary drying optimisation was conducted using a lyomodelling tool for 
primary drying estimation. The tool predicted lyophilisation cycles with accurate 
and significantly shorter primary drying times. 
 




IV. The correlation model developed enables estimation of product moisture and Tg 
using a non-destructive technique. 
 
V. The optimised lyophilisation process did not compromise the biophysical stability 
of the IgG1 formulations after six months with and without cold chain storage and 
can be potentially employed to prolong the shelf-life of selected IgG1 
formulations. The high Tg and low residual moisture achieved make these 
lyophilised products potential good candidates for the elimination of cold chain, 
rending their storage and supply more cost effective.  
7.5 Limitations 
 
The limitations of this study are mainly related to the restricted availability of the IgG1 
material which limited the number and type of protein formulation approaches that could 
be investigated. As a consequence, a limited number of well-established techniques which 
often require dilution were used to evaluate physical and biophysical stability, reducing 
the possibility to investigate additional and novel methods for high concentration protein 
formulations in the liquid or solid state. Finally, in Chapter 4, the impact of different 
primary drying shelf temperatures on the lyophilisation cycle were evaluated. On the 
contrary, the effect of pressure variation during primary drying was not studied. This 
represents a limitation considering the significant impact of pressure on Kv and therefore 
on Tp and primary drying time. Evaluating the impact of pressure allows the construction 
of a complete design space around the target cycle, establishing proven acceptable ranges. 
Finally, the limited amount of IgG did not allow the execution of some experiments that 
could have added value to this thesis. For instance, the activity of the protein pre and post 
lyophilisation was not analysed, therefore this study is limited to the investigation of 
aggregation and structure of the IgG pre and post lyophilisation. 




7.6 Recommendations for future work 
 
This thesis provides new insights into the development of lyophilised high concentration 
antibody formulations. This work can be considered a starting point for future research in 
the field of lyophilisation of high concentration antibody formulations.  
Future work is recommended in the following areas: 
I. Investigation on the effect of different amino acids as ‘novel’ excipients in high 
concentration protein formulations. Amino acids can act as multi-functional 
excipients; they are included in a low number of recent commercial protein 
products and some amino acids seem to have synergistic effects if combined in 
formulation. 
 
II. Identification of new techniques and methods for the characterisation of high 
concentration protein formulations in the liquid and lyophilised state. Aggregation 
can be underestimated when dilution of high concentration protein formulations 
is executed during the analysis at operative conditions; a limited number of 
techniques is available to monitor biophysical stability of lyophilised protein 
formulations. 
 
III. Further optimisation of the proposed lyophilisation cycle can be conducted, 
considering the impact of pressure during primary drying and creating a complete 
design space. The impact of shelf temperature during primary drying was 
evaluated in the study, however, pressure excursion can also impact the process 
and should be assessed to ensure robustness of the lyophilisation process. The 
impact of more aggressive lyophilisation cycles on the biophysical stability of the 
protein could also be explored as future work. 




IV. Exploration of the effect of different fill volumes to develop the best strategy. In 
this study, the use of low fill volumes at high protein and solid concentrations was 
identified as a successful strategy for the development of high concentration 
protein formulations. The effect of larger fill volumes at lower protein 
concentration pre lyophilisation could be investigated as an alternative 
formulation approach. 
 
V. Further investigation into the root causes that can induce cake defects during 
lyophilisation of high concentration formulations (e.g. cracking) could be 
investigated. Generally, root causes responsible for cosmetic defects of the 
lyophilised cakes are not clearly identified. In this study, arg/arg-HCl was 
observed to reduce cracking defects in lyophilised cakes of sucrose rich 
formulations. Additional studies would be required to understand if other 
excipients can play a similar role, identifying their mechanistic behaviour.  
 
VI. Investigation on the reconstitution time of high concentration protein 
formulations. More objective and reproducible methods as well as strategies and 
excipients to reduce reconstitution time are required. In this study, the 
reconstitution time of selected IgG1 formulations was approximately 5 min. In 
literature, however, high concentration protein formulations can show prolonged 
reconstitution times, up to 40 min in some cases (37). Finally, methods currently 
used to determine reconstitution time are extremely operator dependent and 
poorly reproducible. 
  






The overall aim of the thesis was to develop a stable lyophilised high concentration IgG 
formulation. The primary objectives of this thesis were achieved by selecting a successful 
formulation strategy. In particular, the identification of suitable excipients (types and 
ratios) was conducted by a thorough study of the formulation approaches used in 
commercial protein products. Arg/arg-HCl was selected as excipient due to its positive 
roles in the formulation of high concentration protein formulations, also demonstrated in 
this study (e.g. Arg/arg-HCl preserves protein from photo induced aggregation). The use 
of QbD approaches was extremely useful in the selection of formulations with high 
critical temperatures, but also in the development of an optimal lyo-cycle and in the 
estimation of physical parameters (Tg and product moisture). The selected formulation 
showed preserved biophysical stability pre and post lyophilisation and after storage for 6 
months with and without cold chain.  
The use of a model protein (BSA) and QbD tools enabled a more cost effective 
development of stable IgG formulations. The short lyophilisation cycles and the absence 
of cold chain requirement render manufacturing and storage of lyophilised high 
concentration IgG formulations more convenient for pharmaceutical companies, 
healthcare providers and patients. Therefore, this thesis provides a significant 
contribution to the field and improves current knowledge on lyophilisation of high 
concentration protein formulations. Finally, it provides recommendations and new points 
of discussion that could be further investigated, such as the identification of novel 
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Table A1 Input parameters for Kv determination using the gravimetric method. 
Kv input 
information 
Centre vials Edge vials Shuttle vials (1 & 2) 
Vial capacity, mL 5 5 5 
External diameter 
(Dout), cm 
2.2 2.2 2.2 
Weight loss, g 0.88 ± 0.04 
1.087 ± 0.098 (Factor: 
1.24) 
Shuttle 1: 1.078 ± 0.094  
(Factor: 1.23) 
Shuttle 2: 1.055 ± 0.118 
(Factor: 1.21) 
Pressure, mTorr 
99.73 ± 0.32  
(CM, 0.133 mbar)  
99.73 ± 0.32  
(CM, 0.133 mbar) 
99.73 ± 0.32  
(CM, 0133 mbar) 
Shelf inlet 
temperature 
Lyo shelf inlet Lyo shelf inlet Lyo shelf inlet 
Product 
temperature, °C 
Measured using TWTC, 
Ellab RTDs, Tempris 
Measured using TWTC, 
Ellab RTDs, Tempris 
Measured using TWTC, 
Ellab RTDs, Tempris 
Time, hrs 
every minute during the 
ice sublimation step 
every minute during the 
ice sublimation step 
every minute during the 






Table A2 Input parameters for Rp determination. 
Rp input information Value 
Vial capacity, mL 5 






Ice density, g/cm3 0.918 
Solution density, g/cm3 1.2 
Fill volume, mL 1.1 
Water content, g 1.06 (80% of total weight) 
Dry cake thickness, cm 0.35 
Time, hrs 
every minute over primary drying (when CM pressure is stabilised until 
the end of primary drying) 
Shelf inlet temperature, 
°C 
Lyo shelf inlet temperature over primary drying  
Product temperature, 
°C 
Measured using TWTC, Ellab RTDs, Tempris systems over primary 
drying 
Pressure, mTorr CM pressure measured over primary drying (0.99 mTorr → 0.133 mbar) 
 
Table A3 Lyomodelling input parameters (1st part) – Kv and Rp information. 





















Ellab shuttles vials: 
19.50±0.17 
Ellab shuttles vials: 
18.29±0.22 
Ellab shuttle vials: 
17.72±0.21 
Rp 
(Conservative cycle,  
Tshelf= -25 °C) 
 P:S P:S:A P:S P:S:A P:S P:S:A 
Rp0 1.05 0.92 0 0 0.13 0.19 
A1 67.59 69.79 56.99 61.92 71.98 66.10 
A2 0.38 0.30 0 0 0.58 0.88 
Rp values for a general material with high dry layer resistance which increases non-linearly with dry layer thickness 
Rp0= 2, A1= 90, A2=5 (94);  
Rp values for a general material with high dry layer resistance which increases linearly with dry layer thickness 




 Table A4 Lyomodelling input parameters (2nd part) – vial, formulation and lyo-cycle information. 
Vial input information Value 
Vial capacity, mL 5 
Internal diameter (din), cm 2 
External diameter (dout), cm 2.2 
Formulation input information Value 
Ice density, g/cm3 0.918 
Solution density, g/cm3 1.2 
Fill volume, mL 1.1 
Water content, g 1.06 
Dry extract, (% w/w and % w/v) 15.41 and 20 
Dry layer thickness, cm 0.35 
Number of vials 60 (filled), 312 (total) 
Collapse temperature, °C 
P:S P:S:A 
-20.68 ± 1.17 -23.09 ± 1.57 
Lyo-cycle input information Value 
Shelf inlet temperature, °C Lyo shelf inlet 
Pressure, Torr 
CM pressure measured over primary drying 
(0.099 Torr → 0.133 mbar)  
Time, hrs 
every minute over primary drying (when CM 









Figure A1 Examples of the Tg’ determination for 1a) BSA formulations and 1b) IgG formulations in 




Figure A2 Differences observed in the weight loss of Edge, Shuttle 1, Shuttle 2, Center vials. 2a) Mean 
and SD of the weight loss for each group of vials, 2b) Tukey’s multiple comparison of the weight loss 
determined for each group of vials. Weight loss of the centre vials is significantly different if 
compared to the vials located on the first row close to the Ellab shuttles and on the first row at the 




Supplementary Information Chapter 5  
 
 
Figure A3 Comparison of the Tg and product residual moisture levels of selected formulations 
containing BSA and IgG1 as proteins and lyophilised at optimised (Tshelf=-15 °C) and aggressive 
conditions (Tshelf=35 °C). Formulation BSA:S (or IgG1:S) contain sucrose at concentrations of 10% 
w/v; formulation BSA:S:A (or IgG:S:A) contains sucrose at concentrations of 8% w/v and arg/arg-
HCl at concentrations of 2% w/v. Both formulations contain protein at concentrations of 10% w/v. 
Samples analysed were n=3 for BSA formulations and n=3 for IgG1 formulations. 
 
 
Figure A4 Reversing heat flow thermogram showing glass transition temperature (Tg) of the BSA 
and IgG1 formulations selected. BSA:S (blue, dotted line), BSA:S:A (green, dotted line), IgG1:S 





Table A5 Tg and residual moisture of selected IgG1 and BSA formulations. Mean and SD n=3 
samples for the BSA formulations, n=2 samples for the IgG1 formulations. 
Formulation 
Tg (°C)  
(Mean ± SD) 
Residual moisture (%)  
(Mean ± SD) 
IgG1:S 100.7 ± 0.7 0.13 ± 0.03 
IgG1:S:A 99.2 ± 1.2 0.22 ± 0.03 
BSA:S 98.13 ± 1.1 0.22 ± 0.06 
BSA:S:A 96.17 ± 1.2 0.26 ± 0.04 
BSA:S Aggressive cycle  
(Tshelf = 35 °C) 
95.8 ± 1.5 0.31 ± 0.04 
BSA:S:A Aggressive cycle 
(Tshelf = 35 °C) 
95.3 ± 1.0 0.31 ± 0.02 
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Figure A7 Overlap of the SE-HPLC chromatogram of the IgG1 pre formulation, pre and post 










Figure A9 Correlogram for the DLS analysis conducted on the two IgG1 formulations in presence 







Figure A10  SE-HPLC chromatograms of the IgG1 formulations exposed to light at different time 
intervals. A) without Arg/Arg-HCL B) with Arg/Arg-HCl. 
  
 
Figure A11 Reduced SDS Page of the formulation IgG10:S8:A2 (1) post formulation and 
lyophilisation in comparison to (2) an aggregated IgG1 (CHO cells produced, as negative control). 
 
